ABSTRACTS

Abstracts from the 8th International Primary Care Respiratory Group (IPCRG) World Conference

Amsterdam Rai Convention Centre, 25th–28th May 2016

CLINICAL RESEARCH RESULTS ABSTRACTS

npj Primary Care Respiratory Medicine (2016) 26, 16022; doi:10.1038/npjpcrm.2016.22; published online 23 May 2016

CR001

Tuberculosis in the developing countries, just a tip of the iceberg

Taj Muhammad
TB Control Programme, Peshawar, Pakistan

Aim: The aim of the study was to find out the sputum smear positive cases, importance of sputum microscopy and its impact on the other family members living in close vicinity of patient with due importance to cure them resulting in breaking the chain of transmission of the disease in the society and prevention of the drug resistant Tuberculosis, which is the challenging problem for the developing countries with limited resources e.g. culture and sensitivity test for Acid Fast Bacilli. Pakistan contributes 63% of the disease burden having 420,000 new cases in the country every year. The study was carried out in Khyber Pakhtunkhwa province having population as per Pakistan Census Report is 1,774,645 (in 1998).

Method: All TB patients included in the TB registration record having all information including name of patient, address of the contact person and Basic Medical Unit (Rural Health Centre or Hospital where diagnosis was made and where treatment is to be given), Type of patient i.e. New, Relapse, Transfer In, Treatment after default and Treatment after failure.

Results: DOTS program stop the chain reaction of transmission of bacteria which prevents the TB, failures in emergence of even more deadly strains of drug resistant TB. It not only reduces TB recurrence rate but indirectly alleviates poverty resulting to overcome TB as the stigma in the society especially for the young unmarried females. It is a cost effective strategy. Prevalence of the disease for both sputum positive and negative cases is 342 per 100,000 population. Incidence rate is 275 per 100,000 population and for sputum smear positive is 144 per 100,000 of population.

Conclusion: Tuberculosis especially Sputum Smear Positive patients are a challenging problem for the under developing countries with low literacy rate and poor health facilities. The most important priority of the government, health department and health personals is to follow the DOTS components i.e. government commitment, diagnosis by free sputum microscopy at all diagnostic centres, standardize treatment with direct observation, uninterrupted drug supply in order to control and cure the TB patients.

Declaration of Interest: None

Corresponding Author: Taj Muhammad,
Email: drtaj_2000@hotmail.com

Table 2. New Pulmonary Sputum smear microscopy positive cases treatment outcome

<table>
<thead>
<tr>
<th>Types of Patient</th>
<th>Cured</th>
<th>Treatment Completed</th>
<th>Died</th>
<th>Failure</th>
<th>Defaulted</th>
<th>Transferred Out</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear Positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>198 (82.8%)</td>
<td>21 (8.7%)</td>
<td>3 (1.2%)</td>
<td>15 (6.2%)</td>
<td>2 (0.83%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

CR002

Tracing missing contacts of TB, an unprecedented success in TBCP Khyber Pakhtunkhwa Pakistan

Maqsood Ali
TB Control Programme, Peshawar, Pakistan

Aim: Pakistan ranks 5th amongst 22 high burden countries. TB incidence in Pakistan is 276 per hundred thousand populations. Khyber Pakhtunkhwa (KP) is one of the Provinces of Pakistan. Provincial TB Control Program (PTP) KP provides free TB care services to about 27 million populations in the province and people from adjacent tribal agencies including Afghans. There are 232 diagnostic centres in Public sector and more than 314 Private clinics across the province. Free cost sputum smear microscopy and ATT under DOTS strategy is ensured by the Program. The objective is to detect at least 70% of cases and treat successfully 90% of them. Aim is to have TB free community.

Method: This was a retrospective study of two years, 2013 and 2014. Registered patients in different diagnostic centres were counselled to screen their contacts for TB on volunteer basis. All the contacts of the index case were interviewed and counselled for screening on smear microscopy. Clinical history, signs and symptoms were recorded and were correlated with the smear microscopy. Only those contacts were declared positive case whose smear microscopy indicated positive results as per standard protocol of NTP/WHO. These new cases were registered in their respective treatment centre. The rest of the negative patients were educated for the care of patient and personal biosafety. The data is analyzed through spss software.

Results: PTPKP registered 81197 all TB Cases including 32648 B Positive TB cases. There was no significant difference between male to female ratio (P < 0.05). 3882 contacts were screened in 2013, out of which 276 were confirmed Sputum Smear microscopically. The confirmed cases were 7.11% of the contacts screened. In 2014, 4315 contacts were screened, out of which 216 turned positive on sputum smear microscopy, which were 5.0% as an average out of the 7197 contacts screened, 492 positive cases were identified and registered, which are about 6.05%.

Conclusion: Although PTP-KP has played an integral role in controlling TB. However to sustain the performance and to reduce the human suffering, stigma, morbidity and mortality; efforts should be strengthened to catch the missing patients and avert possible risk of MDR TB and TB HIV Co-infection. Strategy may be refined to register more missing cases of TB, especially, by strengthening TB care in Private clinics. Ensuring these efforts will no doubt
Conclusion
completed treatment. Unsuccessful were 92 (24.0%) (Died = 67, Failed = 23, to follow up). 382 were MDR-TB, of which 290 (76.0%) has successfully completed study, 22 cases were XDR TB patient (6 cured, 9 died, 6 failed and 1 was loss. 13 were Poly DR (10 cured, 2 died & 1 was failed). 08 patients culture (18 declared cured and 3 died). 04 were Mono DR-TB (1 completed, 21 were Rif resistant on Xpert testing but were not declared MDR-TB on PMDT centres were not only provided free second line drugs but also social support and travelling allowance on monthly visits. Home visits were also made for each patient for infection control measures, contact screening and to create linkage with nearest DOTS centre at District TB control office. Results: During this time, total of 1079 patients were enrolled in these PMDT centres and among them 742 were MDR. Among enrolled patients 469 (43.5%) male and 610 (56.5%) were female. Most of patients 798 (74.0%) were among 15-45 yrs. Age group. This study included all those patients who were registered up to October 2013 and were completed their treatment. A total of 461 patients were registered up to October 2013 out of which 450 were completed their treatment and included in this study. Among these patients 21 were Rif resistant on Xpert testing but were not declared MDR-TB on culture (18 declared cured and 3 died). 04 were Mono DR-TB (1 completed, 1 cured & 2 died). 13 were Poly DR (10 cured, 2 died & 1 was failed). 08 patients were DR-TB suspect (3 completed, 3 cured, 1 died & 1 was not evaluated). Out of study, 22 cases were XDR TB patient (6 cured, 9 died, 6 failed and 1 was loss to follow up). 382 were MDR-TB, of which 290 (76.0%) has successfully completed treatment. Unsuccessful were 92 (24.0%) (Died = 67, Failed = 23, Lost to follow up =1, not evaluated = 1). Success rate of MDR-TB in this province is 76%, so achieved WHO target. During this time 100% received social support. Conclusion: Multidrug-resistant tuberculosis is an emerging challenge in Pakistan. There is a need to invest in improving the capacity of the TB Program to detect and manage MDR-TB. Declaration of Interest: None Corresponding Author: Mohammad Most Khan Email: mohammadmostkhan@gmail.com

CR003
Overview of Programmatic Management of Drug Resistant TB (PMDT) Program in Khyber Pakhtunkhwa (KP), Pakistan
Mohammad Most Khan
Provincial TB Control Programme Khyber Pakhtunkhwa, Pakistan
Aim: The aim of the study is to have an overview of the PMDT Program in KP. We retrospectively reviewed data at different PMDT centres in KP from 1st Q 2012 - 3rd Q 2015. Method: To control the increasing rate of DR-TB in KP, PTP KP stepped up & started managing M/XDR TB in 2012 with the support of Global fund. 04 PMDT centres have been established in KP. The enrolled DR TB patients at these centres were not only provided free second line drugs but also social support and travelling allowance on monthly visits. Home visits were also made for each patient for infection control measures, contact screening and to create linkage with nearest DOTS centre at District TB control office. Results: During this time, total of 1079 patients were enrolled in these PMDT centres and among them 742 were MDR. Among enrolled patients 469 (43.5%) male and 610 (56.5%) were female. Most of patients 798 (74.0%) were among 15-45 yrs. Age group. This study included all those patients who were registered up to October 2013 and were completed their treatment. A total of 461 patients were registered up to October 2013 out of which 450 were completed their treatment and included in this study. Among these patients 21 were Rif resistant on Xpert testing but were not declared MDR-TB on culture (18 declared cured and 3 died). 04 were Mono DR-TB (1 completed, 1 cured & 2 died). 13 were Poly DR (10 cured, 2 died & 1 was failed). 08 patients were DR-TB suspect (3 completed, 3 cured, 1 died & 1 was not evaluated). Out of study, 22 cases were XDR TB patient (6 cured, 9 died, 6 failed and 1 was loss to follow up). 382 were MDR-TB, of which 290 (76.0%) has successfully completed treatment. Unsuccessful were 92 (24.0%) (Died = 67, Failed = 23, Lost to follow up =1, not evaluated = 1). Success rate of MDR-TB in this province is 76%, so achieved WHO target. During this time 100% received social support. Conclusion: Multidrug-resistant tuberculosis is an emerging challenge in Pakistan. There is a need to invest in improving the capacity of the TB Program to detect and manage MDR-TB. Declaration of Interest: None Corresponding Author: Mohammad Most Khan, Email: mohammadmostkhan@gmail.com

CR004
Do we need tailored smoking cessation interventions for smokers with COPD? - Comparing smokers with and without COPD regarding cigarette smoking and quitting
Eva van Eerd
Maastricht University, The Netherlands
Aim: Background: Smokers with chronic obstructive pulmonary disease (COPD) have a more urgent need to stop smoking than the general smoker. However, the prevalence of smoking in patients with COPD is high and there is some evidence that this group finds it more difficult to quit. In order to increase smoking cessation in smokers with COPD it is important to assess if there are specific smoking-related factors and experiences in these smokers. This information could then be used to tailor future interventions to the needs of smokers with COPD. Aim: To compare smokers with and without COPD on factors associated with cigarette smoking and quitting, and their experiences herewith. Method: We conducted a questionnaire survey in all smoking patients with a recorded diagnosis of COPD from a large Dutch primary healthcare network. We compared this group with twice as many age-, sex-, and healthcare centre-matched smokers without COPD. In purposeful subsamples from both groups we conducted semi-structured in depth interviews. Results: One hundred seven smokers with COPD and 86 smokers without COPD responded to the questionnaire. As well as similarities, there were differences between the groups; smokers with COPD reported higher levels of depression and cigarette dependence, and a lower level of self efficacy to refrain from smoking. The interviews in 10 smokers with and 10 without COPD resulted in three overarching themes: balancing the health impact of smoking, autonomy being challenged by social interference and prerequisites for quitting. Both smokers with and without COPD trivialized the health consequences of smoking, however, smokers with COPD played even more ignorant. Autonomy was very important in both groups of smokers and smokers with COPD in particular had fierce emotions about the lack of empathy from doctors. Lastly, all smokers expressed fluctuation in internal and external motivation for quitting and in smokers with COPD existential feelings were more interrelated with their smoking behavior. Conclusion: Smokers with and without COPD showed a lot of similarities, but smokers with COPD show some specific characteristics and experiences related to cigarette smoking and quitting. These differences offer the possibility to tailor smoking cessation treatments more specifically to the subgroup of smokers with COPD. Declaration of Interest: C.P. van Schayck received unrestricted grants for nicotine addiction studies in both primary care and public health. D. Kotz received an unrestricted grant from Pfizer for a trial on the effectiveness of practice nurse counselling and varenicline for smoking cessation in primary care. Corresponding Author: Eva van Eerd, Email: evavaneerdm@maastrichtuniversity.nl

CR005
Impact of the Asthma APGAR system in US primary care practices: Beyond simply assessing control status
Barbara Yawn1, Peter Wollan1, Susan Bertram1
1Olmed Medical Center, Rochester, Minnesota, USA
Aim: Asthma is common and continues to impart a significant burden on individuals, families and the health care system. Using tools to better facilitate implementation of the 2007 evidence based national asthma guidelines may improve patient outcomes. This study was done to assess the ability of the Asthma APGAR tools to improve asthma outcomes and management in U.S. primary care practices. Method: Using a randomized cluster trial design with cross over from control to intervention in year 3, all practices were provided with short review of the current asthma guidelines. Intervention practices were also taught how to implement and use the Asthma APGAR tools including practice asthma audit with feedback, patient completed Asthma APGAR control assessment, and a care algorithm linked to the Asthma APGAR control assessment. Both patient reported outcomes, patient demographic data and medical record abstraction data were collected at baseline and for the 24 months of enrolment. Results: Use of the Asthma APGAR tools resulted in a significant decrease in rates of visits to the emergency department or hospitalizations for asthma (50% vs 12% reduction, respectively, P<0.001). Intervention practices also increased their adherence to asthma guidelines specifically in the areas of prescribing daily maintenance medications and documenting asthma control assessment and assessing asthma control status. We saw no improvement in rates of asthma control or asthma related quality of life. Intervention practices had a decrease in adherence to the guideline elements in the maintenance year–year 3 of the study but still demonstrated greater adherence to assessment of control status and prescribing of daily medications compared to their baseline year, P = 0.2. Conclusion: The Asthma APGAR tools improved the primary patient outcome (ED visits and hospitalizations) and some practice processes. The Asthma
CR006
Patient coping strategies in COPD across disease severity and quality of life: a qualitative study
Sarah Brien1, George Lewith1, Mike Thomas1
1University of Southampton, UK

Aim: Quality of life (QoL) has a weak relationship with lung function (LF) impairment in COPD; some cope well despite poor LF, while others suffer disproportionate QoL impairment despite well-preserved LF. Adjuvant non-pharmacological interventions such as rehabilitation and psychological/behavioural support may help if acceptable and targeted appropriately, but are under-used and sometimes declined by patients. Our aim was to explore and understand variations in experiences and coping strategies in patients with different severities of disease and disease-specific QoL.

Method: Qualitative research: 34 participants were purposively sampled across a spectrum of LF and QoL impairment, to cover a grid of sub-groups (very severe LF, good QoL; moderate LF, poor QoL etc.). Semi-structured interviews, digitally recorded, were analysed by thematic analysis. Data saturation was achieved.

Results: Four themes emerged: symptom impact, coping strategies, coping challenges, support needs. Most described employing multiple coping strategies yet over half reported significant challenges coping with COPD including: psychological impact, non-acceptance of diagnosis and/or disease progression, effects of co-morbidities and inadequate self-management skills. Approximately half wanted further help, ideally non-pharmacological, across all LF impairment groups but mainly with lower QoL. Those with lower QoL additionally reported greater psychological distress and greater use of non-pharmacological support strategies where accessible.

Conclusion: Patients who develop effective coping strategies, have better quality of life independent of objective LF, whereas others cope poorly, are aware of this, and report more use of non-pharmacological approaches. This study suggests that severely impaired QoL, irrelevant of lung function, is a powerful patient centred indication to explore the positive benefits of psychological and behavioural support for distressed COPD patients.

Declaration of Interest: None
Corresponding Author: Sarah Brien
Email: SBrien@soton.ac.uk

CR007
Health status in chronic obstructive pulmonary disease: measuring the minimal clinically important difference over different periods of time
Harma Alma1, Corina de Jong3, Danijel Jelusic2, Michael Wittmann2, Michael Schuler1, Janwillem Kocks1, Konrad Schultz2, Thys van der Molen1
1University Medical Center Groningen, The Netherlands, 2Klinik Bad Reichenhall, Germany, 3University of Würzburg, Germany

Aim: The Minimal Clinically Important Difference (MCID) might differ depending on the time period of measurement possibly due to recall bias. This study aimed to determine the MCID of several health status instruments (Clinical COPD Questionnaire (CCQ), COPD Assessment Test (CAT) and St. George’s Respiratory Questionnaire (SGRQ)) using different time windows during a 12-month follow-up period.

Method: Health status scores were collected during the RIMTCORE trial (#DRKS00004609), which investigated the effects of Inspiratory Muscle Training during Pulmonary Rehabilitation (PR). CCQ, CAT and SGRQ were administered at baseline, at the end of PR after 3 weeks, and at 3/6/9/12 months. A 15-point Likert Global Rating of Change (GRC) scale was administered for each follow-up moment. The MCID was determined using those patients indicating a minimal change with GRC scores ± 2 and ± 3 for each follow-up measurement. Question 2 of the SF-36 was used as anchor at 12-month follow-up. All measurements evaluated change between follow-up and baseline. The distribution-based methods Standard Error of Measurement (SEM) and half standard deviation of change (0.5 SD) were applied.

Results: In total 561 patients completed PR, of which 451 were included in this analysis (mean age 58 yr, 65% male, mean pack years 43, GOLD II 50%, III 39%, IV 19%). Baseline health status scores were 2.86 (CCQ), 20.23 (CAT) and 50.69 (SGRQ). MCID results are presented in table 1.

Conclusion: The use of anchor-based methods with GRCs and the SF-36 anchor question during various follow-up periods resulted in rather stable MCID estimates for CCQ, CAT and SGRQ. The ranges for improvement were 0.33-0.56 (CCQ), 1.40-3.12 (CAT), 7.58-10.28 (SGRQ). The ranges for deterioration were comparable for CCQ (0.42-0.66) and CAT (1.19-4.21), but slightly different for SGRQ (5.58-7.52). Distribution-based methods were comparable with anchor-based approaches. Recall bias seems of little influence on the MCID of health status tools.

Declaration of Interest: This study was funded by the Junior Scientific Master Class (JSM) MD-PhD programme of the University of Groningen to H.J. Alma. H.J. Alma, C. de Jong, D. Jelusic, M. Wittmann and M. Schuler have nothing to disclose. J.W.H. Kocks and K. Schultz report several personal fees all outside the submitted work. T. van der Molen developed the CCQ and holds the

Table 1. MCID health status vs.time period

<table>
<thead>
<tr>
<th>Global Rating of Change</th>
<th>CCQ</th>
<th>CAT</th>
<th>SGRQ</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Improved</td>
<td>Deteriorated</td>
<td>Improved</td>
</tr>
<tr>
<td>3 weeks</td>
<td>−0.56 (n=196)</td>
<td>−</td>
<td>−3.12 (n=196)</td>
</tr>
<tr>
<td>3 months</td>
<td>−0.44 (n=107)</td>
<td>+0.42 (n=36)</td>
<td>−2.74 (n=107)</td>
</tr>
<tr>
<td>6 months</td>
<td>−0.42 (n=96)</td>
<td>+0.48 (n=42)</td>
<td>−2.73 (n=96)</td>
</tr>
<tr>
<td>9 months</td>
<td>−0.46 (n=80)</td>
<td>+0.50 (n=37)</td>
<td>−2.30 (n=80)</td>
</tr>
<tr>
<td>12 months</td>
<td>−0.50 (n=88)</td>
<td>+0.66 (n=43)</td>
<td>−2.80 (n=88)</td>
</tr>
<tr>
<td>Anchor question SF-36 after 12 months</td>
<td>−0.33 (n=81)</td>
<td>+0.42 (n=71)</td>
<td>−1.40 (n=81)</td>
</tr>
</tbody>
</table>

N=number of patients with a minimal improvement of deterioration.
Negative change indicates improvement, positive change represents deterioration for each questionnaire. All results significant at P < 0.05.

CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; SD, Standard Deviation; SEM, Standard Error of Measurement; SGRQ, St. George’s Respiratory Questionnaire.
**CR008**
The impact of personality traits on health status of patients with chronic obstructive pulmonary disease in primary and secondary care in The Netherlands

Harma Alma¹, Corina de Jong¹, Doede Joustra¹, Janwillem Kocks¹, Thys van der Molen¹
¹University of Groningen, The Netherlands

**Aim:** Various factors may influence health status of patients with Chronic Obstructive Pulmonary Disease (COPD). Aim of this study was to investigate the impact of individual personality traits on health status scores for COPD patients in primary and secondary care.

**Method:** COPD patients have been recruited between September 2015 and January 2016 from primary and secondary care in the Netherlands. Inclusion criteria were ≥ 40 years and diagnosis of COPD GOLD I-IV. Exclusion criteria were asthma overlap; other respiratory co-morbidities; alpha 1 antitrypsin deficiency; and inability to read Dutch questionnaires. Participants filled out the Clinical COPD Questionnaires (CCQ), COPD Assessment Test (CAT), the St. George’s Respiratory Questionnaire (SGRQ) and the Eysenck Personality Questionnaire (EPQ-RSS) at home. The EPQ-RSS measures the traits Psychoticism, Extraversion and Neuroticism (min: 0; max: 12). Correlations were assessed with Pearson or Spearman correlation coefficients depending on normality of distribution.

**Results:** Analysis of the first patients included 175 participants of 47-84 years, 60% male, 38 mean pack years, and COPD GOLD I/II/III/IV 17/37/33/13%. Health status total baseline scores were 2.16 ± 1.04 (CCQ), 18.29 ± 7.12 (CAT), and 43.71 ± 19.45 (SGRQ). Scores on the EPQ-RSS personality traits without lie correction were 2.86 ± 1.67 (psychoticism), 6.21 ± 3.47 (extraversion) and 4.11 ± 3.31 (neuroticism). Extraversion has significant correlations with health status scores (r = 0.23 – 0.15); neuroticism has significant correlations too (r = 0.18 – 0.50) (see Table 1).

**Conclusion:** Moderate correlations exist between neuroticism and scores on the CCQ, CAT and SGRQ, with higher trait scores leading to higher health status scores. Significant correlations exist between health status and extraversion, although these are weak. No significant correlations exist taking into account psychoticism. Certain personality traits seem to have weak to moderate influence on health status scores of patients with COPD.

**Declaration of Interest:** This study was funded by the Junior Scientific Master Class (JSM) MD-PhD programme of the University of Groningen to Miss H.J. Alma. H.J. Alma, C. de Jong and D. Joustra have nothing to disclose. J.W.H. Kocks reports various personal fees, all outside the submitted work. T. van der Molen developed the CCQ and holds the copyright.

---

**Table 1. Personality vs health status**

<table>
<thead>
<tr>
<th></th>
<th>Psychoticism</th>
<th>Extraversion</th>
<th>Neuroticism</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCQ total</td>
<td>−0.05</td>
<td>−0.19*</td>
<td>+0.37*</td>
</tr>
<tr>
<td>CCQ symptoms</td>
<td>−0.06</td>
<td>−0.15*</td>
<td>+0.18*</td>
</tr>
<tr>
<td>CCC functional status</td>
<td>−0.03</td>
<td>−0.19*</td>
<td>+0.35*</td>
</tr>
<tr>
<td>CCQ mental</td>
<td>−0.03</td>
<td>—</td>
<td>+0.50*</td>
</tr>
<tr>
<td>CAT</td>
<td>−0.03</td>
<td>−0.21*</td>
<td>+0.36*</td>
</tr>
<tr>
<td>SGRQ total</td>
<td>−0.04</td>
<td>−0.23*</td>
<td>+0.40*</td>
</tr>
<tr>
<td>SGRQ symptoms</td>
<td>−0.07</td>
<td>−0.18*</td>
<td>+0.26*</td>
</tr>
<tr>
<td>SGRQ activities</td>
<td>−0.06</td>
<td>−0.18*</td>
<td>+0.27*</td>
</tr>
<tr>
<td>SGRQ impact</td>
<td>−0.02</td>
<td>−0.23*</td>
<td>+0.45*</td>
</tr>
</tbody>
</table>

N = 175.
* Data presented as Pearson of Spearman correlation coefficient significant at P < 0.05.

CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; SGRQ, St. George’s Respiratory Questionnaire.

---

**CR009**
Current smoking status and its relationship to COPD outcomes: an observational cohort study using routine data in the Hampshire Health Record Database

Lynn Josephs², David Culliford¹, Matthew Johnson¹, Mike Thomas¹
¹University of Southampton, UK

**Aim:** To determine the relationship between current smoking status and clinical outcomes in a UK Primary Care COPD population.

**Method:** Retrospective observational study, using individual patient-anonymised routine data in the Hampshire Health Record (NHIS database holding clinical data for > 1 million patients in Hampshire, UK). Read codes (classification of clinical terms for electronic coding) used to identify a prevalent cohort with diagnosed COPD on 31/12/2010 and to categorise patients by latest smoking status, age, sex, body mass index (BMI), indices of multiple deprivation (IMD), FEV1/FVC%, FEV1%predicted, and by pre-existing comorbidities (18 diseases). Three outcomes over 3 years (2011-13) analysed by current smoking status: all-cause mortality, respiratory-cause unplanned hospital admissions (ICD-10 codes) and respiratory-cause Emergency Department (ED) attendances. Multivariable logistic regression used to estimate odds ratios (ORs) for each outcome.

**Results:** Total cohort 16479 (male 53.7%) mean (SD) age 70.1 (11.1) years. Smoking status in 97.4%: 37.2% active smokers, 57.7% ex-smokers, 2.4% never-smokers; FEV1%predicted in 89.9%: median (IQR) 60 (46.0-74.0)%; FEV1/FVC%: mean (SD) 59.6 (14.9%); IMD deciles: median (IQR) 6 (3-9); BMI: mean (SD) 27.2 (6.0). One or more pre-existing comorbidities in 90.7%. Outcomes: multivariate analyses (n = 13220): compared to active smokers (n = 5015), ex-smokers (n = 7947) had significantly reduced risk of death, OR 0.875 (CI 0.768-0.998); never smokers (n = 258): OR 0.879 (CI 0.587-1.316). Ex-smokers had significantly reduced risk of hospital admissions, OR 0.807 (CI 0.727-0.897) as did never smokers, OR 0.659 (CI 0.456-0.951). Ex-smokers had significantly reduced risk of ED attendance, OR 0.799 (CI 0.702-0.910); never smokers: OR 0.711 (CI 0.434-1.162).

**Conclusion:** Smoking cessation is known to reduce accelerated FEV1 decline. Even allowing for smoking related comorbidities and lung function, we have shown that current ex-smokers had a significantly lower risk of death, unplanned respiratory-cause hospital admissions and ED attendances compared with active smokers, emphasising the importance of providing more effective smoking cessation support.

**Declaration of Interest:** None

**Corresponding Author:** Lynn Josephs
Email: L.Josephs@soton.ac.uk

---

**CR010**
Asthma ICs prescriptions in primary care in France and the United Kingdom: are they similar?

Sandrine Herbage¹, Laurent Laforest², Maëva Nolin¹, Alexandr Dima², Eric Van Ganse and the ASTROLAB group¹
¹University Claude Bernard Lyon 1, France, ²University of Amsterdam, The Netherlands

**Aim:** International guidelines are developed to align routine care to best current evidence. Their implementation would be reflected in similar prescription practices across countries, while differences may arise from health system-specific factors and variations of local levels of compliance with guidelines. ASTROLAB, a FP7 European project assessing the safety of long acting β2-agonists (LABAs), included a cohort of persistent asthma patients in France and in the United Kingdom (UK) based on four therapy patterns: LABAs without inhaled corticosteroids (ICS), ICS without LABAs, LABAs and ICS as separate inhalers (LABA+ICS) or LABA/ICS fixed-dose combinations (FDCs). In
this analysis, we compared ICs prescribing patterns and associated co-therapies between the two national ICs without LABAs cohorts.

**Method:** Patients (6-40 years) were selected from prescribed LABA and/or ICs: ≥ 6 months with the same prescribed therapy pattern initially described during the 12 months of the selection period. Distribution in the 4 therapy patterns was compared between France and the UK. For patients receiving ICs without LABA, we compared ICs therapy patterns (molecule, frequency of prescriptions/dispensations, dosages/inhalation) and co-therapies. THIN prescription data were used for the UK and claims data for France.

**Results:** Among eligible UK and French patients (n = 29812 and n = 2048), more UK patients received ICs without LABAs in the UK (63.0% vs 23.4%), while the FDC group was predominant in France (64.4% vs 33.3%). In the ICs without LABA group, patients received similar numbers of ICs prescriptions, (UK) or dispensations (France) over 12 months (4.3 vs. 4.0, P = 0.12). However, IC canisters with lower IC dosages/inhalation were more frequent in the UK (Table 1). More French patients received leukotriene-receptor antagonists (18.6% vs 8.3%, P < 0.0001) and oral corticosteroids (51.9 vs 15.5%, P < 0.0001). Conversely, most patients in both countries received short-acting beta-agonists (94.6% vs 90.7% of ICs users P = 0.0651).

**Conclusion:** Marked differences in asthma therapy patterns appeared between France and the UK, among ICs-treated patients. Understanding these further might shed light on system-specific variations in asthma care, and lead to solutions for better guideline implementation and improved health outcomes.

Declarations of Interest: The research leading to these results has received funding from the European Community: the Results of the INSPIRE Study under grant agreement n°282593.
CR013
The diagnostic added value of whole body plethysmography in patients suspected to suffer from asthma
Antonius Schneider1, Andreas Johannes Schwarzbach1, Andreas Hellmann2, Bernhard Fader2, Hubert Hautmann1, Rudolf Jörres3
1The University Hospital Klinikum rechts der Isar, Munich, Germany; 2Private Practice of Pneumologists Augsburg, Germany; 3Ludwig-Maximilians-University, Munich, Germany

Aim: Whole body plethysmography (WBP) is worldwide routinely used in clinical setting for diagnostic investigation of respiratory disease. In Germany, WBP is not only implemented in hospital setting, but also in ambulatory care for investigating common diseases like asthma and COPD. However, the evidence regarding the added value remains unclear up to now. An important tool within WBP analysis is the determination of specific airway resistance (sRAW) response. The aim was to compare the diagnostic accuracy of FEV1 response on bronchial provocation with sRAW response, both determined with WBP measurement.

Method: Diagnostic study with a delayed-type reference standard in 400 patients attending a private practice of pneumologists with complaints suspicious of obstructive airway disease (indicated population design). Positive bronchial provocation required a 20% fall in FEV1 from baseline, alternatively a doubling of sRAW and its increase to 2.0 kPa*s. A follow-up evaluation of patients and their physicians was performed 12 months later by telephone interview.

Results: Prevalence of asthma was 27.5% in 302 patients with complete follow-up data. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of WBP analysis with inclusion of sRAW were 95.2% (95%CI 88.3-98.1), 81.7% (76.1-86.3), 66.4% (57.5-74.2), 97.8% (94.5-99.1). Sensitivity, specificity, PPV, NPV of FEV1 response were 44.6% (34.4-55.3), 91.3% (86.8-94.4), 66.1% (53.0-77.1), 81.3% (76.0-85.7).

Conclusion: Inclusion of sRAW in WBP analysis allowed ruling out asthma with high certainty which would not be possible solely on basis of FEV1 response. Using FEV1 response on bronchial provocation as reference standard implicates that patients are classified false negative in 18.7%. It remains a challenge to increase the positive predictive value of bronchial provocation as this could not be improved by sRAW.

Declaration of Interest: None
Corresponding Author: Antonius Schneider,
Email: antonius.schneider@tum.de

CR014
30-s chair-stand test and 30 meter-walk test are both related to a history of acute visits due to respiratory problems in patients with COPD from the TIE-study
Regina Bendrik,1 Kristina Bröms,2 Marieann Högman,2 Karin Lisspers,1 Björn Ställberg,1 Andrei Malinovski,1 Christer Janson,1 Hans Hedenström,1 Hirsh Koyi, Eva Brandén,1 Alexandra Thornadsson,1 Margareta Gonzállez Lindh,2 Jens Ellingsen,3 Johanna Sulku,1 Jonas Lundkvist2
1Uppsala University, Uppsala, Sweden

Aim: The aim of the study was to investigate if 30-meter walk-test or 30-second chair-stand-test were related to acute visits due to respiratory problems and exacerbations in patients with COPD.

Method: 336 subjects from primary and secondary care (58% women) with physician- and spirometry-verified COPD-diagnosis were recruited. Median age was 70 years (range 49-85 years) and the COPD stages (according to FEV1 (%predicted)), was stage 1: 7%, stage 2: 55% stage, stage 3: 28%, stage 4: 10%. Time to walk 30 meters at maximal velocity was recorded and the number of repetitions of 30- s chair-stand-test was counted. Acute visits due to respiratory problems and exacerbations during last year were assessed by questionnaire.

Results: A trend toward longer time to walk 30 meters was seen along with GOLD-class: 20.8 s in stage 1 vs 19.1 s in stage 2 vs 21.6 s in stage 3 vs 24.4 s in stage 4, P < 0.001. Similarly, less repetitions of sit-to-stand were found along GOLD-class: 11.4 vs 11.2 vs 10.0 vs 9.5, P = 0.001. The need of acute visits due to respiratory problems during last year related to both longer time to walk 30 meters (21.4 vs 19.8 s, P = 0.02) and fewer repetitions of sit-to-stand (10.5 vs 11.6, P = 0.004). Having had exacerbations last year was related with fewer repetitions of sit-to-stand: 10.5 vs 11.4, P = 0.02. Fewer repetitions of sit-to stand related to acute visits due to respiratory problems during last year (P = 0.01) after adjustments for lung function (FEV1 (%predicted)), gender, age and current smoking.

Conclusion: These preliminary data suggests that there is a relation between simple functional tests, such as 30-second chair-stand-test, and previous history of acute healthcare visits due to respiratory problems. Further studies should look at the prospective value of the test as well as its’ additive value to lung function measurements.

Declaration of Interest: None
Corresponding Author: Regina Bendrik,
Email: regina.bendrik@regiongavleborg.se
**CR016**

**Inhalation technique assessment and inhaler device satisfaction in asthma patients**

Rita Pedro¹, Francisco Carvalho²

¹USF Horizonte – ULS Matosinhos, Senhora da Hora, Portugal; ²USF A Ribeirinha – ULS Guarda, Portugal

Aim: Assess the inhalation technique, the inhaler device satisfaction and asthma control in a population sample of a Primary Care Unit.

Method: Observational and descriptive study conducted between January and May 2015, in a Portuguese Primary Care Unit, with adult patients diagnosed with asthma and with a prescription for an inhaler in the last year. All the individuals who refused to participate or whose contact was impossible were excluded, with a final sample of 34 patients. To determine asthma control, the CARAT 10 questionnaire was used; patient satisfaction was assessed through a brief questionnaire; inhalation technique was assessed through direct observation, using a standardized check-list.

Results: 53% (n = 18) of the sample were females, with a mean age of 50.19 years. 53% (n = 18) of the sample had their asthma controlled (CARAT > 24). Regarding satisfaction, 78% of the sample was very pleased with the inhaler. Almost a third (29%) performed inhalation incorrectly, and the most frequent mistake was “not to expire before inhalation”.

Conclusion: Although the sample was very satisfied with the prescribed inhalers, it was found that only about a half had the disease controlled. Inhalation errors are also frequent, which might contribute to the poor control of the disease. Family Physicians – the gateway to the National Health System – must be attentive to asthma control, and should assess inhalation technique in consultations frequently, in order to correct it and improve their patients’ condition.

Declaration of Interest: None

Corresponding Author: Rita Pedro,
Email: rita.meireles90@hotmail.com

---

**CR017**

**Early detection of COPD in general practice: patient or practice managed? A RCT of two strategies in different socio-economic environments**

Joseph Dirven³, Huibert Tange¹, Jean Muris¹, Karin van Haaren², Gerrit Vink³, Onno van Schayck³

¹Maastricht University, The Netherlands; ²Dutch College of General Practitioners; ³Dutch Lung Foundation

Aim: To compare the effectiveness of two strategies for a population-based early-detection, taking into account different socioeconomic status (SES) settings.

Method: Practices were randomized on strategy and stratified on socioeconomic setting. The Respiratory Health Screening Questionnaire (RHSQ) was distributed to all participants. In the practice-managed condition, the practice was responsible for the whole procedure. In the patient-managed condition patients were responsible for calculating their RHSQ risk score and applying for a spirometry test. Main outcome measure was the rate of COPD diagnoses after screening.

Results: In the practice-managed condition more new COPD patients were detected (36%) than in the patient-managed condition (18%). In low-SES practices more high-risk patients were found (16%) than in moderate-high SES practices (9%). Recalculated for a standard Dutch practice (2350 patients) the yield would be 8.9 new COPD diagnoses, which is a 20% increase of known cases.

Conclusion: The practice-managed variant of this screening procedure shows a substantial yield of new COPD diagnoses for both low-SES and moderate-high SES practices. Acknowledgement: This study was published in Prim Care Respir J 2013,22(3):331-7. http://dx.doi.org/10.1016/j.pcrj.2013.000700.

Declaration of Interest: None

Corresponding Author: Joseph Dirven,
Email: dirvenj@gmail.com

---

**CR018**

**A district-orientated view on COPD and its risk factors in the city of Nijmegen, linking general practice and community health services data**

Tjard Schermers¹, Fleur van Veldhuijzen¹, Bianca Schalk¹, Ralf Hermens², Hans Bor¹, Sandra Boersma¹

¹Radboud University Medical Center, Nijmegen, The Netherlands; ²Community Health Services (GGD) Gelderland-Zuid, Nijmegen, The Netherlands

Aim: To identify differences in incidence and prevalence of COPD between districts in the city of Nijmegen, and to identify associations between risk factors and COPD prevalence within these districts.

Method: In this retrospective observational cohort study all COPD patients aged 40+ who were registered in general practices in the city of Nijmegen in 2013 were included (n = 2994). De-identified data about COPD diagnosis and treatment was supplied by GPs through extraction of their electronic patient journal systems. Data about risk/prognostic factors for COPD per district were supplied by the Community Health Services (GGD) Gelderland-Zuid from their annual health questionnaire survey. GGD data consisted of smoking habits, BMI, educational level and exercise level, aggregated and expressed as percentages per postal code area to represent the different districts. COPD incidence and prevalence figures were also calculated per postal code area.

Correlation analysis was performed to compute associations between COPD prevalence and occurrence of risk factors on the district level.

Results: Overall COPD incidence was 3.74 (95%CI 3.28-4.26) patients/1000 person years, overall prevalence 47.2/1000 (95%CI 45.5-48.8). Incidence and prevalence increased with age. COPD incidence was higher among women, prevalence was higher among men. COPD prevalence per district ranged from 12.8/1000 (95%CI 8.6-18.9) to 73.3/1000 (95%CI 64.3-83.4). On the district level correlation analysis showed statistically significant associations between higher age, lower educational level and being overweight (BMI > 25) and the prevalence of COPD. Higher educational level was associated with a lower COPD prevalence on the district level.

Conclusion: Within the city of Nijmegen there are district-level differences in the prevalence of COPD and the occurrence of its risk factors. Our district-
CR019
Association between chronic comorbidity and exacerbation rate in primary care COPD patients. Preliminary analysis of real-life general practice data (PROSPECT1)

Tjard Schermer1, Janine Westerik1, Esther Metting2, Job van Boven3, Waling Tiersma1, Janwillem Kocks2, Tjard Schermer1
1Radboud University Medical Center, The Netherlands, 2University Medical Center Groningen, The Netherlands

Aim: COPD often coexists with other chronic conditions that may influence disease prognosis. Our aim was to study associations between a wide range of chronic comorbidities and the occurrence of exacerbations in a real-life cohort of primary care patients with COPD.

Method: Retrospective cohort study based on 2012-2013 electronic health records of general practices in the Netherlands. Patients with physician-diagnosed COPD were analysed for their comorbidities which were categorized according to International Classification of Primary Care (ICPC) codes. Chi square tests were used to univariately explore associations between comorbidities and occurrence of exacerbations, defined by prescriptions of oral corticosteroids.

Results: 16,427 patients with COPD from 178 practices were included. Mean age at study start was 67 years [SD 12], 47.1% were women. At baseline 89.1% of patients suffered from ≥1 comorbidities, while 23.1% had ≥5 comorbidities. Most prevalent comorbid conditions were hypertension (35.2%), coronary heart disease (19.2%), osteoarthritis (17.6%), diabetes (17.3%), peripheral vascular disease (14.3%). 32% of patients had ≥1 exacerbation and 5.7% ≥4 exacerbations during the 2 years study period. Patients with ≥1 comorbidity conditions more often had ≥2 exacerbations per year compared to patients without comorbidity (5.9% vs 4.0%, P<0.001). Patients with another chronic respiratory disease next to their COPD, (n=2,188, 13.3%) more often had ≥2 exacerbation per year compared to patients without respiratory comorbidity (7.3% vs 5.4%, P<0.001). Table 1 shows the results for other ICPC categories.

Conclusion: Chronic comorbidity is highly prevalent in COPD patients in general practice. Primary care patients with more comorbidities seem to experience more exacerbations.

Declaration of Interest: This study was funded by GlaxoSmithKline.

Corresponding Author: Tjard Schermer, Email: tjard.schermer@radboudumc.nl

Table 1. Prevalence of comorbidity in COPD patients by ICPC category and frequency of patients with ≥2 exacerbations per year

<table>
<thead>
<tr>
<th>Comorbidity category</th>
<th>Total COPD patients, n (%)</th>
<th>Patients with ≥2 exacerbations/year, n (%)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>9606 (59.0)</td>
<td>593 (61)</td>
<td>0.006</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>4078 (24.8)</td>
<td>264 (6.5)</td>
<td>0.014</td>
</tr>
<tr>
<td>Mental Health</td>
<td>2635 (16.0)</td>
<td>188 (7.1)</td>
<td>0.001</td>
</tr>
<tr>
<td>Eye and Ear</td>
<td>3484 (13.3)</td>
<td>242 (6.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Urogenital (male and female)</td>
<td>2635 (9.5)</td>
<td>194 (7.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Respiratory (excl. pulmonary cancer)</td>
<td>2188 (13.3)</td>
<td>160 (7.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Skin</td>
<td>1561 (9.5)</td>
<td>87 (5.6)</td>
<td>0.867</td>
</tr>
<tr>
<td>Digestive</td>
<td>3150 (19.2)</td>
<td>215 (6.8)</td>
<td>0.002</td>
</tr>
<tr>
<td>Endocrine, metabolic and feeding</td>
<td>5483 (33.4)</td>
<td>305 (5.6)</td>
<td>0.596</td>
</tr>
<tr>
<td>Neurological</td>
<td>483 (2.9)</td>
<td>24 (5.0)</td>
<td>0.483</td>
</tr>
<tr>
<td>Blood (forming organs) and Lymphatics</td>
<td>128 (0.8)</td>
<td>10 (7.8)</td>
<td>0.300</td>
</tr>
<tr>
<td>Infectious</td>
<td>102 (15.4)</td>
<td>8 (7.8)</td>
<td>0.348</td>
</tr>
<tr>
<td>Non-pulmonary cancer</td>
<td>2528 (15.4)</td>
<td>140 (5.5)</td>
<td>0.706</td>
</tr>
<tr>
<td>Pulmonary cancer</td>
<td>389 (2.4)</td>
<td>37 (9.5)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

* P-values displayed are calculated for the difference between the subgroup of patients with specific comorbidity versus those without comorbidity. We performed Chi-square tests for categorized variables. P-values < 0.05 were considered statistically significant.

npj Primary Care Respiratory Medicine (2016) 16022
© 2016 Primary Care Respiratory Society UK/Macmillan Publishers Limited
CR021
Telehealthcare interventions in the management of obstructive sleep apnoea hypopnoea syndrome (OSAHS) - a systematic review
Phyllis Murphie¹, Stuart Little¹, Hilary Pinnock², Brian McKinstry²
¹NHS Dumfries and Galloway, UK, ²Edinburgh University, UK

Aim: Telehealthcare solutions potentially offer an option for reviewing people with Obstructive sleep apnoea hypoxia syndrome (OSAHS) using Continuous positive airway pressure (CPAP) therapy living remotely to their main sleep medicine centre. We aimed to identify and systematically review the evidence for the effectiveness of telehealthcare CPAP review versus face-to-face care in any healthcare setting.

Method: We systematically searched 11 electronic databases, scanned reference lists of included studies, (English language only), plus manual journal searches for clinical trials of telehealthcare for reviewing CPAP users. Two researchers selected, quality appraised and extracted data. Outcomes of interest were adherence to CPAP, subjective sleep, patient/clinician satisfaction, and cost effectiveness. We undertook a narrative analysis because of heterogeneity of outcomes.

Results: From 363 potentially relevant papers we identified 5 trials (total 224 patients) that met our inclusion criteria. The trials were small at moderate/high risk of bias; the largest randomised 114 patients. Adherence was measured as number of hours used/night (n = 3) or proportion using > 4 hours/night (n = 2). Telemonitoring (TM) improved adherence to CPAP compared to usual care (UC) in x /5 trials. There was no difference in the Epworth Sleepiness score (n = 2) trials. 4/5 trials reported similar levels of satisfaction with the clinical review. 2/2 trials reported significant cost reductions with TM compared to UC. 4/5 used teleconsultation and/or telephone consultation and telemonitoring and 1 used teleconsultation with monitoring of adherence at each virtual visit by a study nurse.

Conclusion: A telehealthcare model of clinical review in CPAP user’s shows promise as a cost effective and acceptable model of care, which improved adherence to CPAP therapy, but not subjective sleepiness measured by the Epworth sleepiness scale. However the evidence is limited to 5 small, generally poor quality studies. Fully-powered, well designed studies are required to demonstrate clinical and cost effectiveness of using available technologies for people living remotely to access specialist sleep services.

Declaration of Interest: None
Corresponding Author: Phyllis Murphie,
Email: phyllis.murphie@nhs.net

CR022
What are the most common respiratory diseases encountered in clinical practice? Results of a pilot study in 737 Indian patients
Komalkirti Apte¹, Madhuragauri Shevade¹, Sapna Madas¹, Sushma Jadhav¹, Sundeept Salvi¹
¹Chest Research Foundation, Pune, India

Aim: We have previously reported that respiratory diseases are the most common diseases for which a patient visits a doctor in India. A better understanding of the respiratory disease pattern and respiratory symptoms will help determine the appropriate health care management strategies and set up the necessary health care services. This pilot study was aimed to investigate the respiratory symptoms and the most common respiratory diseases for which a patient visits a doctor in India.

Method: A total of 1560 Pulmonologists, Internists and Paediatricians from our database were invited to participate in this 7-day study across India. The study questionnaire based on ICD-10 classification captured patients’ demographics, smoking and biomass exposure history along with respiratory symptoms and disease diagnoses. 10 doctors consented and completed the study and provided data of 737 patients of respiratory diseases. Simple descriptive analysis was performed.

Results: 63% patients (mean age 43.6±18.5 yrs; M: 58.9%) presented to the doctors for chronic respiratory diseases (CRD). The most common CRDs were Chronic Obstructive Pulmonary Disease (COPD) (29.6%), Tuberculosis (TB) (23%), Asthma (22.5%) and Allergic Rhinitis (8.4%). Table 1 provides a specialty-wise prevalence of the top CRDs.

Conclusion: Chronic respiratory diseases namely COPD, Asthma, Tuberculosis and Allergic Rhinitis, are the most common reasons for a doctor visit by patients with Respiratory diseases.

CR023
Patient experiences of using a digital health intervention in COPD (EDGE): a qualitative study
Veronika Williams¹, Lionel Tarassenko¹, Andrew Farmer¹
¹University of Oxford, UK

Aim: Digital health applications are increasingly seen as a way to bridge the gap between professional care and patient self-management. We aimed to explore patients’ experiences of how they incorporated an internet-linked tablet computer based digital health intervention (EDGE) for COPD into their everyday lives using qualitative methods.

Method: The data presented here were part of a qualitative interview study nested within a randomised clinical trial (EDGE COPD). Interview participants were purposefully recruited from the trial sample and interviewed before receiving the intervention and after the 12 month follow up was completed. We used a modified grounded theory approach to collect and analyse data. We then compared findings to those of a recently published conceptual framework (1) assessing implementability of telehealth interventions to explore fit and identify any divergences.

Results: Twenty-five participants with moderate to severe COPD took part in the interview study, of whom 23 (nine women) completed both the initial and follow up interview. Findings were broadly in agreement with the previously identified concepts of ‘fit’, ‘visibility’ and ‘relationships’. However, existing co-morbidities created tension in terms of self-management priorities and thus the intervention was less of a fit for these patients. In addition, for those patients who experienced relatively stable symptoms, the idea of ‘visibility’ was perceived as less beneficial compared to those with great variation in their monitoring data.

Conclusion: Patients living with co-morbidity or stable symptoms perceived the digital health intervention less beneficial and reported reduced engagement within their everyday lives. The conceptual framework we used proved useful in identifying how this intervention is incorporated in day-to-day life and self-management. We need to further explore areas where experiences do not fit established implementation frameworks to further develop our approaches and ensure digital health interventions can be implemented in the most effective way.

Declaration of Interest: None. ISRCTN: ISRCTN40367841 DOI 10.1186/ISRCTN40367841
Corresponding Author: Veronika Williams,
Email: veronika.williams@phc.ox.ac.uk

Reference
CR024
Self-management support using an Internet-linked tablet computer based intervention in chronic obstructive pulmonary disease (EDGE): randomised controlled trial
Andrew Farmer1, Veronika Williams1, Carmelo Velardo1, Syed Ahmar Shah1, Ly-Mee Yu1, Heather Rutter2, Louise Jones1, Carl Heneghan1, Jonathan Price1, Maxine Hardinge3, Lionel Tarassenko1
1University of Oxford, UK, 2Oxford Health NHS Foundation Trust, UK, 3Oxford University Hospitals NHS Foundation Trust, UK

Aim: We conducted a randomised controlled trial of an affordable Internet-linked tablet computer (EDGE) based digital health intervention for monitoring and self-management support in community based people with moderate to very severe chronic obstructive pulmonary disease (COPD). (1)

Method: Participants were recruited from respiratory outpatient clinics, pulmonary rehabilitation courses, and primary care and community clinics. Participants used the EDGE intervention daily to complete a symptom diary and record oxygen saturation and pulse with a Bluetooth linked pulse oximeter. We compared use of EDGE with usual care for twelve months. The primary outcome was the St. George's Respiratory Questionnaire for COPD (SGRQ-C). 166 patients were randomised (110 EDGE, 56 usual care). All patients were included in an intention to treat analysis.

Results: The estimated difference in SGRQ-C at twelve months (EDGE - usual care) was -1.7 with a 95% confidence interval of -6.6 to 3.2 (P=0.49). The relative risk of hospital admission for EDGE was 0.83 (0.56 to 1.24, P=0.37) compared to usual care. Generic health status (EQ-5D) between the groups differed significantly with better health status for the EDGE group (0.076, 95% CI: 0.008, 0.14, P=0.0025). The median number of visits by general practitioners for EDGE vs. usual care respectively were 4 vs. 5.5, (P=0.062) and by practice nurses 1.5 vs. 2.5 (P=0.033).

Conclusion: Although this clinical trial does not provide evidence for an effect from EDGE on COPD specific health status, there may be an overall benefit in generic health status. The findings confirm acceptability and feasibility previously found in pilot work (2,3). If an intervention with the effect sizes for reduced hospital admissions and primary care visits of the magnitude reported in this trial were implemented at scale it would make an important contribution to monitoring and self-management support for people with moderate to very severe COPD.

Trial registration number: ISRCTN40367841.

Declaration of Interest: None

Corresponding Author: Andrew Farmer, Email: andrew.farmer@phc.ox.ac.uk

References

CR025
Are COPD outcomes different in patients who have also been diagnosed with asthma? A real-life UK cohort study
David Culliford1, Matt Johnson1, Lynn Josephs1, Mike Thomas1
1University of Southampton, UK

Aim: To assess whether those also diagnosed with asthma within a UK primary care COPD cohort have different outcomes and demographic characteristics compared to those without.

Method: A retrospective observational study, using individual patient-anonymised routine data in the Hampshire Health Record Analysis Database containing linked primary and secondary care clinical data for around 1.4 million patients in Hampshire, UK. Clinical terms (Read codes) were used to identify a cohort with prevalent COPD as at 31/12/2010. Patients were categorised by smoking status, age, sex and body mass index (BMI) and by a range of comorbid conditions, including asthma. All-cause mortality, respiratory-cause unplanned hospital admissions and respiratory-cause Accident and Emergency department (A+E) attendances were the outcomes recorded over a 3-year period (2011-13). Logistic regression was used to estimate odds ratios (ORs) for each outcome, adjusting for potential confounders and testing for interactions between asthma and the main demographic variables.

Results: Of a total of 16479 COPD patients (53.7% men, mean age 70.1 years), 7858 (47.7%) also had a diagnosis of asthma at some time in the medical record. The presence of an asthma diagnosis had a statistically significant and positive association with hospital admission (OR 1.218, 95% CI:1.124-1.319, P < 0.001) and with A+E attendance (OR 1.277, CI:1.106-1.361, P < 0.001), but not with death (OR 0.924, CI:0.843-1.013, P=0.094). After adjusting for age, gender, BMI, smoking status, area deprivation and comorbidities, these relationships were maintained (respectively ORs 1.208, 1.215, 1.013, P < 0.001, P=0.002, P=0.520).

Conclusion: Almost half of all patients diagnosed with COPD in a large primary care cohort also had a diagnosis of asthma made at some point. Those with an asthma diagnosis were over 20% more likely to be admitted to hospital or to attend A+E as an emergency, even when potential confounders were allowed for.

Declaration of Interest: None.

Corresponding Author: David Culliford, Email: djc202@soton.ac.uk

CR026
Systematic overview of supported self-management for asthma: a healthcare service perspective
Luke Daines1, Maria Panagioti2, Hannah Parke3, Gemma Pearce4, Eleni Epiphaniou5, Stephanie Taylor3, Hilary Pinnock1
1University of Edinburgh, UK, 2University of Manchester, UK, 3Queen Mary University of London, UK, 4Coventry University, UK

Aim: Implementation of self-management as a routine component of proactive asthma care is a challenge for healthcare services. Our systematic overview synthesised evidence from systematic reviews of supported asthma self-management to inform policy makers and healthcare providers. Key questions were: Does supported self-management improve health outcomes? Which components, and which contextual factors influence effectiveness? Is it cost effective?

Method: We synthesised two parallel programmes of work, both followed Cochrane methodology. The Practical Systematic Review of Self-Management Support (PRISMS) searched for systematic reviews and randomised controlled trials (RCTs) since the last search date of included reviews. Reducing Care Utilisation through Self-management Interventions (RECURSIVE) completed a meta-analysis of RCTs reporting health economic outcomes. Existing searches were updated in March and September 2015 respectively.

Results: PRISMS included 25 systematic reviews and 14 RCTs; RECURSIVE included 26 RCTs. Supported self-management reduces hospitalisations (in 5/11 reviews), A&E attendances (in 7/9 reviews) and unscheduled consultations (in 6/8 reviews), and improves markers of control for people with asthma (in 5/9 reviews). Core components are patient education, provision of a personal asthma action plan and supported by regular review. Tailoring content and mode of delivery to cultural, clinical and demographic groups is crucial. Self-management interventions are associated with significant decreases in hospitalisation costs. Total healthcare costs are similar to usual care.

Conclusion: Supported self-management for asthma is a cost effective intervention that reduces unscheduled care, and improves asthma control. In order to implement optimal self-management, healthcare providers should take responsibility for providing the necessary skills training for professionals,
and ensuring that the healthcare system values and embeds self-management support.

**Declaration of Interest:** NIHR Health Service and Delivery Research. LD is supported by a Clinical Academic Fellowship from the Scottish Primary Care Research Network.

**Corresponding Author:** Luke Daines, Email: luke.daines@ed.ac.uk

---

**CR027**  
**Evaluation of indoor air pollution and prevalence of COPD among highlanders in Kyrgyzstan**

Aizhamal Tabysheva, Bermet Estebesova, Meerim Akmatalieva, Maarmed Mademilov, Ulan Sheraliev, Talant Sooronbaev

**1National Centre of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan**

**Aim:** Evaluation the level of indoor air pollution and the frequency of COPD among highlanders in Kyrgyzstan.

**Method:** To determine the indoor air pollution we studied the level of respirable particles PM2.5 in the air in 37 houses on the Akskai high altitude plateau located 3200-3800 meters above sea level using special equipment TSI SidePak AMS10 Personal Aerosol Monitor. To estimate respiratory function we performed spirometry with bronchodilation test (salbutamol 200mg/kg) and using NDD EasyOne TM Spirometer, which was approved by the ATS in terms of quality measurement and suitability for field use Pre - and post bronchodilation FVC, FEV1, FEV1 / FVC 70% was evaluated. COPD was defined according to the GOLD criteria.

**Results:** All mountaineers use biomass for cooking and heating in all the 37 houses that we have investigated. We found high levels of indoor air pollution in houses of highlanders, and it was confirmed by the high values of respirable particles PM2.5 in the air in these houses. Thus, the maximum value of the respirable particles PM2.5 (Maxm g /m3) was 7.03 ± 1.14. The average value PM2.5 (Avgmg/m 3) - 0.289 ± 0.066, and TWA (8hr) was 0.169 ± 0.037. Importantly, that we also found higher values of carbon monoxide (COppm) - 1.5 ±0.11. We found a strong association of indoor air pollution with a frequency of COPD, in this way COPD I detected in 9.7% (n=6), COPD II in 8% (n=5) patients.

**Conclusion:** The results demonstrate that in the houses of the inhabitants of the highlands of Kyrgyzstan has a high level of indoor air pollution and it can be cause of high prevalence of COPD.

**Declaration of Interest:** None

**Corresponding Author:** Aizhamal Tabysheva, Email: ajimono@mail.ru

---

**CR028**  
**Once-daily tiotropium add-on to at least ICS improves control and reduces exacerbation risk in symptomatic asthma, independent of serum IgE or blood eosinophils**

Mike Thomas, Johann Christian Virchow, Mark Vandewalker, Michael Engel, Petra Moroni-Zentgraf, Reinhold Luehmann, Thomas Casale

**1University of Southampton, UK, 2University Clinic Rostock, Germany, 3Clinical Research of the Ozarks, Springfield, Missouri, USA, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, 5University of South Florida Morsani College of Medicine, Tampa, Florida, USA**

**Aim:** Once-daily tiotropium (via the Respimat soft-mist device) add-on to ICS ± other maintenance therapies improves asthma symptom control and reduces risk of severe exacerbations and asthma worsening in adults with symptomatic asthma, independent of serum IgE or blood eosinophil cut-offs in conventional subgroup analyses. We assessed asthma control and exacerbation risk across a continuous range of IgE and eosinophil values following tiotropium add-on therapy.

**Method:** Four Phase III double-blind, placebo-controlled, parallel-group trials: PrimoTinA (two 48-week trials; NCT00776984/NCT00772538; n=912), once-daily tiotropium 5 μg or placebo (via Respimat) add-on to ICS (≥800 μg budesonide or equivalent)+LABA; MezzoTinA (two 24-week trials; NCT01172808/NCT01172821; n=2100), once-daily tiotropium 5 μg or 2.5 μg (via Respimat), twice-daily salmeterol 50 μg (via HFA-MDI) or placebo (double-dummy protocol) add-on to ICS (400-800 μg budesonide or equivalent). Patients had symptomatic asthma requiring at least ICS for ≥4 weeks before screening, COPD was excluded. Post hoc logistic regression modelling analyses of ACQ-7 responder rate and post hoc Cox regression modelling of severe exacerbations and asthma worsening were performed across continuous ranges of IgE (2-2000 μg/L) and eosinophils (0.05-2.00 × 109/L) following tiotropium or salmeterol (MezzoTinA only) therapy.

**Results:** Tiotropium consistently improved ACQ-7 responder rate versus placebo across IgE and eosinophil ranges (odds ratio [OR] ≥1). Salmeterol improved ACQ-7 responder rate versus placebo across IgE levels (OR ≥1), and with eosinophils, as levels increased, ACQ-7 responder rate OR decreased (9/L). Generally, both tiotropium and salmeterol reduced the risk of severe exacerbations and asthma worsening at all levels of IgE and eosinophils versus placebo (hazard ratio <1).

**Conclusion:** Once-daily tiotropium add-on to ICS ± other maintenance therapies improved asthma symptom control and reduced exacerbation risk in patients with moderate or severe symptomatic asthma, across IgE and eosinophil ranges.

**Declaration of Interest:** Trial funded by Boehringer Ingelheim. Editorial assistance provided by Complete HealthVizion.

**Corresponding Author:** Mike Thomas, Email: D.M.Thomas@soton.ac.uk
Rapid assessment of the demand and supply of tobacco dependence pharmacotherapy in Uganda

Rupert Jones, Bruce Kirenga, Sian Williams

1Plymouth University, UK, 2Makerere University College of Health Sciences, Kampala, Uganda, 3IPCRG

Aim: Among inpatients with a tobacco attributable disease (TAD) at a tertiary hospital in Uganda, we aimed to determine the prevalence of current smoking and the willingness of smokers to quit and pay for tobacco dependency pharmacotherapy (TDP). To explore the supply of TDP drugs through a survey of pharmacies licensed to import medicines and whether costs is a barrier to their use.

Method: Two elements - demand for and supply of treatment. Demand for treatment was measured in patients admitted in Mulago Hospital with TAD by medical officers using a questionnaire on smoking (status, duration and products smoked) and willingness to quit and pay for TDP. The availability of TDP in pharmacies was assessed in terms of the types of TDP and their cost.

Results: We interviewed 56 patients (71% male; mean age was 57.5 years (SD 16.4). 23 patients (41%) were hospitalized with COPD, 8 for stroke (14%), 8 (14%) for cardiovascular disease, 7 (13%) for asthma, 7 (13%) for diabetes and 3 (5%) for lung cancer. Thirty-five of the 56 patients (63%) interviewed were current smokers, 24 current smokers (43%) desired to quit and 10 (18%) were willing and able to pay for TDP. Of the 38 pharmacies surveyed, one was public and one was private not for profit and 36 were private. Only seven (18%) pharmacies had at least one NRT (gum, lozenge or spray), 3 (7.8%) had bupropion and one (2.6%) had nortriptyline. The mean cost for a monthly dose of an NRT was 15.7 US dollars (USD) while that for bupropion was 17.1 USD.

CR030

Table 1. Availability of negative comments on recommendations and questions from the survey on 12 recommendations of standards of care for COPD. Survey and analysis performed by YouGov in March/April 2015 for the European COPD Coalition (ECC).

| Cost/resources/not cost effective | 15% |
| Need to examine each individual case/different patients have different needs | 10% |
| All patients should have spirometry tests/gold standard diagnostics should always be used | 9% |
| People who smoke do so of their own free will/should not pay for this | 6% |
| Patient has to be motivated/have to want to help themselves/will power | 6% |
| Should already be occurring/already available at pharmacies/GPs | 6% |
| Not effective/helpful | 6% |
| Patients with COPD are almost always active smokers/smoking is the key issue | 4% |
| Too complicated/not meaningful | 4% |
| Wrong focus/way of addressing it | 3% |
| Unnecessary | 3% |

CR031

Defining and testing recommendations for COPD care to improve value

Sian Williams, Catherine Hartmann

1European COPD Coalition (ECC), Brussels, Belgium

Aim: COPD is estimated to affect up to 10% of the European population and presents a significant burden for patients and health care systems [1]. Yet standard measures to halt its development and to deliver high value care for patients are not widely shared or implemented. To review available COPD guidelines, frameworks and emerging measures to identify recommendations for care and test their acceptability with patients and healthcare professionals (HCPs). [1] European Lung White Book (ERS), Chronic Obstructive Pulmonary Disease, Key Points, 2012.

Method: In August 2014 we undertook a literature review of national and regional COPD guidelines, research studies and programme evaluations, generated recommendations and then commissioned YouGov to test their acceptability in 5 countries using a quantitative online survey.

Results: We identified 44 COPD guidelines, strategies and studies from which we generated 12 recommendations for high value care: 1. Help smokers quit using evidence-based treatment; 2. Control occupational exposure to dusts, chemicals and smoke; 3. Perform earlier targeted COPD diagnosis; 4. Confirm COPD diagnoses with spirometry; 5. Promote whole system implementation; 6. Develop co-ordinated multidisciplinary approaches; 7. Provide necessary COPD training and support; 8. Acknowledge central role of patient and carer and educate them; 9. Agree a personalised management plan with every person with COPD; 10. Vaccinate staff and patients against flu, provide pulmonary rehabilitation and oxygen services to those who will benefit; 11. Treat the whole person addressing comorbidities including mental health 12. Encourage responsible prescribing to optimise value. 1020 people were surveyed. All recommendations had over 80% of respondents’ support; agreement was slightly higher in patients than HCPs. Agreement was highest in Spain, Poland. Base: all: 1,020: patients: 515/HCPs: 505- Countries surveyed: UK, France, Germany, Spain, Poland. Rec.: recommendations; HCPs: healthcare professionals; GPs: general practitioner.

Conclusion: We offer 12 recommendations that give policymakers, patients, payors and providers the basis for high value services to reduce the COPD burden.

CR032

A systematic review of the explanatory factors enhancing the adoption of asthma self-management behaviour in the South Asian and black population

Salina Ahmed, Stephanie JC Taylor, Hilary Pinnock, Liz Steed

1Queen Mary University, London, UK, 2University of Edinburgh, UK

Aim: UK born South Asians suffer poorer asthma outcomes and have a higher emergency hospital admissions rate than the majority White population.
Table 2. Overall findings of survey on 12 recommendations of standards of care for COPD Survey and analysis performed by YouGov in March/April 2015 for the European COPD Coalition (ECC)

<table>
<thead>
<tr>
<th>12 recommendations</th>
<th>Overall support (in %)</th>
<th>HCPs (in %)</th>
<th>Patients (in %)</th>
<th>Country with highest approval rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rec. 1: All patients who smoke should be helped to quit using evidence-based interventions</td>
<td>-</td>
<td>87</td>
<td>85</td>
<td>Poland</td>
</tr>
<tr>
<td>Rec. 2: Control occupational exposure to dusts and chemicals and second hand smoke</td>
<td>-</td>
<td>92</td>
<td>90</td>
<td>UK</td>
</tr>
<tr>
<td>Rec. 3: Encouraging earlier diagnosis of COPD by implementing targeted screening, including early detection of Alpha1</td>
<td>-</td>
<td>85</td>
<td>81</td>
<td>Germany</td>
</tr>
<tr>
<td>Rec. 4: Ensuring that COPD diagnoses are confirmed with a spirometry test, where spirometry is available</td>
<td>-</td>
<td>89</td>
<td>90</td>
<td>Poland</td>
</tr>
<tr>
<td>Rec. 5: Promoting effective implementation of the national guidelines at all level of care</td>
<td>-</td>
<td>89</td>
<td>88</td>
<td>Poland</td>
</tr>
<tr>
<td>Rec. 6: Developing COPD programmes and plans for the prevention and care of COPD</td>
<td>-</td>
<td>88</td>
<td>87</td>
<td>Poland</td>
</tr>
<tr>
<td>Rec. 7: Ensuring that HCPs have the necessary training, skills and support to deliver quality care and good health outcomes</td>
<td>-</td>
<td>94</td>
<td>94</td>
<td>Poland</td>
</tr>
<tr>
<td>Rec. 8: Recognising the central role the patient and his/her carer in the management and treatment of COPD</td>
<td>-</td>
<td>92</td>
<td>91</td>
<td>Poland/UK</td>
</tr>
<tr>
<td>Rec. 9: Developing a personalised care management plan with all people with COPD</td>
<td>-</td>
<td>91</td>
<td>89</td>
<td>Poland</td>
</tr>
<tr>
<td>Rec. 10: Rehabilitation and oxygen services should be made available to all those who would benefit</td>
<td>-</td>
<td>92</td>
<td>90</td>
<td>Poland</td>
</tr>
<tr>
<td>Rec. 11: Recognising the complex nature of COPD care by treating patients with COPD as “whole person” including their mental health</td>
<td>-</td>
<td>90</td>
<td>87</td>
<td>Poland</td>
</tr>
<tr>
<td>Rec. 12: Encouraging responsible prescribing to optimise the use of medicines, improve health outcomes, and reduce waste</td>
<td>-</td>
<td>89</td>
<td>88</td>
<td>Poland</td>
</tr>
</tbody>
</table>

Base: All 1,020 patients: S15/HCPs: 505– Countries surveyed: UK, France, Germany, Spain, Poland. Rec.: recommendations; HCPs: healthcare professionals.

Possible reasons for these ethnic differences may be that self-management strategies either have been insufficient for their needs or have not been implemented in the first place [1]. This review aims to identify key barriers and facilitators to implementing self-management in ethnic groups and define the essential components of culturally tailored asthma interventions.

Method: We systematically searched eight electronic databases, research registers, manually searched journals and reference lists of identified systematic reviews for randomised control trials of asthma self-management in South Asian and Black populations. We extracted data on study characteristics, theoretical domains framework, barriers and facilitators, key components of interventions and outcome measures including process measures (e.g. self-efficacy), asthma control measures (e.g. health service use) and objective/validated behavioural measures (e.g. adherence).

Results: 17 studies (8 South Asian, 9 African-American) were included in the final analysis and a narrative synthesis was conducted. Only one intervention was found to be culturally tailored [2], compared to 16 culturally modified interventions. Further, there were various ethnic and minority-specific barriers and facilitators identified. Early narrative analysis of South Asian trials suggest significant impact on several self-management outcomes (e.g. knowledge) and mixed findings for other outcomes (e.g. unscheduled care).

Conclusion: There is a lack of evidence around culturally tailored interventions (as opposed to modified interventions). Early analysis suggests variable benefit on self-management outcomes. Further analysis will identify those associated with effective outcomes for qualitative exploration.

Declaration of Interest: This research project is funded by Asthma UK Centre for Applied Research.

Corresponding Author: Salina Ahmed, Email: salina.ahmed@qmul.ac.uk

References

CR033
The use of mobile technology to support self-management for people with asthma: a systematic review
Chi Yan Hui, Hilary Pinnock, Robert Walton, Brian McKinstry, Tracy Jackson
1The University of Edinburgh, UK, 2Barts and The London School of Medicine and Dentistry, UK

Aim: We aimed to systematically review randomised controlled trials (RCTs) of technology-supported self-management in adults/teenagers with asthma to assess clinical effectiveness, and identify features associated with improved adoption of, and adherence to the technology.

Method: We systematically searched nine databases, scanned reference lists, and undertook manual searches. We assessed all eligible papers for quality, and synthesised data on health outcomes (e.g. asthma control questionnaire and/or exacerbation rate), process or intermediate outcomes (e.g. adherence with monitoring or treatment, self-efficacy), level of adoption of and adherence to the intervention.

Results: We included 11 RCTs (published January 2000 –January 2015). The effect on health outcomes varied, but there were no examples of harm. No interventions explicitly reported the adoption of and adherence to the technology system by patients and healthcare professionals. Interventions included 10 common features, which we grouped into seven categories (education, monitoring and electronic diary, action plans, reminders or prompts to promote medication adherence, professional support for patients, raising patient awareness of asthma control, and supporting the healthcare professional) which had variable impact on process and health outcomes.

Mobile technology, including an electronic diary and action plan, and incorporating education and professional support improved asthma control.

Conclusion: Mobile technology has the potential to support asthma self-management, but further studies evaluating the features associated with improved adoption of and adherence to mobile technology are needed.

Declaration of Interest: None

Corresponding Author: Chi Yan Hui, Email: io.hui@ed.ac.uk
CR034
Primary care of the patient with chronic obstructive pulmonary disease in rural province, Vietnam
Quynh Nguyen Nhat1, An Pham1, Vinh Nguyen1
1University of Medicine and Pharmacy, Hochiminh City, Vietnam

Aim: The aim of this survey was to investigate guideline-compliant COPD management among primary care physicians (PCPs) in rural province.

Method: One hundred PCPs from 11 district-level sub divisions in Tien Giang province (8 districts, 2 district-level town and 1 provincial town) involved in survey by using the set of multiple-choice questionnaire that focused on the key aspects international COPD guidelines (GOLD 2015).

Results: Several important disparity from the guidelines were remarked. In rural area, no PCPs performed spirometry themselves and about 10% of the COPD diagnosis confirmed by using spirometry. For treatment of new COPD patients, most of PCPs prescribed inhaled short-acting β2-agonists (SABA) (41%), followed by oral SABA (37%) and oral corticosteroids (31%), further by inhaled corticosteroids (ICS) (25%) and ICS/LABA or the combination of a SABA and a short acting anticholinergic (22%). 32% PCPs indicated ICS to all COPD patients and only 16% of them used ICS with correct indication guided by GOLD. In acute exacerbation, systemic steroids were used by 38% PCPs, followed closely by theophylline (37%) and increased dose of bronchodilators (34%), only 12% PCPs prescribed antibiotics during exacerbation. In smoking cessation, 68% PCPs offered a structured programme to all COPD patients and 49% of them using brief and single advice to educate.

Conclusion: The survey showed a large discrepancy between practice and GOLD COPD guidelines in rural area. COPD diagnosed by spirometry was still low in PCPs’ practical sites. Guideline compliant COPD among PCPs in our sample was still low than our expectation also the same picture with given structure program of cessation smoking and the consultation for COPD. These specific deviations from the guidelines will be addressed in a second phase implementation project.

Declaration of Interest: None
Corresponding Author: Quynh Nguyen Nhat,
Email: nhatquynh13787@gmail.com

CR035
PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term – A Cluster Randomised Controlled Trial
Steven Julious1, Michelle Horspool1,2
1University of Sheffield, UK, 2NHS Sheffield Clinical Commissioning Group, UK

Aim: Asthma episodes and deaths are known to be seasonal. A number of reports have shown peaks in asthma episodes in school-aged children associated with the return to school following the summer vacation. A drop in prescription collection in August has been observed which is associated with an increase in the number of unscheduled medical contacts after the return to school in September. The aim of the study was to assess if an NHS delivered public health intervention reduced the number of unscheduled medical contacts after the school return in September.

Method: Cluster randomised trial with health economic analysis. Setting: Primary care. Participants: School aged children aged 5-16 with asthma.
Interventions: A letter sent, from the GP to parents/carers of school-aged children with asthma, prior to the start of school summer holidays, reminding them of the importance of taking their medication and to ensure they have sufficient medication prior to the start of the new school year (September). The control group received usual care. The primary outcome was proportion of children aged 5-16 who had an unscheduled contact in September 2013 after the return to school. Supporting endpoints include the proportion of children who collected prescriptions in August 2013 and unscheduled contacts through the following 12 months.

Results: In terms of unscheduled contacts in September there is no evidence of effect. Among children aged 5-16 the odds-ratio was 1.11 (95% CI 0.97 to 1.27) against the intervention. The intervention did increase the proportion of children collecting a prescription in August (odds-ratio 1.46; 95% CI 1.29 to 1.66) as well as scheduled contacts in the same month. For the wider time intervals (Sep-Dec 2013 and Sep-Aug 2014) there is weak evidence of the intervention reducing contacts. The economic analysis estimated a high probability that the intervention was cost saving. There was no increase in quality-adjusted life-years.

Conclusion: The intervention did not reduce unscheduled care in September although it succeeded in increasing the proportion of children collecting prescriptions as well as increasing scheduled contacts in August. After September there is weak evidence in favour of the intervention. The intervention had a favourable impact on costs but did not demonstrate any impact on quality-adjusted life-years. The intervention could be implemented to pneumococcal pneumonia are immunocompromised, kidney disease, liver disease, respiratory disease, chronic cardiovascular disease, autoimmune, diabetes, HIV, transplanted solid organ and / or hematopoietic progenitors in waiting for solid organ transplant, receiving chemotherapy, corticoids, immune-suppressants, biological, anatomical or functional asplenia. In our awaiting for solid organ transplant, receiving chemotherapy, corticoids, immune-suppressants, biological, anatomical or functional asplenia. In our

### Validation of the ‘Control of allergic rhinitis and asthma test’ (CARAT) 1-week version and app

Corina de Jong1, Bertine Flokstra-de Blok1, Jorn de Kroon1, Ellen van Heijst1, Tsiligianni Ioanna1,2, Fonseca Joao3, Thys van der Molen1

1University Medical Center Groningen, The Netherlands, 2University of Crete, Greece, 3Faculdade de Medicina da Universidade do Porto, Porto, Portugal

**Aim:** Asthma and allergic rhinitis often occur together. The CARAT was designed to assess asthma and rhinitis control, covering a 4 week period, using paper-and-pencil. This study aimed at validating both the 1-week version (1wCARAT) and the digital CARATapp.

**Method:** Once a week for 4 weeks the 1wCARAT and 1wCARATapp were completed by asthma patients. At baseline also the Asthma Control Questionnaire (ACQ), Visual Analog Scale (VAS), General Initiative for Asthma (GINA) assessment and the Allergic Rhinitis And Its Impact On Asthma (ARIA) assessment were completed. At final visit the 4wCARAT and app-satisfaction questionnaire were completed. Internal consistency was analysed using Cronbach’s alpha, test-retest reliability of 1wCARAT and CARATapp using Spearman’s correlation, relation between 4wCARAT and 1wCARAT (mean of 4 measurements) as well as Cronbach’s alpha, test-retest reliability of 1wCARAT and CARATapp using Spearman’s correlation, relation between 4wCARAT and 1wCARAT (mean of 4 measurements) as well as Spearman’s correlation between the different measuring moments were all significant (all(P<0.001; r≥0.724≤0.906) for 1wCARAT and CARATapp. No significant differences in score were found between 1wCARAT and CARATapp. 84.4% of patients found the app (very) easy to use. 41.3% prefers the app and 4.6% paper.

**Conclusion:** This final analysis indicates 1wCARAT is valid and reliable, both as paper and app version.

**Declaration of Interest:** C.d.J, BFdB, J.dK, EVH, IT, JF and TvdM report no conflicts of interest. The study was funded by unrestricted grant by AstraZeneca.

**Corresponding Author:** Corina de Jong, Email: c.de.jong02@umcg.nl

### CR037

**Comorbidities in patients with pneumococcal pneumonia**

Maria Lledo Viciano Fabregat1, Helena Molina Raga1, Enrique Mascarós Balaguer1, Lucia Ribadulla1

1GRAP, Spain

**Aim:** Pneumonia is a serious health problem among adults. It is more common in patients with certain comorbidities and it will be more severe and worst evolving processes. This disease causes 1.6 million deaths annually. It has an incidence of 14 cases per 1,000 people per year requiring hospitalization for 75% of cases. Currently we have tools to avoid these cases, the use of vaccines. There are two types; VNP23 polysaccharide vaccine (without generating immune memory); PCV13 more potent immune response. The aim of our study is to determine the association between comorbidities with the incidence of pneumococcal pneumonia and disease progression. Also, see the immunization status of each patient as directed by the consensus on the anti-pneumococcal vaccination in adults with underlying disease of 2013 and see if it meets the general population.

**Method:** The study was realized from January 2016 to April 2016 from data obtained during the year 2015 (January to December). The study includes all patients admitted to the Hospital Dr. Peset diagnosed with pneumococcal pneumonia by Orion computer system during 2015. Using the patient’s information of the health center informatic system (Abucasis) we can have their information about comorbidities and vaccine’s schedule.

**Results:** In previous studies it has been shown that comorbidities more related to pneumococcal pneumonia are immunocompromised, kidney disease, liver disease, respiratory disease, chronic cardiovascular disease, autoimmune, diabetes, HIV, transplanted solid organ and / or hematopoietic progenitors in waiting for solid organ transplant, receiving chemotherapy, corticoids, immune-suppressants, biological, anatomical or functional asplenia. In our study we analyzed the possible relation between vaccination with
comorbidities and the prevalence of developing pneumococcal pneumonia and severity of income. About vaccines we consider it especially for patients vaccinated against influenza and Pneumococcal VNP23 and PCV13.

Conclusion: Currently this study is being analyzing the data collected. Unable to get results that we hope to present at the conference.

Declaration of Interest: None

Corresponding Author: Maria Lledo Viciano Fabregat, Email: mara988@msn.com

CR038
An internet-delivered handwashing intervention to modify respiratory infection transmission (PRIMIT): sub-group analysis among COPD patients
Rachel Jordan1, Beth Stuart2, Lucy Yardley2, Peymane Adab1, Mike Thomas2, Paul Little2
1University of Birmingham, UK, 2University of Southampton, UK

Aim: An internet-delivered handwashing intervention reduced episodes of respiratory tract infection (RTI) by 25% among healthy adults in winter. Common respiratory infections are the main cause of exacerbations among COPD patients. The aim of this analysis was to evaluate the potential effectiveness of the intervention among a sub-group of patients with diagnosed COPD.

Method: 20,666 adults identified from 344 primary care practices were individually randomised to receive either access or no access to a customised tailored web-based intervention to encourage increased handwashing behaviour in the winter and followed-up for 16 weeks. The primary outcome was the number of participants reporting one or more episodes of RTI (using standard consensus definitions) at 16 weeks. Secondary outcomes included number of episodes, number of days with symptoms, severity of symptoms, and from patient records in a sub-group, health service utilisation. For this analysis, a sub-group of COPD patients was identified from GP records and multiple logistic (converted to RR) or negative binomial regression was used as appropriate, adjusting for sex, age > 65 years, ongoing health problem, skin condition, presence of children.

Results: Among 355 registered COPD patients, 187 received the intervention and 169 were controls. Based on completed questionnaires at 16 weeks (n = 297), 92 (57.5%) and 89 (65%) respectively reported one or more RTIs in the last 4 months (RR 0.88 (95%Cl 0.74, 1.05)). There was a statistically significant reduction in the number of RTIs (IRR 0.72 (0.55, 0.95)) and number of days with moderate/bad symptoms (IRR 0.70 (0.51, 0.96)). There was also a possible reduction in antibiotic use (RR 0.79 (0.54, 1.15)) and exacerbations over 12 months (IRR 0.91 (0.54, 1.53)) although the results were not statistically significant.

Conclusion: In a sub-group of COPD patients within the PRIMIT trial, the reduction in RTIs with an internet-delivered handwashing intervention was comparable to or greater than observed among healthy adults. Despite small numbers and post-hoc non-randomised analyses, there is potential to reduce exacerbations among COPD patients and further trials among this group are warranted.

Declaration of Interest: The PRIMIT study was funded by the Medical Research Council (09/800/22). There are no competing interests. ISRCTN75058295
Corresponding Author: Rachel Jordan, Email: r.e.jordan@bham.ac.uk

CR039
Valved holding chambers (VHCs): Can drug residue promote microbial growth?
Mark Sanders1, Ronald Bruin1
1Clement Clarke International Ltd, Harlow, UK

Aim: We have reported on survival of Klebsiella pneumoniae on plastic VHC-body samples (Thorax 2014,69,Suppl12,A114). The data indicated a potential value of an antimicrobial additive. We have now examined the effect of inhaled drugs on bacterial growth to better understand drug-related VHC hygiene.

Method: Drugs (salbutamol sulphate, formoterol fumarate, beclometasone dipropionate, fluticasone furoate, ciclesonide, budesonide) were dissolved in methanol, ethanol or acetone at a concentration indicative of 2 weeks’ VHC drug residue. Growth kinetics of three pathogenic respiratory microbes, Streptococcus pneumoniae (ATCC33400), K. pneumoniae (ATCC15380), or Haemophilus influenzae (ATCC19418) in two minimal media (M9 minimal salts, R2A agar) and Tryptone Soya Broth growth medium (TSB) with different solvent concentrations were measured using the automated Bioscreen-C Analyzer. Controls were growth media with/without solvent supplementation. Drug in solvent effect on bacterial growth was measured over 48 h by bacterial plate count.

Results: Solvent concentration chosen (3%) did not interfere with bacterial growth. The bacteria tested behaved differently (Table). All drugs except ciclesonide appeared to promote K.pneumoniae growth (TSB data), and appeared not to be used as a nutrient source for S.pneumoniae and H.influenzae, particularly at 24 h, less so at 48 h (M9, R2A data).

Conclusion: Our data show interesting drug-specific bacterial effects and suggest that generally drugs do not retard the growth of Gram-negative K.pneumoniae. The presence of VHC-resident bacteria in vivo is common and known (Cohen & Cohen, JAMA 2003;290:195-196). Our work suggests that if water soluble drugs (for example salbutamol) form a biofilm in the humid VHC environment bacterial growth may ensue. We do not yet know, however, if microbes aerosolize through the one-way valve and within the chamber, or the effectiveness of antimicrobial plastics in this clinical scenario. Answers to these questions may inform manufacturer and Guideline-recommended wash/ dry cycles, and therefore the relative importance of static-related performance effects versus VHC hygiene.

Declaration of Interest: Clement Clarke International Ltd. sponsored this research, and wishes to recognize the work of the Cardiff School of Pharmacy and Pharmaceutical Sciences, UK.
Corresponding Author: Mark Sanders, Email: msanders@clement-clare.com

Table 1. Log10 bacterial growth data after 24 and 48 hours incubation with drug and 3% solvent

<table>
<thead>
<tr>
<th>Drug</th>
<th>24 HOURS</th>
<th>K. pneumoniae</th>
<th>S. pneumoniae</th>
<th>H. influenzae</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>M9</td>
<td>R2A</td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td>TSB</td>
<td>4.81</td>
<td>4.26</td>
<td>3.77</td>
</tr>
<tr>
<td>salbutamol</td>
<td>8</td>
<td>1.98</td>
<td>1.54</td>
<td>3.93</td>
</tr>
<tr>
<td>formoterol</td>
<td>0.2</td>
<td>2.09</td>
<td>1.56</td>
<td>3.62</td>
</tr>
<tr>
<td>fluticasone</td>
<td>2</td>
<td>1.71</td>
<td>0.99</td>
<td>3.22</td>
</tr>
<tr>
<td>ciclesonide</td>
<td>1</td>
<td>2.07</td>
<td>1.66</td>
<td>3.14</td>
</tr>
<tr>
<td>budesonide</td>
<td>1</td>
<td>2.08</td>
<td>1.86</td>
<td>3.31</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>48 HOURS</th>
<th>K. pneumoniae</th>
<th>S. pneumoniae</th>
<th>H. influenzae</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>M9</td>
<td>R2A</td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td>TSB</td>
<td>3.77</td>
<td>3.13</td>
<td>3.22</td>
</tr>
<tr>
<td>salbutamol</td>
<td>8</td>
<td>2.31</td>
<td>1.66</td>
<td>3.75</td>
</tr>
<tr>
<td>formoterol</td>
<td>0.2</td>
<td>2.30</td>
<td>1.64</td>
<td>3.79</td>
</tr>
<tr>
<td>beclometasone</td>
<td>2</td>
<td>2.36</td>
<td>1.26</td>
<td>3.08</td>
</tr>
<tr>
<td>fluticasone</td>
<td>2</td>
<td>2.45</td>
<td>1.89</td>
<td>3.75</td>
</tr>
<tr>
<td>ciclesonide</td>
<td>1</td>
<td>2.73</td>
<td>1.62</td>
<td>3.77</td>
</tr>
<tr>
<td>budesonide</td>
<td>1</td>
<td>2.39</td>
<td>1.85</td>
<td>3.62</td>
</tr>
</tbody>
</table>

Data in solid black lines and in shaded cells represent >0.5 Log10 increase and decrease, respectively, relative to medium-only Control.
CR040
**TIQtropium Safety and Performance In Respimat**: (TIOSPIR®): Safety and efficacy in patients naïve to treatment with anticholinergics

Alan Kaplan1, Robert Wise2, Peter Calverley3, Ronald Dahl4, Daniel Duesser5, Norbert Metzendorf6, Achim Mueller7, Andy Fowler7, Antonio Anzueto8

1Family Physician Airways Group of Canada, 2Johns Hopkins University School of Medicine, Baltimore, USA, 3University of Liverpool, UK, 4Odense University Hospital, Denmark, 5Université Paris Descartes, France, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, 7Boehringer Ingelheim Ltd, Bracknell, UK, 8University of Texas, USA

**Aim**: TIOSPIR® showed similar safety and exacerbation efficacy profiles for tiotropium Respimat® and HandiHaler® in patients with chronic obstructive pulmonary disease (COPD). We present the results for patients naïve to anticholinergic treatment at baseline.

**Method**: TIOSPIR® (N = 17,135), a 2-3-year, randomized, double-blind, parallel-group, event-driven trial, compared safety and efficacy of once-daily tiotropium Respimat® 5 and 2.5 μg with HandiHaler® 18 μg in patients with COPD. Primary endpoints were time to death (noninferiority of Respimat® 5 or 2.5 μg versus HandiHaler®) and time to first COPD exacerbation (superiority of Respimat® 5 μg versus HandiHaler®); safety was assessed.

**Results**: Overall, 6,966 anticholinergic-naive patients from TIOSPIR® were randomized (n = 2,343, n = 2,312 and n = 2,309 for tiotropium Respimat® 2.5, 5 μg and HandiHaler® 18 μg, respectively). There was similar risk of death (vital status follow-up) (time to death) for the Respimat® groups versus HandiHaler® (Respimat® 5 μg: hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.75-1.17; Respimat® 2.5 μg: HR, 1.05; 95% CI, 0.84-1.30) with similar results for the on-treatment analysis (Respimat® 5 μg: HR, 0.91; 95% CI, 0.71-1.17; Respimat® 2.5 μg: HR, 1.11; 95% CI, 0.87-1.40). Risk of exacerbation was also similar for the Respimat® groups versus HandiHaler® (time to first exacerbation) (Respimat® 5 μg: HR, 0.99; 95% CI, 0.90-1.08; Respimat® 2.5 μg: HR, 1.04; 95% CI, 0.95-1.14). Risk of major adverse cardiovascular event (MACE) or fatal MACE were also similar for the Respimat® groups versus HandiHaler® (MACE: Respimat® 5 μg: HR, 1.20; 95% CI, 0.88-1.63; Respimat® 2.5 μg: HR, 1.11; 95% CI, 0.81-1.51; fatal MACE: Respimat® 5 μg: HR, 1.14; 95% CI, 0.75-1.71; Respimat® 2.5 μg: HR, 1.12; 95% CI, 0.75-1.69).

**Conclusion**: Analogous to the global analysis, patients naïve to anticholinergic treatment and treated with tiotropium Respimat® or HandiHaler® in the TIOSPIR® trial exhibited similar safety and exacerbation efficacy profiles.

**Declaration of Interest**: AK participates in advisory boards or speakers bureau for Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Meda, Merck, Novartis, Pfizer, Purdue, Takeda and Teva; Raw received grants/fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Meda, Merck, Mylan, Novartis, Pfizer, Pulmonox, Roche/Genezyme, Sanofi, Shapiro, Sunovion, Takeda, Teva, Theraexact, Verona and Vertex; PMAC received grants/fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Takeda; RD received grants/fees from Boehringer Ingelheim and Novartis; DD received grants/fees from Boehringer Ingelheim, Chiesi, Dey Pharma, Novartis, Nycomed and Pfizer; NM, AM and AF are employees of Boehringer Ingelheim; AA received grants/fees from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline and Novartis. NCT01126437

**Corresponding Author**: Alan Kaplan, Email: for4kids@gmail.com

**Reference**

Wise, et al. npj Primary Care Respiratory Medicine (2015) 25, 15067

CR041
**Asthma health and wellbeing study**

Michele Dunne, June Considine

_Asthma Society of Ireland, Dublin, Ireland_

**Aim**: The main objectives of this study were to investigate how adults perceive their health and wellbeing, explore how asthma severity affects their everyday life, investigate whether there is a relationship between both the concept of health and the wellbeing of those affected, and to distinguish how perceptions of health and perceptions of wellbeing affect one another.

**Method**: An on-line survey was used. The survey consisted of a 33-item instrument devised for the study. The study population was a convenience, self-selection sample recruited by on-line advertising. Inclusion criteria – adults (over 18yrs), who had an asthma diagnosis for 1 year or more. Demographic data were collected, with questions regarding age, gender, primary principal status etc., and multiple choice questions related to determine asthma severity in order to allow for comparisons to be drawn during data analysis.

**Results**: 339 responded, 218 were included. Female, n = 162 (76%). Age 18yrs – 64+yrs. 14 (7%) rated their health excellent, 82 (38%) rated their health good, and 15 (7%) rated their health poor. 14 (7%) reported difficulty with simple tasks, 11 (5%) reported extreme limitation with social activities. Other forms of coexisting illness were reported by 71 participants (33%), with 30 (14%) of the overall sample reporting two or more coexisting illnesses. No participants reported having Cancer, however other illnesses included depression (n = 20, 9.3%), COPD (n = 13, 6.1%), rheumatoid arthritis (n = 6, 2.8), diabetes (n = 5, 2.3%) and heart disease (n = 4, 1.9%). Sleep was the daily activity which 19 (9%) respondents felt was interfered with most as a result of their physical health, followed by recreational activities by 18 (8%). Depressive symptoms were reported as being non-existent by 84 (39%) of respondents, 12 (6%) admitting to feeling depressed ‘most of the time’, and one respondent (0.5%) reporting feeling depressed ‘all of the time’.

**Conclusion**: In conclusion, it is evident that health and wellbeing are influenced by a number of factors. This study provides an in-depth insight into how people with asthma perceive their health and wellbeing in Ireland today. Findings suggest that functional or disease status, and measurement of symptom control should not be considered as the only measure of health. Health and wellbeing should be addressed as separate, yet co-existing components in optimising the quality of life of people with asthma.

**Declaration of Interest**: None

**Corresponding Author**: Michele Dunne, Email: dunnemichele@gmail.com

CR042
**Determinants of Client’s Adherence to Public-Private Mix DOTS (PPMD) Treatment**

John Carlo Divina

Talisay District Hospital, The Philippines

**Aim**: The study aimed to determine the significant relationship between the selected predictors and adherence to PPMD treatment.

**Method**: Grounded on Pender’s Health Promotion Model, the study employed a descriptive correlational research. Anti-Tuberculosis Chemotherapy Adherence Index, consisting of a researcher-made and standardized tool, was based on literature reviewed, content was evaluated by experts and reliability was tested through Cronbach alpha. Seventy respondents (adherent and non-adherent) were selected through simple random sampling. Data was processed using Statistical Package for Social Sciences (SPSS) version 16. A discriminant analysis was conducted to predict adherence with age, educational attainment, income, sputum smear status, accessibility, co-morbidity, perceived self-efficacy, quality of health services, perceived social support, perceived social stigma, motivation, side-effects and adverse reactions to treatment as the variables.

**Results**: The discriminant analysis results presented three variables which have bearing on adherence to PPMD treatment, namely, quality of health services (F = 0.007), income (F = 0.030) and perceived social stigma (F = 0.032). Quality of health services directly affects adherence. Situational influences in the external environment can increase or decrease commitment to or participation in health-promoting behaviour such as adherence to a treatment regimen. Indirect cost of treatment may not be an issue for those with high income level but may constitute a problem for program providers since patients may intentionally drop-out from the National TB Program because they can well afford the cost of treatment while avoiding the hassle of constant follow-up to the TB DOTS unit. Perceived social stigma inversely
influences adherence. This constitute both a barrier and unfavourable environment where adherence might occur. This isolation may lead to poor follow-up in TB DOTs unit especially where the patient can be seen or identified as seeking treatment for Tuberculosis.

Conclusion: Client’s adherence to Public-Private Mix DOTs (PPMD) treatment is an interplay of healthcare delivery system and socio-economic factors.

Declaration of Interest: None

Corresponding Author: John Carlo Divina,
Email: dvynejc2000@yahoo.com

CR043
Factors associated with exacerbations, admissions and overall mortality of patients with Chronic Obstructive Pulmonary Disease (COPD) in Primary Care
Maria José Bujalance-Zafra,1 Miguel Dominguez-Santaella,1 Antonio Baca-Osorio,1 Leovigildo Giné-Mendoza,1 Francisco Jesús Fernández-Vargas,1 Rafael Poyato-Ramos1
1Servicio Andaluz de Salud, Malaga, Spain

Aim: The exacerbations of Chronic Obstructive Pulmonary Disease (COPD) have an impact both on the patient and on the health system. Factors associated with exacerbations, admissions and overall mortality of patients with COPD are analyzed in Primary Care conditions both for their early identification and for the improvement of results in health.

Method: An analytical study was carried out with retrospective and prospective cohort in exacerbated COPD patients attended/treated in the extra hospital emergency services of a Primary Care District (N = 523, 21% loss). The analysis of exacerbations (01/08/2013–31/03/2014), admissions (01/04/2013–31/03/2014), overall mortality (01/03/2014–31/03/2015), and their relation with spirometry parameters, clinic and follow up variables, was performed using a logistic regression model for each dependent variable.

Results: 410 COPD patients were included. The risk of having ≥ 2 exacerbations was 4 (95%CI 2.4-6.8) if ≤ 1 previous admissions, 2.1 (95%CI 1.3-3.2) in influenza vaccination and 1.7 (95%CI 1.1-2.7) if they had inhaled corticosteroids. The risk of having ≥ 1 admission was 1.6 (IC95% 1.1-2.6) in males, 1.5 (95%CI 1.01-2.3) if anti-pneumococcal vaccine and 4.1 (95%CI 2.5-7.04) if ≥ 2 exacerbations. The overall mortality was related to age (OR = 1.8) (1.02-1.07), chronic renal failure (OR = 3.1, 1.5-7.1), diabetes (OR = 1.8, 1.1-2.9), treatment with oral corticosteroids (OR = 2.1, 1.1-3.9), having protective factors such as long-acting beta adrenergics (OR = 0.47, 0.3-0.7) and influenza vaccination (OR = 0.45, 0.2-0.7).

Conclusion: Exacerbations and previous admissions, immunization status, presence of Diabetes and Chronic Renal Insufficiency as well as treatment are easily identifiable factors in order to act on highest risk patients.

Declaration of Interest: None

Corresponding Author: Maria José Bujalance-Zafra,
Email: mbujalance@hotmail.com

CR044
The impact of ethnicity and socioeconomic factors on the prevalence of COPD in a low income country of sub-Saharan Africa: FRESH AIR Uganda
Frederik van Gemert1, Niels Chavannes2, Bruce Kirenga3, Rupert Jones4, Sian Williams5, Ioanna Tsiliigiani1, Corina de Jong1, Thys van der Molen1
1University Medical Centre Groningen, The Netherlands, 2Leiden University Medical Centre, Leiden, The Netherlands, 3Mulaga Hospital, Makerere University, Kampala, Uganda, 4University of Plymouth, UK, 5International Primary Care Respiratory Group

Aim: In Uganda, biomass fuel use seems the largest risk factor for COPD. Socioeconomic factors (such as ethnicity) may play a mediating role. Therefore, more in-depth research was needed to better understand the risk factors of COPD. The aim was to investigate the impact of ethnicity (Bantu and non-Bantu) and socioeconomic factors on COPD prevalence in Uganda.

Method: The population comprised of 588 randomly selected participants (≥ 30 years) in Masindi who previously participated in the FRESH AIR Uganda study. In this post-hoc analysis, the impact of several socioeconomic characteristics on the prevalence of COPD was assessed using direct subgroup comparisons (for ethnicity and gender) and logistic regression analyses.

Results: Ninety-five (16.2%) participants had COPD. Ethnicity had significant impact on COPD prevalence: Bantu 12.9% and non-Bantu 20% (P = 0.020). Further analysis showed a difference in socioeconomic factors between these groups, reflected in active smoking (32.6% in non-Bantu vs 10.7%), living in tobacco-growing areas (72% in non-Bantu vs 14%), charcoal usage (22% in non-Bantu vs 40%), and education (no education 25% in non-Bantu vs 12%). Cough (non-COPD 18.1% and COPD 30.5%, P = 0.005), wheeze (non-COPD 6.5% and COPD 16.8%, P = 0.001) and men with ≥ 2 chest infections per year (non-COPD 33.3% and COPD 57.8%) were more prevalent in COPD patients. Among men, logistic regression analyses showed that both coughing during the day (OR 3.17, CI 1.14-8.77, P = 0.026) and ethnicity (non-Bantu OR 2.12, CI 1.06-4.26, P = 0.034) were associated with COPD. Among women, breathlessness with wheezing (OR 3.28, CI 1.07-10.01, P = 0.037) and former smoking (OR 3.21, CI 1.29-8.02, P = 0.012) were associated with COPD.

Conclusion: Within the two ethnic groups, a difference in COPD prevalence was found; this is probably associated with lower socioeconomic circumstances. Therefore, more research is needed to clarify the complexity of the different risk factors on the development of COPD in low- and middle-income countries.

Declaration of Interest: None

Corresponding Author: Frederik van Gemert,
Email: fgemert@xs4all.nl

CR045
Glycopyrronium significantly improves lung function, dyspnoea and health status in COPD patients in all GOLD groups
Anthony D’Urzo1, Giovanni Bader2, Pankaj Goyal3, Pablo Altman3
1University of Toronto, Toronto, Canada, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, United States

Aim: Glycopyrronium and tiotropium are inhaled long-acting muscarinic agonists recommended for COPD patients in all GOLD groups (A, B, C & D) [1]. Glycopyrronium is effective and well tolerated in moderate-to-severe COPD patients, similar to tiotropium, and has faster onset and better bronchodilation. The present study was initiated to assess whether there was a difference between glycopyrronium and tiotropium.

Method: An observational, non-comparative, one-arm, multi-center, multinational study in moderate-to-severe COPD patients from 157 centers in 22 countries. Patients were randomized to glycopyrronium (n = 472) or tiotropium (n = 472). Dyspnoea was assessed using the modified Medical Research Council Dyspnoea Scale (MRC) at baseline and week 12. Primary efficacy analyses were performed for trough FEV1 (tFEV1) and other key endpoints including lung function, COPD Assessment Test (CAT), St George Respiratory Questionnaire (SGRQ), and health status (HRQoL).

Results: Of the 2599 patients (glycopyrronium, n = 1628; tiotropium, n = 971), 29.7% and 13.1% were in groups A and C, with baseline mean (SD) tFEV1 scores of 8.19 (1.29) and 7.95 (1.33), respectively, and baseline FEV1/% predicted normal mean (SD) 64.66 (8.58) and 41.85 (5.68); 30.6% and 26.7% patients were ≥ 2 exacerbations. The primary efficacy variables showed statistically significant improvements in tFEV1, tFEV1≥ 50% predicted, and baseline dyspnoea index (BDI ≥ 5; low symptoms; BDI < 5; high symptoms) for glycopyrronium versus tiotropium (P < 0.01).

Conclusion: Glycopyrronium was superior to tiotropium for all primary efficacy variables in moderate-to-severe COPD patients. Glycopyrronium is a new, effective, and well-tolerated long-acting muscarinic anticholinergic bronchodilator that could replace tiotropium in this patient population.
Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyPharma, KOS Pharmaceuticals and Almirall. This study was sponsored by Novartis Pharma AG. Giovanni Bader, Pablo Altman and Pankaj Goyal are employees of Novartis.

Corresponding Author: Anthony D’Urzo,
Email: tonydurzzo@sympatico.ca

References

Table 1. Mean change from baseline in trough FEV₁, TDI and SGRQ score (glycopyrronium treatment) at Week 12

<table>
<thead>
<tr>
<th>GOLD groups</th>
<th>tFEV₁ (L)</th>
<th>TDI score</th>
<th>SGRQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD A</td>
<td>0.09 (0.01)*</td>
<td>2.28 (0.14)*</td>
<td>–5.99 (0.50)*</td>
</tr>
<tr>
<td>GOLD B</td>
<td>0.09 (0.01)*</td>
<td>1.90 (0.14)*</td>
<td>–9.53 (0.60)*</td>
</tr>
<tr>
<td>GOLD C</td>
<td>0.09 (0.01)*</td>
<td>2.40 (0.22)*</td>
<td>–5.89 (0.77)*</td>
</tr>
<tr>
<td>GOLD D</td>
<td>0.09 (0.01)*</td>
<td>1.80 (0.15)*</td>
<td>–7.18 (0.61)*</td>
</tr>
</tbody>
</table>

*P < 0.0001; Data is least square mean (standard error).
SGRQ, St George’s Respiratory Questionnaire; TDI, transition dyspnea index; tFEV₁, trough forced expiratory volume in 1 sec.

CR046
Glycopyrronium and tiotropium comparison: lung function, dyspnoea and health status in COPD patients in all GOLD groups

Anthony D’Urzo1, Giovanni Bader2, Pankaj Goyal2, Pablo Altman3
1University of Toronto, Toronto, Canada, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, United States

Aim: Inhaled long-acting muscarinic antagonists are recommended for COPD patients in all GOLD groups (A, B, C, and D). Glycopyrronium 50 μg is effective and well tolerated in moderate-to-severe COPD patients, similar to tiotropium 18 μg with faster onset and better bronchodilation in the first 4 h after the first dose.

Method: The effect of glycopyrronium and tiotropium in patients categorised by GOLD group was analysed post hoc using data from four randomised controlled clinical trials pooled and adjusted using mix-model. GOLD classification was done based on baseline St George’s Respiratory Questionnaire (SGRQ) score (cut point = 25) and lung function (FEV₁; 1 (tFEV₁), SGRQ score, and Transition Dyspnoea Index (TDI) score.

Results: Of the 2599 patients (glycopyrronium, n = 1628, tiotropium, n = 971), 7.6%, 52.6%, 2.8% and 37.0% were classified in GOLD groups A, B, C and D, respectively. Glycopyrronium significantly improved tFEV₁ in patients in all groups after 12 weeks treatment compared with baseline; tiotropium showed significant improvement only in B and D groups. In group A, glycopyrronium was significantly better than tiotropium (Table 1). Glycopyrronium significantly improved TDI score in patients in all GOLD groups, similar to tiotropium. Glycopyrronium and tiotropium showed similar and significant improvement in SGRQ score in GOLD groups B and D (Table 1). Conclusion: Glycopyrronium and tiotropium significantly improved dyspnoea score (in all GOLD groups) and health status (GOLD groups B and D). Glycopyrronium provided significant improvement in tFEV₁ in patients in all GOLD groups, while tiotropium showed statistically significant improvement in tFEV₁ only in patients in group B and D.

Declaration of Interest: Anthony D’Urzo has received research, consulting and lecturing fees from Glaxo SmithKline, Sepracor, Schering Plough, Altaba, Methapharma, AstraZeneca, ONO pharma, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyPharma, KOS Pharmaceuticals and Almirall. This study was sponsored by Novartis Pharma AG. Giovanni Bader, Pablo Altman, Pankaj Goyal are employees of Novartis.

CR047
Benefits of tiotropium-olodaterol on symptoms and health-related quality of life in moderate to severe COPD patients with chronic bronchitis and/or emphysema

Gary Ferguson, Roger Abrahams1, Leif Bjerner2, Lars Grönke3, Florian Voβ3, Dave Singh4
1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, Michigan, USA, 2Morgantown Pulmonary Associates, Morgantown, West Virginia, USA, 3Lund University, Lund, Sweden, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, 5The Medicines Evaluation Unit, Manchester, UK

Aim: Chronic bronchitis and emphysema are common features of chronic obstructive pulmonary disease (COPD) and are associated with adverse symptoms and poor health-related quality of life. Efficacy and safety of tiotropium, a long-acting muscarinic antagonist, +olodaterol, a long-acting β2-agonist, have previously been established in COPD. This post hoc analysis of data from two Phase IIib studies assessed the effect of tiotropium+olodaterol on lung function, symptoms and health-related quality of life in patients with COPD (GOLD 2–3) with chronic bronchitis and/or emphysema.

Method: In two replicate, randomised, double-blind, parallel-group, 12-week studies (OTEMTOP® 1 and 2, 1237.25 and 1237.26, NCT01964352 and NCT02006732), patients received tiotropium+olodaterol 5/5 or 2.5/5 μg, tiotropium 5 μg or placebo. Patients were classified as having chronic bronchitis, emphysema or both based on the investigator’s clinical judgement (chest computed tomography scan or assessment of diffusion capacity may not have been performed). Forced expiratory volume in 1 second (FEV₁) area under the curve from 0–3 hours (AUC₀–₃), trough FEV₁, and St George’s Respiratory Questionnaire (SGRQ) were primary end points; secondary end points included Mahler Transition Dyspnoea Index (TDI). Comparisons between tiotropium+olodaterol 5/5 μg, tiotropium 5 μg and placebo are presented.

Results: Patients numbers were: bronchitis, n = 506, emphysema, n = 476; both, n = 206. Baseline patient characteristics were generally comparable. After 12 weeks of treatment, there were significant improvements in FEV₁, AUC₀–₃, trough FEV₁, SGRQ and TDI in all groups with tiotropium+olodaterol 5/5 μg, compared to placebo, with similar improvements across groups (Table 1). Conclusion: Tiotropium+olodaterol 5/5 μg provided significant improvements in lung function, dyspnoea and health-related quality of life in patients with moderate to severe COPD with bronchitis, emphysema or both.

Declaration of Interest: Trial funding provided by Boehringer Ingelheim. Editorial assistance provided by Complete HealthVision.

Corresponding Author: Gary Ferguson,
Email: gary.ferguson@msn.com
Table 1. Primary and secondary end-point results from the OTEMTÖ 1 and 2 studies in patients with chronic bronchitis and/or emphysema

<table>
<thead>
<tr>
<th>End point</th>
<th>Treatment comparison</th>
<th>Adjusted mean difference (95% confidence interval) at Week 12</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bronchitis</td>
<td>Emphysema</td>
</tr>
<tr>
<td>FEV1, AUC_o, response, mL</td>
<td>Tiotropium+olodaterol 5/5 μg vs placebo</td>
<td>306 (264, 347)**</td>
</tr>
<tr>
<td></td>
<td>Tiotropium+olodaterol 5/5 μg vs tiotropium 5 μg</td>
<td>97 (55, 138)**</td>
</tr>
<tr>
<td>Trough FEV1, response, mL</td>
<td>Tiotropium+olodaterol 5/5 μg vs placebo</td>
<td>157 (115, 199)**</td>
</tr>
<tr>
<td></td>
<td>Tiotropium+olodaterol 5/5 μg vs tiotropium 5 μg</td>
<td>24 (–18, 66)</td>
</tr>
<tr>
<td>TDI, Δ</td>
<td>Tiotropium+olodaterol 5/5 μg vs placebo</td>
<td>–2.63 (–4.66, –0.61)**</td>
</tr>
<tr>
<td></td>
<td>Tiotropium+olodaterol 5/5 μg vs tiotropium 5 μg</td>
<td>2.11 (1.52, 2.69)**</td>
</tr>
</tbody>
</table>

CR048
Effect of indacaterol versus salmeterol/fluticasone on COPD exacerbations using baseline blood eosinophil count: A post-hoc analysis from the INSTEAD study

Pankaj Goyal1, Andrea Rossi2, Giovaani Bader1, Pablo Altman3
1Novartis Pharma AG, Basel, Switzerland, 2Azienda Ospedaliera Universitaria Integrata, Verona, Italy, 3Novartis Pharmaceuticals Corporation, East Hanover, United States

Aim: To assess if baseline blood eosinophil count has an impact on exacerbation risk, this post hoc analysis from the INSTEAD study(1) compares the effect of once-daily indacaterol (IND) 150 μg versus twice-daily salmeterol/fluticasone combination (SFC) 50/500 μg on COPD exacerbation rates in subgroups of patients with moderate COPD, stratified using baseline blood eosinophil count.

Method: Data from the patients (N=581) from the INSTEAD study were analysed to assess the exacerbation rate (mild, moderate or severe) using baseline absolute blood eosinophil count (<150/mm³), ≥150 to <300/mm³ and ≥300/mm³) and blood eosinophils as percentage of total leukocyte count (TLC, 2% [≥2% versus ≥3%]; 3% [<3% versus ≥3%]; 4% [<4% versus ≥4%] and 5% [<5% versus ≥5%]).

Results: At Week 26, no significant difference was observed (IND versus SFC) in the rate of all exacerbations (incidence rate ratio [IRR] 0.86; 95%CI: 0.62, 1.20; P=0.367)(1). When patients were categorised using baseline absolute blood eosinophil count (<150/mm³), ≥150 to <300/mm³ and ≥300/mm³) and blood eosinophils as percentage of total leukocyte count (TLC, 2% [≥2% versus ≥3%]; 3% [<3% versus ≥3%]; 4% [<4% versus ≥4%] and 5% [<5% versus ≥5%]), a significant difference between the exacerbation rates (IND versus SFC) in any of these sub-groups was observed (Figure 1). Patients with COPD with high load of anxiety symptoms are less likely to complete the PR program with odds ratio (95% CI) 0.93 (0.89–0.97), P<0.002. Other clinical variables did not contribute to the model.

Conclusion: This post hoc analysis shows that indacaterol was as effective as salmeterol/fluticasone combination in reducing exacerbation risk in COPD patients, irrespective of the baseline blood eosinophil count.

Declaration of Interest: Andrea Rossi received grants, personal fees and non-financial support from Novartis, personal fees and non-financial support from GlaxoSmithKline and Boehringer Ingelheim; grants and personal fees from Chiesi Farmaceutici SPA, outside the submitted work. Pankaj Goyal, Giovanni Bader and Pablo Altman are employees of Novartis.

Corresponding Author: Pankaj Goyal, Email: pankaj.goyal@novartis.com

Reference

CR049
Why anxiety associates with non-completion of pulmonary rehabilitation program in patients with COPD?

Abebaw Mengistu Yohannes1, Sheila Dryden2, Nicola Alexander Hanania3
1Manchester Metropolitan University, UK 2St. Annes Primary Care Center, UK 3Pulmonary 3Baylor College of Medicine, Houston, Texas, USA

Aim: Recently, we have designed a disease-specific anxiety scale that measures anxiety (1,2) in patients with chronic obstructive pulmonary disease (COPD). Thus, we examined whether the Anxiety Inventory for Respiratory disease (AIR) is a predictor of non-completion of eight-week pulmonary rehabilitation (PR) programme.

Method: We have prospectively collected baseline data of patients with COPD who participated in eight-week PR. Pre and post-rehabilitation outcome measures were obtained: exercise capacity was assessed by incremental shuttle walk test (ISWT), quality of life measured using the St-Georges Respiratory Questionnaire (SGRQ), and severity of dyspnoea was assessed using the Medical Research Council scale. Anxiety was measured using the self-administered AIR scale. Completion was defined as attending 75% of the designated PR schedules and completed the eight weeks evaluation.

Results: Two hundred fifty seven COPD patients were recruited into community-based PR program. 192 (75%) COPD patients completed the eight weeks PR program. Table shows baseline differences between completers and non-completers of PR program. Non-completers had lower exercise capacity, higher dyspnoea and higher level of anxiety compared to completers. Logistic regression analysis showed that only those with high load of anxiety symptoms were less likely to complete the PR program with odds ratio (95% CI) 0.93 (0.89–0.97), P<0.002. Other clinical variables did not contribute to the model.

Conclusion: Patients with COPD with high load of anxiety symptoms are less likely to complete the PR program. Thus, those with high load of anxiety symptoms may benefit with additional practical support of including psychological therapy to complete PR.

Declaration of Interest: None

Corresponding Author: Abebaw Mengistu Yohannes, Email: Ayohannes@mmu.ac.uk

References
CR050

Tiotropium+olodaterol shows clinically meaningful improvements in quality of life versus placebo

Dave Singh1, Gary T Ferguson2, Josef Bolitschek3, Lars Gronke4, Christoph Hallmann4, Nathan Bennett5, Roger Abrahams6, Olaf Schmidt7, Leif Bjermer8

1The Medicines Evaluation Unit, Manchester, UK, 2Pulmonary Research Institute of Southeast Michigan, Farmington Hills, Michigan, USA, 3Krankenhaus der Elisabethinen, Linz, Austria, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, 5Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA, 6Morgantown Pulmonary Associates, Morgantown, West Virginia, USA, 7Lungen- und Bronchialheilkunde, Koblenz, Germany, 8Lund University, Lund, Sweden

Aim: Efficacy and safety of tiotropium, a long-acting muscarinic antagonist, +olodaterol, a long-acting β2-agonist, have previously been established in pivotal Phase III studies in chronic obstructive pulmonary disease (COPD). The present studies (OTEMTO® 1 and 2; 1237.25 and 1237.26; NCT01964352 and NCT02006732) evaluated forced expiratory volume in 1 second (FEV1) and St George’s Respiratory Questionnaire (SGRQ) score after 12 weeks of treatment with tiotropium+olodaterol (2.5/5 μg and 5/5 μg) and tiotropium 5 μg, compared to placebo, in patients with moderate to severe COPD.

Method: Two replicate, randomised, double-blind, parallel-group, Phase IIIb, 12-week studies assessed the efficacy and safety of tiotropium+olodaterol 2.5/5 μg or 5/5 μg and tiotropium 5 μg, compared to placebo, in patients with moderate to severe COPD. Key inclusion criteria were age ≥ 40 years, diagnosis of COPD and post-bronchodilator FEV1 ≥ 30 and < 80% predicted (GOLD 2–3).

Results: 1621 patients were evaluated. Baseline patient characteristics were similar between OTEMTO®1 and 2: mean post-bronchodilator FEV1 was 1.52 L and 1.55 L (55.3% and 54.8% predicted), respectively. Both studies met primary

---

**Table 1.** Baseline differences between completers versus non-completers of PR program in patients with COPD Mean (SD)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Completers (n = 192)</th>
<th>Non-completers (n = 65)</th>
<th>t-value</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>71.1 (8.51)</td>
<td>69.42 (9.86)</td>
<td>1.32</td>
<td>0.18</td>
</tr>
<tr>
<td>FEV1 (% predicted)</td>
<td>56.91 (15.16)</td>
<td>55.68 (14.48)</td>
<td>0.49</td>
<td>0.62</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>45.91 (20.16)</td>
<td>44.71 (14.29)</td>
<td>0.48</td>
<td>0.64</td>
</tr>
<tr>
<td>Sex (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>48.95</td>
<td>52.31</td>
<td>χ² = 0.67</td>
<td>0.37</td>
</tr>
<tr>
<td>Female</td>
<td>51.05</td>
<td>47.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIR score</td>
<td>5.36 (5.37)</td>
<td>8.05 (7.13)</td>
<td>3.19</td>
<td>&lt; 0.002</td>
</tr>
<tr>
<td>SGRQ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms</td>
<td>65.12 (20.39)</td>
<td>68.78 (21.41)</td>
<td>1.24</td>
<td>0.21</td>
</tr>
<tr>
<td>Impact</td>
<td>37.91 (19.93)</td>
<td>41.63 (19.81)</td>
<td>1.30</td>
<td>0.19</td>
</tr>
<tr>
<td>Activity</td>
<td>67.17 (23.73)</td>
<td>73.82 (20.35)</td>
<td>2.02</td>
<td>0.04</td>
</tr>
<tr>
<td>Total</td>
<td>51.22 (19.06)</td>
<td>41.63 (19.81)</td>
<td>1.78</td>
<td>0.07</td>
</tr>
<tr>
<td>ISWT</td>
<td>213.85 (127.38)</td>
<td>177.69 (117.53)</td>
<td>2.01</td>
<td>0.04</td>
</tr>
<tr>
<td>MRC dyspnea</td>
<td>2.79 (1.12)</td>
<td>3.12 (1.24)</td>
<td>1.96</td>
<td>0.05</td>
</tr>
</tbody>
</table>

MRC = Medical Research Council; ISWT = Incremental Shuttle Walk Test; AIR = Anxiety Inventory for Respiratory Disease; SGRQ = St. Georges Respiratory Questionnaire.
end points and significantly improved FEV1 area under the curve from 0–3 hours (AUC0–3), trough FEV1, and SGRQ with all treatments, versus placebo (Table 1). There were no relevant safety findings.

Conclusion: These studies show a consistent clinically meaningful improvement in SGRQ with tiotropium+olodaterol 5/5 μg, versus placebo, while confirming its effects on lung-function parameters and safety.

Declaration of Interest: Trial funding provided by Boehringer Ingelheim. Editorial assistance provided by Complete HealthVizion.

Corresponding Author: Dave Singh,
Email: DSingh@meu.org.uk

Table 1. Primary end-point results from the OTEMTO1 and 2 studies

<table>
<thead>
<tr>
<th>Treatment comparison vs placebo</th>
<th>Adjusted mean difference at Week 12</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SGRQ, FEV1, AUC0–3, Trough, FEV1, mL</td>
</tr>
<tr>
<td></td>
<td>SGRQ, FEV1, AUC0–3, Trough, FEV1, mL</td>
</tr>
<tr>
<td>Tiotropium</td>
<td>−4.89*, 331*, 162*</td>
</tr>
<tr>
<td>+olodaterol 5/5 μg</td>
<td>−4.56*, 299*, 166*</td>
</tr>
<tr>
<td>Tiotropium</td>
<td>−4.12*, 300*, 150*</td>
</tr>
<tr>
<td>+olodaterol 2.5/5 μg</td>
<td>−3.67*, 284*, 169*</td>
</tr>
<tr>
<td>Tiotropium</td>
<td>−2.40†, 219*, 134*</td>
</tr>
<tr>
<td>+olodaterol 5 μg</td>
<td>−2.85†, 194*, 127*</td>
</tr>
</tbody>
</table>

*P < 0.0001; †P < 0.05; ‡P < 0.02.

CR050

Globally differences in baseline characteristics of COPD patients: pooled analysis of pivotal clinical trials of Indacaterol/ Glycopyrronium from IGNITE programme

Ioanna Tsiligianni1, Karen Mezzi2, Robert Fogel3, Sebastian Fucile3, Konstantinos Kostikas2
1University of Crete, Heraklion, Greece, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, USA

Aim: Chronic obstructive pulmonary disease (COPD) has been perceived as a disease of men; however, the perspective has changed with an increase in COPD prevalence and mortality rate among women.1 Here, we present a pooled analysis of pivotal indacaterol/glycopyrronium trials from IGNITE programme to investigate the differences in baseline characteristics of COPD patients across both genders.

Method: Baseline data were pooled from 6 pivotal randomised clinical trials (≥6 months duration) of indacaterol/glycopyrronium 110/50 μg once daily conducted in patients with moderate-to-severe COPD. Gender differences based on baseline demographics and disease characteristics were analysed.

Results: A total of 6134 patients were included in 6 IGNITE trials (SHINE [N = 2144], SPARK [N = 2224], ILLUMINATE [N = 523], ENLIGHTEN [N = 339], ARISE [N = 160], and LANTERN [N = 744]), of whom 6108 (4719 men and 1389 women) were included in this pooled analysis. All baseline parameters, except symptom score (e-diary), differed significantly between men and women (Table 1). Women patients with COPD were relatively younger and had lower total exposure to smoking. More women than men were current smokers. The percentage of COPD patients with a diagnosis of moderate COPD and a history of COPD exacerbations was higher among women. Post-bronchodilator forced expiratory volume in 1 second (FEV1) % predicted and FEV1/forced vital capacity (FVC) % differed significantly between the genders (favouring female). Baseline dyspnoea index (BDI) scores were somewhat lower for women compared to men and St. George’s Respiratory Questionnaire (SGRQ) score was relatively higher for women indicating a worse quality of life. Use of rescue medication (number of puffs per day, P = 0.0001) was also higher in women.

Conclusion: Results suggest significant differences in demographics and disease characteristics across both genders, and may provide clinical guidance on gender-specific approach to COPD management.

Declaration of Interest: Sebastian Fucile, Karen Mezzi, Robert Fogel, and Konstantinos Kostikas are employees of Novartis Pharmaceuticals Corporation. Ioanna Tsiligianni has received honoraria for educational activities, speaking engagements and advisory boards from Boehringer lngelheim, Novartis, AstraZeneca and GlaxoSmithKline, but none related to this study.

Corresponding Author: Ioanna Tsiligianni,
Email: i.tsiligianni@umcg.nl

Reference

CR051

Gender differences in baseline characteristics of COPD patients: pooled analysis of pivotal clinical trials of Indacaterol/ Glycopyrronium from IGNITE programme

Ioanna Tsiligianni1, Karen Mezzi2, Robert Fogel3, Sebastian Fucile3, Konstantinos Kostikas2
1University of Crete, Heraklion, Greece, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, USA

Aim: Chronic obstructive pulmonary disease (COPD) has been perceived as a disease of men; however, the perspective has changed with an increase in COPD prevalence and mortality rate among women.1 Here, we present a pooled analysis of pivotal indacaterol/glycopyrronium trials from IGNITE programme to investigate the differences in baseline characteristics of COPD patients across both genders.

Method: The questionnaire of items (framed in English language) evaluated the evidence in feedback mechanisms, ease of inhalation, and ease of use/comfort of mouthpiece are important attributes of inhalation devices for COPD patients across both genders. The questionnaire of items (framed in English language) evaluated the evidence in feedback mechanisms, ease of inhalation, and ease of use/comfort of mouthpiece are important attributes of inhalation devices for COPD patients across both genders.
relevance of items, and to gather feedback on modifications to improve the content validity of the measure. Data were analysed using ATLAS.ti (version 7.5.2) software.

Results: The study included 10 patients (50% male; mean age 60.3 years), diagnosed with COPD for ≥ 6 months. Participants generally perceived the questionnaire items to be clear and easy to understand, and interpreted the questions as intended. Wherever the items were unclear, participants suggested an alternative wording to enhance clarity. Sixty percent of the patients preferred the 5-point verbal rating scale as it supports standardised interpretation and reporting.

Conclusion: A final questionnaire consisting of five items with a 5-point verbal rating scale was considered content valid measure suitable for use in trial settings to assess inhaler device preferences in patients with COPD.

Declaration of Interest: Pankaj Goyal, Lorena García Conde are employees of Novartis Pharma AG, Basel, Switzerland. Pablo Altman is employee of Novartis Pharmaceuticals Corporation, East Hanover, USA. Margaret Vernon, Evan Davies, Savita Bakhshi Anand have nothing to disclose.

CR053
Association between baseline symptom scores and future risk of severe exacerbations in patients with moderate-to-severe COPD data from the SPARK study
Jadwiga A Wedzicha1, Karen Mezzi2, Robert Fogel3
1Imperial College London, UK, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Aim: We investigated the correlation between baseline daily symptom scores and future risk of severe exacerbations in patients from the SPARK study.

Method: The SPARK study was a 64-week, multicentre, double-blind study that evaluated the effects of a dual bronchodilator versus long-acting muscarinic antagonists on exacerbations in patients with severe-to-very severe COPD with a history of ≥ 1 exacerbations in the previous year. Patients were randomised (1:1:1) to receive a once-daily dose of either indacaterol/glycopyrornium (IND/GLY), 110/50 μg fixed-dose combination or glycopyrornium 50 μg or open-label tiotropium 18 μg.[1] This post hoc analysis compares the baseline daily symptom scores, recorded by means of electronic diaries, of 2182 patients from the SPARK study who experienced ≥ 1 severe exacerbations (n = 248), ≥ 1 mild-moderate exacerbations (n = 1628) and no exacerbations (n = 306) during the study.

Results: Patients who experienced ≥ 1 severe exacerbations had significantly higher baseline total symptom scores (BSST) as compared to those who experienced ≥ 1 mild-moderate exacerbations (7.45) or no exacerbations (7.18), LSM difference: 1.13 and 1.39, respectively (both p < 0.0001). Several individual symptoms, including dyspnoea, cough, wheeze and sputum production, were also significantly greater in patients with severe exacerbations than in those from the other two strata (Figure). There was no significant correlation between the baseline symptom scores of fever, cold and sore throat in patients with severe and non-severe exacerbations. However, patients with severe exacerbations had significantly higher baseline symptom scores of fever, cold and sore throat as compared to those with no exacerbations.

Conclusion: In the SPARK study, patients with significantly higher baseline symptom scores, specifically with respect to dyspnoea, experienced more severe exacerbations during the study as compared to those with lower baseline symptom scores. Thus, a high level of daily symptom burden may reflect a group of patients who should be carefully followed for risk of severe exacerbations.

Declarations of Interest: Professor Jadwiga A. Wedzicha has received fees for speaking and/or advisory board from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Takeda, Chiesi, Respifor, and Almirall as well as travel reimbursements from Boehringer Ingelheim and research grants from GlaxoSmithKline, AstraZeneca, Chiesi, Takeda and Novartis, with no stock holdings in pharmaceutical companies. Karen Mezzi, and Robert Fogel are employees of Novartis.

Corresponding Author: Jadwiga A. Wedzicha, Email: j.wedzicha@imperial.ac.uk

Reference

Figure 1. Individual symptom scores across groups

CR054
ENERGITO*: efficacy and safety of once-daily tiotropium + olodaterol versus twice-daily fluticasone propionate + salmeterol
Kai-Michael Beeh1, Eric Derom2, Jose Echave-Sustaeta3, Lars Grönke4, Alan Hamilton5, Dongmei Zhai6, Leif Bjerrum7
1InsaI GmbH Institut für Atemwegsforschung, Wiesbaden, Germany, 2Ghent University Hospital, Ghent, Belgium, 3Hospital Universitario Quirón Madrid, Madrid, Spain, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, 5Boehringer Ingelheim, Burlington, Ontario, Canada, 6Ventiv Health Clinical, Wilmington, Delaware, USA, 7Lund University, Lund, Sweden

Aim: Combination of tiotropium, a well-established long-acting muscarinic antagonist, and olodaterol, a long-acting β2-agonist (LABA), has been shown to provide consistent improvements in lung function over tiotropium or olodaterol alone in Phase III studies in chronic obstructive pulmonary disease (COPD). Addition of an inhaled corticosteroid (ICS) to a LABA has also demonstrated lung-function improvements over LABA alone in some studies. The ENERGITO* study (1237.11; NCT01969721) evaluated bronchodilator efficacy and safety of once-daily tiotropium+olodaterol compared to twice-daily fluticasone+salmeterol.

Method: This Phase IIb, randomised, double-blind, double-dummy, four-period crossover trial evaluated lung function after 6 weeks of treatment with once-daily tiotropium+olodaterol 2.5/5 or 5/5 μg versus twice-daily fluticasone + salmeterol 250/50 or 500/50 μg. End points were forced expiratory volume in 1 second (FEV1) area under the curve from 0–12 hours (AUC0–12) (primary end point), FEV1 from 0–24 hours (AUC0–24), FEV1 from 12–24 hours (AUC12–24), and trough FEV1 responses. Key inclusion criteria were age ≥ 40 years, smoking history > 10 pack-years, and post-bronchodilator FEV1 ≥ 30 and < 80% predicted (GOLD 2–3).

Results: 229 patients were enrolled and treated: 64.6% male and 72.1% GOLD 2. Tiotropium+olodaterol significantly improved FEV1, AUC0–12, and response and all other FEV1 end points over fluticasone+salmeterol (Table 1). No safety signals were identified.

Conclusion: This study suggests that using LABA+ICS (fluticasone+salmeterol) in patients with moderate to severe COPD may provide sub-optimal lung-function improvements compared to tiotropium+olodaterol.
Table 1. FEV1 end-point results from the ENERGITO® study

<table>
<thead>
<tr>
<th>Treatment comparison</th>
<th>Adjusted mean difference (95% confidence interval) at Week 6, ml.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FEV1, AUC0–12</td>
</tr>
<tr>
<td>Tiotropium+olodaterol 5/5 &amp; fluticasone-salmeterol 250/50 μg</td>
<td>125*** (103, 147)</td>
</tr>
<tr>
<td>Tiotropium+olodaterol 5/5 &amp; fluticasone-salmeterol 500/50 μg</td>
<td>129*** (107, 150)</td>
</tr>
<tr>
<td>Tiotropium+olodaterol 2.5/5 μg &amp; fluticasone-salmeterol 250/50 μg</td>
<td>103*** (81, 124)</td>
</tr>
<tr>
<td>Tiotropium+olodaterol 2.5/5 μg &amp; fluticasone-salmeterol 500/50 μg</td>
<td>106** (85, 128)</td>
</tr>
</tbody>
</table>

*P < 0.05; **P < 0.001; ***P < 0.0001.

Declaration of Interest: Trial funding provided by Boehringer Ingelheim.
Editorial assistance provided by Complete HealthVizion.
Corresponding Author: Kai-Michael Beeh,
Email: kbee@insa-wed.de

CR055
ICS and risk of pneumonia in Swedish COPD patients: ARCTIC study

Christer Janson1, Gunnar Johansson1, Björn Stallberg1, Karin Lisspers3, Petter Olsson2, Dorothy Keininger2, Leif Jorgensen3, Patrik Sobocki3,4, Christer Janson1, Gunnar Johansson1, Björn Ställberg1, Karin Lisspers1.

Aim: To assess the risk of pneumonia among Swedish chronic obstructive pulmonary disease (COPD) patients treated with inhaled corticosteroids (ICS).
Method: Retrospective electronic medical records (EMRs) data were collected from COPD patients and a matched reference group from Swedish primary care centres (2000-2014) and linked to information from national primary and secondary care registries. The COPD and matched reference group (non-COPD patients) were divided into three groups: high- (>800 μg daily budesonide), low- (1 > 50% predicted).

Results: There were 593, 1,453 and 2,124 COPD patients and 3,464, 10,619 and 18,800 non-COPD patients in the high-, low- and no-ICS dose groups, respectively. Mean follow-up was 5.7 years (SD = 4.1). ICS use at both low and high doses was associated with higher prevalence of pneumonia in COPD (low, HR = 1.15 [95% CI 1.00, 1.32]; high, HR = 1.23 [95% CI 1.04, 1.46]) compared to COPD patients not using ICS (table). An association between ICS use and pneumonia was also found in non-COPD patients (low, HR 1.66 [95% CI 1.56, 1.76]; high, HR 1.76 [95% CI 1.61, 1.93]) compared with no-ICS use in non-COPD patients (table). COPD patients had a higher risk of pneumonia than non-COPD patients (HR = 3.33 [95% CI 3.12, 3.56]).

Conclusion: Having COPD or taking high- or low-dose ICS are both associated with increased risk of pneumonia.

Table 1. Proportion of patients with pneumonia, stratified by disease status and ICS group

<table>
<thead>
<tr>
<th></th>
<th>Non-COPD</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>No ICS</td>
<td>0.5%</td>
<td>19%</td>
</tr>
<tr>
<td>Low dose ICS</td>
<td>7%</td>
<td>22%</td>
</tr>
<tr>
<td>High dose ICS</td>
<td>10%</td>
<td>22%</td>
</tr>
</tbody>
</table>

CR056
TIotropium Safety and Performance In Respimat® (TIOSPIR®): Safety and efficacy in patients with tiotropium HandiHaler® use at baseline

Ioanna Tsiligianni1, Peter Calverley2, Antonio Anzueto3, Ronald Dahl4, Achim Mueller5, Andy Fowler6, Norbert Metzdorf5, Robert Wise7, Daniel Dusser8, Kai-Michael Beeh9.

Aim: To assess the safety and efficacy of tiotropium HandiHaler® at baseline.
Method: TIOSPIR® (N = 17,133), a 2-3-year, randomized, double-blind, parallel-group, event-driven trial, compared safety and efficacy of once-daily tiotropium Respimat® 5 and 2.5 μg with HandiHaler® 18 μg in patients with COPD. Primary endpoints were time to death and first COPD exacerbation. Patients receiving tiotropium at baseline from countries where only tiotropium HandiHaler® was available at the time of study initiation were analyzed.

Results: 2784 patients treated with tiotropium HandiHaler® 18 μg at baseline were analyzed (n = 914 and n = 18 for tiotropium Respimat® 2.5 and 5 μg, n = 952 for HandiHaler® 18 μg). Baseline characteristics were similar across groups. Risk of death was similar for the Respimat® groups versus HandiHaler® (Respimat® 5 μg: hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.58-1.07; Respimat® 2.5 μg: HR, 0.87; 95% CI, 0.64-1.17). Risks of major adverse cardiovascular event (MACE) and fatal MACE were similar for Respimat® versus HandiHaler® (MACE: Respimat® 5 μg: HR, 0.69; 95% CI, 0.44-1.08; Respimat® 2.5 μg: HR, 0.73; 95% CI, 0.47-1.15; fatal MACE: Respimat® 5 μg: HR, 0.67; 95% CI, 0.33-1.34; Respimat® 2.5 μg: HR, 0.57; 95% CI, 0.27-1.19). Overall risk of a fatal event (ontreatment) was lower for Respimat® 5 μg versus HandiHaler® (Respimat® 5 μg: HR, 0.62; 95% CI, 0.43-0.89). Risk of exacerbation was similar across groups (Respimat® 5 and 2.5 μg versus HandiHaler®: HR [95% CI]: 0.96 [0.86-1.08] and 1.03 [0.92-1.16]).

Conclusion: Patients treated with tiotropium HandiHaler® 18 μg at baseline, and who subsequently received tiotropium Respimat®, had similar risk of all-
cause mortality, fatal MACE, MACE and exacerbation as those who continued to be treated with tiotropium HandiHaler®.

Declaration of Interest: IT received fees for educational activities, speaking engagements and advisory boards from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis; PMAC received grants or fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis; RA received grants or fees from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline and Novartis; RD received grants or fees from Boehringer Ingelheim, Novartis, AF and NM are employees of Boehringer Ingelheim; RAW received grants or fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Novartis, Pearl Therapeutics, Pfizer, Pulmox, Roche, Spiration, Sunovon, Takeda and Theravance; DD received grants or fees from Boehringer Ingelheim, Chiesi, Dey Pharma, Novartis, Nycomed and Pfizer. NCT01126437

Corresponding Author: Ioanna Tsiligianni,
Email: itsiligianni@umcg.nl

Reference

CR057
Asthma impacts on workplace productivity and daily activities in employed patients who are symptomatic despite background therapy: a multi-national survey

Kevin Gruffydd-Jones1, Mike Thomas2, Miguel Roman Rodriguez4, Antonio Infantino5, Katharina Opitz6, Valerie Hargreaves6

1Box Surgery, Wilts, UK. 2University of Southampton, UK. 3Primary Care Respiratory Research Unit, IuliSpa, Palma de Mallorca, Spain. 4Italian Interdisciplinary Society for Primary Care, Italy. 5Boehringer Ingelheim Pharma GmbH, Germany. 6Cohn & Wolfe, UK

Aim: Despite treatment according to current recommendations, ≥40% of patients with asthma have disease that remains uncontrolled.1,2 Poorly controlled asthma is associated with reduced work productivity and increased activity impairment versus well-controlled asthma,3,4 but research is limited. This multi-national survey aimed to increase understanding of the impact of symptomatic asthma on work productivity and daily activities in adults receiving maintenance therapy.

Method: The Work Productivity and Activity Impairment Specific Health Problem questionnaire is an internationally recognised and validated, six-question, patient-administered, quantitative assessment of absenteeism, presenteeism (reduced on-the-job effectiveness) and daily activity impairment attributable to a specific health problem, during the past 7 days.4 Adults (aged ≥18 years) with asthma, diagnosed by a healthcare professional, in full/part-time employment and confirmed as symptomatic (using Royal College of Physicians Three Questions tool), despite receiving long-term asthma control medication, were identified from a consumer panel using initial screening questions and surveyed via an internet questionnaire.

Results: Of 6140 participants, 1598 fulfilled screening criteria and completed the survey: Brazil, n = 200; Canada, n = 200; Germany, n = 293; Japan, n = 305; Spain, n = 300; UK, n = 300. Mean scores at respondent level were: absenteeism, 9.1%; presenteeism, 31.5%; overall work impairment, 35.7%; non-work activity impairment, 38.1%. On average, 74% of participants reported some reduction (question score ≥1/10) in work productivity, while 42% and 51% of participants reported a prominent reduction (question score ≥4/10) in work productivity and ability to perform daily activities, respectively, because of asthma. Respondents reported missing, on average, 3 working hours per week because of asthma symptoms. The majority of participants indicated that asthma at work affects them physically and mentally, only 13% reported no impact.

Conclusion: For a substantial proportion of adult patients in employment with symptomatic asthma despite long-term maintenance medication, asthma has a large negative impact on work productivity and daily activity.

Declaration of Interest: Survey funding: Kantar Health received funding from Boehringer Ingelheim to conduct the WPAI survey; Complete HealthVizion received funding from Boehringer Ingelheim to provide the authors with editorial assistance. Editorial assistance: Complete HealthVizion.

CR058
Experiences of using a mobile phone application to motivate physical activity in persons with COPD: a mixed method study

Ann-Britt Zakrisson1, Terese Anéros2, Gabriella Eliason3, Anette Forsberg4

1University Healthcare Research Centre, Region Orebro County, Sweden. 2Orebro University, Sweden

Aim: To describe the experiences of using a saturation meter with a mobile application with alarm to motivate physical activity, explore if this application increases the level of physical activity and describe persons with COPD experiences of reasons to be physical active.

Method: A mixed method design was used. Persons with COPD at GOLD stage II and III who had fulfilled both a quantitative intervention and an interview participated (n = 10). The intervention consisted of one group information followed by six weeks using the mobile application. Quantitative data of physical activity was collected by accelerometer one week before and one week after the intervention period, and analysed statistically; such data were available for seven participants. The qualitative interview study investigated experiences of using the technical devices as well as motivation and barriers for physical activity and was analysed with qualitative content analysis.

Results: The participants were mostly at sedentary level. Two of the participants increased their level of physical activity from baseline to follow up after 6 weeks. Three of the participants reached the recommended 30 minutes per day of physical activity. The qualitative findings revealed two themes, “My use of saturation meter connected to a mobile application with alarm meant difficulties with the technical devices” and, “My relation to physical activity is a sense of resignation when I want to do more than I can”.

Conclusion: There were unexpectedly much technical problems experienced. To manage physical activities to handle daily life, they walked slower, stayed and rest and avoided activities with others. Participants were very active for only one or two hours per day but the rest of the day the accelerometer registered only low or no levels of activity. However, participants experienced that they were very active. That would be valuable to investigate further.

Declaration of Interest: None

Corresponding Author: Ann-Britt Zakrisson,
Email: ann-britt.zakrisson@regionorebrolan.se

CR059
‘Time without exacerbations’ as a novel approach to assess the impact of exacerbations on patients with COPD

Lonneke Boer1, Xandra Borgijink2, Jan Vercoulen1, Reinier Akkersmans3, Huib Kerstjens2, Erik Bischoff1, Tjard Schermer1

1Radboud University Medical Centre, The Netherlands. 2University Medical Centre Groningen, The Netherlands

Aim: Traditionally, studies on pharmaceutical or non-pharmaceutical treatments of COPD exacerbations use exacerbation frequency as the primary outcome measure. However, measuring the time without exacerbations may better reflect the impact of exacerbations from the patient’s perspective. We examined the association between exacerbation-free weeks and exacerbation
frequency, and assessed how these relate to disease-specific quality of life (dsQoL).

**Method:** Two existing datasets were used for retrospective analyses. Symptom changes were recorded every fortnight using an automated telephone system. A worsening of at least one major and one minor symptom for at least two consecutive days was considered an exacerbation. dsQoL was measured with the Chronic Respiratory Questionnaire (CRQ). Pearson’s correlations were calculated between exacerbation-free weeks and exacerbation frequency, and between exacerbation-free weeks and exacerbation frequency subgroups ‘infrequent exacerbators’, ‘medium frequent exacerbators’, and ‘high frequent exacerbators’. Finally, regression analyses were used to test if exacerbation-free weeks were a better predictor of dsQoL than exacerbation frequency.

**Results:** Demographics are shown in Table 1. Analyses on 208 subjects showed a strong negative correlation between exacerbation-free weeks and exacerbation frequency ($r = -0.68$) (See Table 2 and Figure 1). The correlation between exacerbation-free weeks and infrequent exacerbators was strong ($r = -0.73$). Correlations of exacerbation-free weeks with medium-frequent and high-frequent exacerbators were low ($r = -0.22$ and -0.32, respectively). Linear regression of data of 127 patients showed that exacerbation frequency explained 5.3% of the variance of the CRQ total scores at 12 months, whereas exacerbation-free weeks explained 11.9%.

**Conclusion:** In frequent exacerbators the frequency of exacerbations is not related to the time without exacerbations. In addition, time without exacerbations was a better predictor of disease-specific QoL than exacerbation frequency. This suggests that time without exacerbations should be preferred above exacerbation frequency as an outcome in studies on the impact of exacerbations in patients with COPD.

**Declaration of Interest:** None

**Corresponding Author:** Lonneke Boer, Email: lonneke.boer@radboudumc.nl

### Table 1. Demographics at baseline and study descriptive

<table>
<thead>
<tr>
<th>N</th>
<th>Primary care/Secondary care (%)</th>
<th>Age (SD)</th>
<th>Male/Female (%)</th>
<th>FEV1%pred (SD)</th>
<th>GOLD 1 (%)</th>
<th>GOLD 2 (%)</th>
<th>GOLD 3 (%)</th>
<th>GOLD 4 (%)</th>
<th>BMI (SD)</th>
<th>Currently smoking (%)</th>
<th>Exacerbation frequency (SD)</th>
<th>Exacerbation-free weeks (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>208</td>
<td>132 (63.5) / 76 (36.5)</td>
<td>65.1 (8.4)</td>
<td>143 (68.8) / 65 (31.3)</td>
<td>60.8 (17.9)</td>
<td>29 (13.9)</td>
<td>123 (59.1)</td>
<td>46 (22.1)</td>
<td>9 (4.3)</td>
<td>26.4 (4.5)</td>
<td>55 (26.4)</td>
<td>4.7 (2.6)</td>
<td>32.8 (12.5)</td>
</tr>
</tbody>
</table>

FEV1%pred: Percentage of predicted Forced Expiratory Volume in one second; GOLD: Global Initiative for Lung Disease; BMI: Body mass index.

### Table 2. Range of exacerbation frequency within groups, and Pearson’s correlations between exacerbation-free weeks and exacerbation frequency groups

<table>
<thead>
<tr>
<th>N</th>
<th>Range</th>
<th>$r$ exacerbation-free weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infrequent exacerbators</td>
<td>208</td>
<td>0.1-3.7</td>
</tr>
<tr>
<td>Medium frequent exacerbators</td>
<td>73</td>
<td>3.5-5.8</td>
</tr>
<tr>
<td>High frequent exacerbators</td>
<td>66</td>
<td>5.8-13.7</td>
</tr>
</tbody>
</table>

*P < 0.01.

**Figure 1.** Scatterplot of Pearson’s correlation between exacerbation frequency and exacerbation-free weeks. Dotted lines show distribution of exacerbation frequency in tertiles.

**Abstracts**

**Table 2.** Range of exacerbation frequency within groups, and Pearson’s correlations between exacerbation-free weeks and exacerbation frequency groups.
The prevalence of comorbidities in Swedish COPD and non-COPD patients: The ARCTIC study
Bjorn Stallberg1, Christer Janson1, Kjell Larsson2, Gunnar Johansson3, Konstantinos Kostikas2, Jean-Bernard Gruenberger4, Leif Jorgensen1, Patrik Sobocki4, Karin Lisspers1
1Uppsala University, Sweden, 2Karolinska Institutet, Sweden, 3Novartis Pharma AG, Sweden, 4IMS Health Sweden

Aim: To quantify the comorbidities of chronic obstructive pulmonary disease (COPD) patients and to compare the healthcare utilization of COPD patients with a non-COPD reference population.

Method: Medical records data from COPD patients were collected from 52 primary care centres in Sweden (2000–2014) and linked to national registries with information from primary and secondary care. Data included drug prescriptions, mortality, hospital care, income and social characteristics. Comorbidities were obtained from primary care records and from secondary care registries. The percentage of patients with a specified comorbidity was calculated for each day of the study period relative to the date of COPD diagnosis (index date) and compared with an age-, gender- and calendar year-matched reference population. Comorbidities were analyzed pre- and post-diagnosis and healthcare costs were categorized as COPD-related and non-COPD related, and comprised drug costs and primary and secondary care visits.

Results: There were 17,545 COPD and 84,514 reference group patients. A higher pre-COPD diagnosis comorbidity of asthma, depression, type II diabetes, osteoporosis, fractures, cardiovascular disease, rheumatoid arthritis, and lung cancer was observed in COPD patients compared with the reference population (table). Two years post-diagnosis, the comorbidity rate increased for both the COPD and the reference patients, but the proportion of COPD patients with each comorbidity was considerably higher than the reference population (table). Costs of treating COPD comorbidities were higher than COPD-related costs at all time points (e.g. €8,295 vs €620 for non-COPD vs COPD-related hospital nights, respectively, in 2013).

Conclusion: Comorbidities are more prevalent in COPD patients than non-COPD patients and are the major contributor to healthcare costs.

Declaration of Interest: The study was funded by Novartis BS has received honoraria for educational activities/lectures/advisory boards from AstraZeneca/Boehringer Ingelheim (BI)/GlaxoSmithKline/Novartis/MEDA/TEVA. C. J. has received honoraria for educational activities/lectures/advisory boards from AstraZeneca/BI/Chiesi/Novartis/TEVA. K. Larsson has served in advisory board/speaker/education roles for AstraZeneca/BI/GlaxoSmithKline/MEDA/MSD/Takeda/Novartis/Chiesi/Teva. C. J. is a steering committee member for this study and served on advisory boards for AstraZeneca/Novo Nordisk/Takeda. K. Lisspers has received honoraria for educational activities/lectures/advisory boards from AstraZeneca/GlaxoSmithKline/Novartis/MEDA/Takeda. KK and J-BG are Novartis employees.

References:

1. Erasmus MC, Rotterdam, The Netherlands

Lung cancer epidemiology: Two decades’ records collected by the cancer registry of Crete
Dimitra Sifaki-Pistolla1, Ioanna Tsiliigianni1, Vasiliki-Eirini Chatzea1, Fillip Kounis1, Nikos Tzanakis1, Vassilios Georgoulas1, Christos Lionis1
1School of Medicine, University of Crete, Greece

Aim: Greece lacks national systematic records of lung cancer (LC) cases. The regional Cancer Registry of Crete (CRC) operates since 1992 aiming to collect cancer mortality/morbidity data and propose reliable preventive and management measures.

Method: Data of LC cases (1992-2013) were obtained from the CRC. Age-standardized Mortality Rates (ASMR), Age-Standardized Incidence Rates (ASIR) and Age-standardized Ratios (SMR) were estimated to assess the LC burden. Survival analysis was performed (1st, 5th, 10th and 15th year after diagnosis). Kappa statistic and Getis Ord G were estimated to capture the present status (a = 0.05), while a prediction model (Bayesian Kriging) spatio-temporally estimated the expected rates for the next decade.

Results: LC mortality differs significantly among Crete's municipalities (Pvalue = 0.02), mean ASMR of 36.5/100,000/year [males:66.8/100,000/year, females: 10.3/100,000/year], while 9% of new cancer cases are accredited to LC (40.2 new LC cases/100,000/year). LC hot spots were observed in south-east and north-west Crete (RR = 2.1; 95%CI = 1.381-3.205). LC mortality rates varied
among years for both genders, with men presenting slightly increasing rates (1992: 66.5; 2013: 66.8) and women significantly ranging from 6.9 in 1992 to 10.9 in 2013 (Pvalue = 0.01). Around 8% survived LC for 10 or more years, while survival decreases based on the year of diagnosis (1st: 35%; 5th: 12.7%; 10th: 8.1% and 15th: 7.8%). Women present different trends in terms of mortality and morbidity as well as survival, while their rates are expected to increase within the next 10years (predicted ASMR = 12.1/100,000/year and predicted ASIR 13.7/100,000/year).

Conclusion: Burden of LC in Crete is lower than in Europe, but presents constantly increasing trends especially among female residents of eastern Crete. Therefore, targeted preventive measures and comprehensive rehabilitation programmes should be adopted, within Primary Care settings at LC hot spots in Crete to cover the full spectrum of LC care and prevention.

Declaration of Interest: None

Corresponding Author: Dimitra Sifaki-Pistolla
Email: spdimi11@gmail.com

CR064
“A different kind of breath”: Re-perceiving breathlessness after mindfulness training
Alice Malpass,1 Gene Feder,1 James Dodd1
1University of Bristol, UK

Aim: Patients with asthma and COPD often experience anxiety and depression in relation to their respiratory condition. The aim was to explore, through qualitative interviews, the experiences of patients with asthma and COPD participating in an 8 week Mindfulness Based Cognitive Therapy (MBCT) course. Our analysis of the data used the multi-dimensional model of dyspnea (MDP) framework to explore differences within the individual patient’s experience and response to dyspnea after the course.

Method: 22 patients were recruited from primary and secondary care to receive an 8 week course in MBCT, delivered in a community setting. Of the 22 patients who attended the course, 12 patients were purposively sampled to take part in an in-depth qualitative interview two months after completion. We also collected enquiry data from each weekly session (discussions that took place between participants and the mindfulness teachers). Verbatim enquiry and interview data were recorded, transcribed and analysed. Within a framework analysis we used different components of the MDP model (i.e. descriptions of sensory intensity, descriptions of immediate unpleasantness, descriptions of emotional responses, immediate (reactive behaviour) and long term behavioural changes (lifestyle changes)) to organise the verbatim data. The analysis then articulated different types of mindfulness attention that may be useful for dyspnea. This allowed us to build up examples of different types of mindfulness attention and see their relationship to the components of the MDP model. We also looked across the data set for disconfirming cases.

Results: Mindfulness training appears to develop three types of mindful attention (broad attention, informative attention and re-directive attention) which impact upon the sensory perception of breathlessness. In the affective stage 2 of the MDP model, all three types of mindfulness attention are influential in reducing the intensity of emotions experienced.

Conclusion: MBCT appears to target affective and sensory perceptions outlined in the MDP model. The findings reported here improve our understanding of differences in dyspnea for chronic respiratory disease. Training in mindfulness may improve the ability to detect and monitor respiratory load and immediate ventilatory needs by cultivating a non-evaluative awareness of interoceptive (internal) sensations which over time may mediate perceptions of these sensations. MBCT may help primary care patients learn how to adjust to breathing related anxiety and other psychological barriers that impede coping and living with a chronic respiratory condition.

Declaration of Interest: None

Corresponding Author: Alice Malpass
Email: a.malpass@bristol.ac.uk

CR065
The economic burden of COPD in a Swedish cohort: The ARCTIC study
Karín Lisspers 1, Kjell Larsson2, Gunnar Johansson3, Christer Janson1, Madlaina Costa-Scharplatz3, Jean-Bernard Gruenberger4, Milica Uhde4, Leif Jorgensen5, Patrik Sobockij6, Bjorn Stallberg4
1Uppsala University, Sweden, 2Karolinska Institutet, Sweden, 3Novartis Pharma AG, Sweden, 4TJS Health

Aim: To assess healthcare utilisation and societal costs associated with chronic obstructive pulmonary disease (COPD) in a large Swedish retrospective cohort.

Method: Primary care medical records data from Swedish COPD patients (2000–2014) were linked with information from national primary and secondary care registries. Data included prescriptions, mortality, hospital care, income and social characteristics. Direct costs were categorized as COPD-related or not COPD-related. Drug costs (patient fees+subsidized prices), outpatient/inpatient costs, and primary care visits (divided into nurse and physician visits) were also calculated. Indirect costs (i.e. loss of income) were calculated by comparing age group-specific income levels between COPD patients and case control-matched reference patients. Income was defined as pre-tax earnings, excluding pensions or welfare benefits.

Results: 17,545 COPD patients and 84,514 reference patients were analysed. The economic burden of COPD varied markedly by age group (Figure). The main driver of direct costs across all age-groups was hospital nights not related to COPD (predominantly associated with cardiovascular disease). Respiratory drug costs were similar across age-groups; however, costs of COPD-related and non-COPD-related nights in hospital increased with age. Direct COPD-related costs increased with disease severity: €7,320 for mild (FEV1 > 80% predicted), €8,280 for moderate (FEV1 50–80%), €9,230 for severe (FEV1 < 50–30%) and €11,810 for very severe (FEV1 < 30%) disease. For patients of working age (<67 years), indirect costs was the largest contributor to total economic burden (Figure). The mean total cost per year was €17,518, €10,750 as direct and €6,768 as indirect costs. COPD patients’ income was, on average, less than half that of the reference population (e.g. €11,500 vs. €29,000 in 2012).

Conclusion: Non-COPD related hospital nights are the largest direct cost and increase with age. Direct COPD-related costs increase with disease severity. Indirect costs represent the largest economic burden associated with COPD patients of working age.

Declaration of Interest: The study was funded by Novartis. K.Lisspers has received honoraria for educational activities/lectures/advisory boards from AstraZeneca/GlaxoSmithKline/Novartis/MDA/Takeda. BS has received honoraria for educational activities/lectures/advisory boards from

Figure 1. Direct and estimated indirect costs stratified by age category. Note. Costs in EUR during 2013 Brown = COPD; orange = not COPD; yellow = primary care; blue = loss of income (indirect costs). PC = primary care.
CR066
PAMA (Minimum asthma package). Approach from Primary Attention

Xavier Flor-Escriche1, Laia Lamarca-Fornell2, Silvia Álvarez-Alvarez1, Sara-Anna Davies-Daunas1, María-Victòria Feijóo-Rodríguez1, Ainhoa Toscano-Rivera1

1Barcelona ICS. CAP Chafarinas, Barcelona, Spain, 2ABS Vall de Tenes CAP, Bigues i Riells, Spain

Aim: Analyse if “PAMA”s application in primary attention: Improves asthma control level and its quality of life; reduces the number of asthma exacerbations and visits. Secondary aims: To determine which time interval is more effective for “PAMA’s” application. PAMA’s cost effect.

Method: 3 year randomized clinical trial including 10 primary attention centres. 498 asthmatic patients (18 to 75 years old) recruited at the beginning were divided in 4 groups: Group I PAMA’s application every 6 months (n = 124); II: every 12 months (n = 120); III: every 18 months (n = 115); control group: regular clinical practice (n = 139). “PAMA” consists of: explaining the disease, inhaler systems and exacerbations symptoms, application of asthma control test (ACT), delivery of an asthma action plan for the exacerbations and an avoidance plan.

Results: Baseline results compared to the ones after one year were the following. Taking into account that after one year follow-up 392 patients were still participating in the study: 110 in the control group, 84 in group I, 98 in group II and 100 in group III. Average age of 49 and 50.6 years old respectively. 72/73.5% women. 18.7/16.1% of smokers (significant differences P = 0.05). 70.1/73.2% of the patients had well-controlled asthma, 24.1/18.6% poorly controlled and 5.8/4.8% poorly controlled. 36.9/39.6% of patients had intermittent asthma, 17.3/22.2% mild persistent asthma, 40/35.7% moderate persistent and 5.8/4.1% severe persistent. The average ACT score was 20.9 (SD 4.2) at baseline and 21.8 (SD 4.14) after one year, and mini-AQLQ was 5.7 (SD 1.1) and 5.98 (1.05) respectively. No significant differences. The percentage of patients who presented exacerbations one year prior and one year after the study (46.76% vs 39.8% in the control group, 58.06% vs 43.02% in group I, 52.17% vs 43.88% in group II and 49.19% vs 52.55% in group III respectively) did not show significant differences between groups. Costs only due to exacerbation visits were: in the control group 7447/5182 euros, 7391/3330 euros in group II, 5897/5466 in group II, and 8116/5357 euros in group III.

Conclusion: Study groups are comparable between each other. Patients included in the study maintain a good asthma control (ACT) and good quality of life (mini-AQLQ). There is a lower percentage of higher severity asthma patients. There has been a reduction in the total number of exacerbations and the patients who present them. Therefore a cost reduction has also taken place. There has been an increase in the number of patients who treat their exacerbations following an action plan.

Declaration of Interest: None

Corresponding Author: Xavier Flor-Escriche,
Email: xavier.florescriche@gmail.com

CR067
Analysis of an intervention on primary care professionals for the improvement of health outcomes in acute exacerbation of COPD in primary care

MariaJosé Bujalance-Zafral, Miguel Domínguez-Santaella1, Antonio Baca-Osorio1, Leovigildo Ginel-Mendoza1, Francisco Jesús Fernández-Vargas1, Rafael Poyato-Ramos1

1Servicio Andaluz de Salud, Málaga, Spain

Aim: To examine the impact of an intervention on Primary Care (PC) professionals of a Health District on the clinical outcomes for treating COPD exacerbations by analysing indicators of process and outcome (Clinical audit).


Results: Average age was 75 (± 9.3), 63.7% males with a BMI of 29.4 (± 7.1), 21% active smokers. Average FEV1, 48.2% (± 18.7). Average of exacerbations in the first period, 2.86 (± 2.29) and in the second 1.36 (± 1.56) (P < 0.001). Average admissions in the first and second period, 0.56 (± 0.94) and 0.31 (± 0.66) (P < 0.001) respectively. The decrease in the number of exacerbations was directly associated with having ≥ 2 exacerbations in the first period, revised in primary care, and inversely with Heart Failure and with having ≥ 2 exacerbations in the second period (R2 = 0.28, P < 0.001).

Conclusion: The number of exacerbations and admissions in both assessed periods decreased significantly. However, the evaluated process indicators did not improve. Prospective intervention studies are necessary to establish the possible cause relationship.

Declaration of Interest: None

Corresponding Author: Maria José Bujalance-Zafran,
Email: mjbujalance@hotmail.com

CR068
Severe health status impairment in COPD patients treated in general practice: is it a problem?

Erik Bischoff, Laura Elbers1, Tjard Schermer1, Jan Vercoulen1

1Radboud University Medical Centre, The Netherlands

Aim: The vast majority of COPD patients are treated by the general practitioner (GP). It is assumed that these patients experience only mild health status impairment compared to patients treated by the pulmonologist. However, studies providing a detailed assessment of health status of COPD patients treated in general practice are lacking.

Method: We assessed health status using the Nijmegen Clinical Screening Instrument (NCSI). The NCSI provides a detailed assessment of health status by measuring eight sub-domains, covering symptoms, functional impairment, and quality of life. Normative data indicate sub-domain scores as normal functioning, mild impairment or severe impairment. We compared COPD patients treated by Dutch GPs with patients treated in a specialized respiratory care outpatient clinic.

Results: We collected data from 134 COPD patients (57% male, mean post-BD FEV1 66% predicted) treated in five general practices in the Nijmegen region and compared these with 303 patients (63% male, mean post-BD FEV1 55% predicted) treated in the University Centre for Chronic Diseases Dekkerswold. Percentages of GP patients with severe impairment varied from 21% (sub-domain “satisfaction with relations”) to 65% (sub-domain “general quality of life”). This was comparable to patients treated by the pulmonologist. Fifty percent of GP patients experienced severe impairment in at least three of the eight NCSI sub-domains compared to 63% of patients treated by the pulmonologist.
Conclusion: One in every two COPD patients treated by the GP seems to experience severe health status impairment, which is unexpected and only slightly lower than in patients treated by the pulmonologist. Assessing health status in detail should form an important part of COPD disease management in general practice as it supports GPs in providing personalized COPD care.

Declaration of Interest: None
Corresponding Author: Erik Bischoff,
Email: erik.bischoff@radboudumc.nl

CR069
Utility of the Nijmegen Clinical Screening Instrument (NCSI)-method as a tool for personalised COPD disease management in general practice
Erik Bischoff1, Jan Vercoulen1, Laura Elbers1, Robbert Behr2, Tjard Schermer1
1Radboud University Medical Centre, The Netherlands, 2Organisation for Chronic Primary Care, The Netherlands

Aim: To understand the impact of COPD on the individual patient, assessment of health status should form an important part of routine COPD care. The Nijmegen Clinical Screening Instrument (NCSI)-method provides a detailed assessment of health status, but has not been used in general practice so far. Our aim was to assess the utility of the NCSI-method in COPD disease management in general practice.

Method: We conducted a mixed-method non-experimental study in which we integrated the NCSI-method in an existing COPD disease management programme in five Dutch general practices. We assessed the utility of the NCSI-method by evaluating (i) the severity of health status impairment by using the NCSI-questionnaire, (ii) whether the NCSI-method fitted in the framework of the existing COPD disease management programme by using digital registration and logs, and (iii) how patients and practice nurses valued the NCSI-method by using focus group interviews.

Results: Of the 180 COPD patients enrolled in the COPD disease management programme, 134 (74%) filled in the NCSI-questionnaire, mainly by computer at home. Prior to the study, 81% of patients in the COPD disease management programme were estimated to have mild health status impairment. However, according to the NCSI-method, 50% of COPD patients experienced severe impairment in at least three of the eight NCSI sub-domains. The NCSI-method fitted well in the framework of the existing COPD disease management programme. Patients as well as practice nurses thought the NCSI-method was a helpful tool for tailoring COPD care to individual patient needs.

Conclusion: Severe health status impairment in COPD patients treated in general practice is more common than expected. The NCSI-method helps to assess health status in detail, fits in the framework of COPD disease management programmes and supports personalised COPD care according to patients and practice nurses.

Declaration of Interest: None
Corresponding Author: Erik Bischoff,
Email: erik.bischoff@radboudumc.nl

CR070
Improving the quality of spirometry through use of Spirometry360, an online training and feedback system, in an outpatient setting in Bangladesh
Gain Mohammad Monsur Habib1, David Martenson2, James W Stout2, Kamrun Nahar3
1Primary Care Respiratory Group, Bangladesh, 2University of Washington, Seattle, WA, USA, 3Khulna Medical College Hospital, Bangladesh

Aim: Spirometry is an important objective measure of lung function available in outpatient settings. This simple tool is increasingly available in low resource settings, but training on proper use and interpretation of spirometric data is limited. Spirometry360 was developed as a comprehensive online interactive training and feedback system for distance learning. We hypothesized that implementation of this training system would improve quality of spirometry at an outpatient respiratory clinic in Bangladesh.

Method: The Spirometry360 program was made available through University of Washington (UW) for five months. Funding was provided by the UW CoMotion Program. Our team of seven primary care physicians and one medical assistant was trained on the available modules: Spirometry Fundamentals and Self-Paced Learning Labs. Spirometry was performed on patients deemed appropriate for evaluation by their clinician. Personal health information was disabled when uploading tests to ensure patient anonymity. Tests were graded using ATS/ERS criteria. Monthly meetings were conducted with the clinical group to review feedback reports provided by Spirometry360 and discuss improvement strategies.

Results: A total of 3622 tests were uploaded from the beginning to the end of the intervention period from February to June 2015. A test was considered clinically useful if receiving a grade A, B, or C. Useful test rate improved from 85% (779/914) to 91% (488/ 538) (Chi-sq P-value < 0.01) over the course of the study, with Grade A tests increasing from 66% (599/914) to 77% (416/538) (Chi-sq P-value < 0.001). The most common failure types were submaximal effort, early termination, and variable flow.

Conclusion: Implementation of an online learning and feedback system improved quality of spirometry in a busy outpatient setting in Bangladesh. By improving the quality of testing, we may more accurately identify and treat obstructive and restrictive lung disease in low resource settings.

Declaration of Interest: None
Corresponding Author: Gain Mohammad Monsur Habib,
Email: gmmhabib@gmail.com

CR071
Validation of a novel smart-phone spirometer in adult and pediatric patients with respiratory diseases: a cross-sectional pilot study
Gain Mohammad Monsur Habib1, James W Stout2, Kamrun Nahar3, Mayank Goel2
1Primary Care Respiratory Group, Bangladesh, 2University of Washington, Seattle, WA, USA, 3Khulna Medical College Hospital, Bangladesh

Aim: There is an unmet need for user friendly and low-cost objective self-management tools for chronic lung diseases. A smart-phone based spirometer has the potential to make remote lung function monitoring available to anyone with a smart-phone. SpiroSmart is a novel spirometer software application for smart-phones that extracts pulmonary function measurements from the microphone as the user blows at the device from arm’s length. In head-to-head comparisons of healthy subjects, SpiroSmart produces results very comparable to commercial spirometers. Creating a mathematical model for obstructive lung disease has presented unforeseen challenges, requiring many more patients than originally anticipated. Accordingly, the SpiroSmart team has welcomed involvement of both domestic and international partners. We report here on the user experience from Community Respiratory Clinic in Khulna, Bangladesh.

Method: After informed consent, during a single visit, head-to-head data are collected from patients with obstructive lung disease using SpiroSmart and the nidd EasyOne Diagnostic as the “gold standard” spirometer. Device sequence is randomly chosen. A quality grade is assigned to the SpiroSmart effort and tracing based on visual inspection by a clinical expert (MH). These data are then uploaded to train the algorithm for obstruction.

Results: To date, we have had 2002 patients contribute head-to-head data from this site, ranging in age from 5 to 90 years, and representing patients with all severity levels of obstruction. These data comprise the majority of our dataset. Analysis is currently ongoing and our first inspection of obstructed patient models will occur in February.

Conclusion: from these analyses are pending, and will be presented at the IPCRG meeting. We will also share the wealth of experience gained from using SpiroSmart in a busy clinical setting.

Declaration of Interest: None
Corresponding Author: Gain Mohammad Monsur Habib,
Email: gmmhabib@gmail.com
Pilot study to examine the feasibility of automatically providing results and treatment advices from lung function assessments directly to the patient
Esther Metting1, Joy van den Berg1, Thys van der Molen1, Janwillem Kocks1
1University of Groningen, The Netherlands

Aim: Patients nowadays are well educated and the Internet provides easy accessible disease information which enhances patients’ involvement in their treatment. Along with this development, previous research by our department showed that many asthma and COPD patients would like to have access in their medical results. We examined the feasibility of automatically providing results from lung assessments. Additionally, we evaluated patients’ feedback.

Method: We included 46 patients (19.6% male, mean age 61.0 [range 20-86] years, 41.3% asthma, 30.4% COPD) who were assessed by an asthma/COPD-service for primary care. In the regular AC-service procedure patients are assessed using spirometry, the Asthma COPD Questionnaire (ACQ), the Clinical COPD Questionnaire (CCQ) and a history questionnaire. A pulmonologist judges the results from the assessments through the internet and provides patient’s GP with diagnosis and treatment advice. For our study, we asked the GPs from the included patients to discuss these results with their patients within 3 weeks. After 3 weeks patients received their results at home by mail. An algorithm was developed to automatically generate a results overview for patients according to the 3 formats below (see table 1). We examined participants’ opinions and preferences with an evaluation questionnaire.

Results: The algorithm was able to generate a clear overview for all 46 patients. In some cases, the pulmonologist gave an inconsistent medication advice. It was then not possible to automatically generate a clear advice for the patient and manual adaptations had to be made. Preliminary results from 24 evaluation questionnaires showed that 95.8% of participants want to view their lung function test results again, 79.2% preferred to view all formats. 75.0% to 95.8% considered the information to be understandable (depending on the format). Information about diagnosis and disease severity caused some patients to feel anxious (respectively 8.3% and 4.2%) which might have been caused by the fact that 50% of the patients were not informed about the results by their GP within 3 weeks. 75% considered the information to be helpful in dealing with their respiratory symptoms.

Conclusion: This study has shown that automatically providing results from lung function tests is feasible and well appreciated by patients. Some patients got worried by the diagnostic results and require extra attention when providing patients with their results. Questionnaires are still coming in, more extensive data will be presented at the IPCRG.

Declaration of Interest: This study was funded by the University Medical Center Groningen. TvdM is member of the board of trustees of Certe Laboratories.

Corresponding Author: Esther Metting,
Email: e.i.metting@umcg.nl

Table 1. Description and rating of the 3 provided formats

<table>
<thead>
<tr>
<th>Format 1</th>
<th>Format 2</th>
<th>Format 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Content</strong></td>
<td>As format 1, with additionally:</td>
<td>As format 2, with additionally:</td>
</tr>
<tr>
<td>Diagnosis and explanation of diagnosis</td>
<td>Disease severity and explanation of disease severity based on ACQ, CCQ and pulmonary function testing</td>
<td>Raw/Crude pulmonary function test results, expressed in numbers</td>
</tr>
<tr>
<td>Disease severity and explanation of disease severity based on ACQ, CCQ and pulmonary function testing</td>
<td>Raw/ACQ and CCQ outcomes, along with a legend</td>
<td></td>
</tr>
<tr>
<td>Medication advice and explanation of medication advice</td>
<td>Correspondence between pulmonologist and GP</td>
<td></td>
</tr>
<tr>
<td>Lifestyle advice and explanation of lifestyle advice</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Overall rating, mean [range]*

<table>
<thead>
<tr>
<th>Format 1</th>
<th>Format 2</th>
<th>Format 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>8[5-10]</td>
<td>7[2-10]**</td>
<td>8[4-10]**</td>
</tr>
</tbody>
</table>

*Participants rated our information on a scale of 1 to 10 (1 = lowest, 10 = highest).
Format 1 is very basic whereas format 2 and 3 also display crude test results. In format 3, patients see their own flow-volume curve along with a standardized “healthy” flow-volume curve.
however inhaler technique is poor and this leads to poor asthma control. Current guideline guided inhaler instructions are not enough to improve inhaler technique in all patients. We have evaluates patients’ perspectives on inhaler technique instructions.

Method: Semi-structured interviews were used to interview 24 young asthma patients (average age 21.9±3.7 years) about their experiences and preferences with inhaler instructions. Additionally we have evaluated their inhaler technique using video recordings. The interviews were audio-recorded, transcribed verbatim and analysed using grounded theory. We used a history questionnaire and the Asthma Control Questionnaire (ACQ) for background information. This data was analysed using SPSS.

Results: Male, 43 years: “I need at least an instruction about the inhaler technique. You can easily swallow a pill, but this is something else, something you have to get used to. I think that if you have practiced the technique once or twice you will do fine.” 46% (n=11) participants had controlled asthma (ACQ < 0.75). 25% of them used their inhaler correct while 75% rated their inhaler technique correct. All patients have had one or more inhaler instruction by GP, practice nurse or pharmacist. Remarkable was that most patients did not search for solutions regarding inhaler technique if they had trouble using their device at home. Inhaler instructions should be 1) personal, 2) given by a qualified instructor, 3) include hands-on training and feedback, 4) include information about asthma and the working mechanism of the medication. Some patient would like to have additional (digital) information to use at home. Follow-up assessment were not preferred by all patients.

Conclusion: Woman, 23 years: “I do not remember very well whether it (aero-chamber) had to make a sound or not. I remember that they said you could use it to check if you inhale correctly but it was not clear how.” We obtained new ideas for improving inhaler technique. The most important finding is that inhaler instruction should be embedded in information about asthma: healthcare professionals should explain the reasoning behind inhaler technique. This study is part of the European study from the Inhaler Research Workgroup.

Declaration of Interest: This study was funded by AstraZeneca with an unrestricted grant.

Corresponding Author: Esther Metting.
Email: e.i.metting@umcut.nl

CR075
Prevalence of subjective swallowing dysfunction in patients with stable COPD. The TIE-study
Margareta Gonzalez Lindh1, Andrei Malinovschi1, Marieann Högman1, Regina Bendrik1, Björn Stallberg1, Karin Lisspers1, Monica Blom Johansson1, Hirsh Koyi1, Christer Janson1, Eva Brandén1, Hans Hedenström1, Johanna Suiku1, AlexandraThorndalssen1, Jens Ellingsen1, Kristina Bröms1
1Uppsala University, Sweden

Aim: The Swedish TIE-study is a prospective multi-centre study in primary and secondary care to identify the underlying etiology of exacerbations in COPD patients. The aims of this study were to investigate the prevalence of subjective swallowing dysfunction, i.e. oropharyngeal dysphagia (OPD), and to determine the relation to COPD disease stage (GOLD), gender, exacerbations and physical activity.

Method: In total 335 patients (58% female) with a physician- and spirometry-verified COPD diagnosis were included. Data pertaining patients’ subjective swallowing ability was gathered through a questionnaire where patients were asked: 1. If food gets stuck in the throat when swallowed. 2. If they cough when eating and 3. If they choke when eating. Physical capacity was assessed by means of 30 seconds sit-to-stand test and 30 meters walking test.

Results: 117 (35%) experienced signs or symptoms (s/s) of OPD. Table 1 shows the distribution of patients. No significant difference was found between men and women. Subjects reporting OPD had a similar age (median, range) as subjects without OPD. 70 years (50-84) vs 70 years (49-85), P=0.90. Patients who experienced a swallowing dysfunction were found in all stages with no difference between the stages (P=0.58). No relation between dysphagia symptoms and acute visits due to respiratory problems (P=0.93) or COPD exacerbations (P=0.59) during preceding year were found. Subjects with dysphagia had poorer physical capacity, assessed by both number of sit to stand repetitions during 30 seconds (P=0.01) and time to walk 30 meters at maximal speed (P=0.04).

Conclusion: Swallowing dysfunction is more commonly experienced by COPD patients than in the general geriatric population (15-22%). Speech pathologists are trained to diagnose and treat OPD and could potentially play an important role in the multidisciplinary management of COPD.

Declaration of Interest: None

Corresponding Author: Margareta Gonzalez Lindh,
Email: margareta.gonzalez.lindh@regionavleborg.se

Table 1. Distribution of patients experiencing oropharyngeal dysphagia (OPD) according to COPD disease stage (GOLD)

<table>
<thead>
<tr>
<th>Stage (GOLD)</th>
<th>Study population (n)</th>
<th>Patients with subjective s/s of OPD (n)</th>
<th>OPD by COPD stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>23</td>
<td>11</td>
<td>44%</td>
</tr>
<tr>
<td>2</td>
<td>185</td>
<td>61</td>
<td>33%</td>
</tr>
<tr>
<td>3</td>
<td>94</td>
<td>35</td>
<td>37%</td>
</tr>
<tr>
<td>4</td>
<td>34</td>
<td>10</td>
<td>29%</td>
</tr>
<tr>
<td>Total</td>
<td>335</td>
<td>117</td>
<td>35%</td>
</tr>
</tbody>
</table>

CR076
Assessment of risk factors in acute bronchiolitis patients referring to emergency department
Pinar Köksal1, Umut Gök Balci2, Didem Çekiç2, Serkan Gulanay2, Duygu Çam3, Hande Kutlu4, Murat Anıl2, Kurtulus Ongel1
1Çelebi University, Izmir, Turkey, 2Tepecik Research and Training Hospital, Tepecik, Turkey, 3Katip Çelebi University, Izmir, Turkey

Aim: Acute bronchiolitis is an inflammation and edema of the bronchioles resulting lower respiratory tract infection mostly caused by viruses in 0-24
months older children. In this study, we aimed to investigate the risk factors in patients with acute bronchiolitis.  

Method: In this cross-sectional descriptive study, patients were children who diagnosed with acute bronchiolitis referring with wheezing complaints to emergency department of Izmir Tepeck Training and Research Hospital in the period of March 2015 - April 2015. Parents of the individuals were given a questionnaire investigating smoking at home, maternal smoking during pregnancy, heating source of the current residence, sharing the same environment with the child at night. Data distributions displayed using percentages.  

Results: In the study, 9 patients were 0-3 months old, 18 patients were 3-6 months old, 25 cases were 6-12 months old, 21 patients were older than 12 months. We determined that %70 of the 74 cases has smoking in the family and in %44 of these cases also pregnancy maternal smoking occurred. Smoking took place in the homes of all the subjects of the ages 0-3 months old, of %61 were 3-6 months old, of %60 were 6-12 months old and of %77 were older than 12 months. Maternal smoking during pregnancy has been noticed in the largest group with the 25 cases of 6-12 months old. %33 patient of up to three-months-old cases -which is the most critical group in terms of mortality- has been also associated with the maternal smoking during pregnancy. Home heating sources of the patients’ were stove (n = 60), air conditioning (n = 8), electric stove (n = 4), gas (n = 2). Moreover 73 of 74 patients found to be sharing the same environment with the child at night. 17 children had suffered multiple bronchiolitis attacks and 8 patients had no history of smoking in the family.  

Conclusion: Results of our study indicate variables as the use of smoke in the family, maternal smoking during pregnancy, heating sources and sleeping in the same room are significant environmental risk factors for acute bronchiolitis.  

Declaration of Interest: None  

Corresponding Author: Yong Loo Lin School of Medicine, National University of Singapore, Singapore  

Email: dr.pinarkoksal@gmail.com

CR077  
A survey of knowledge, attitudes and practices of doctors in general practice in Singapore towards chronic obstructive pulmonary disease  
Cher Chee David Cheong,1 Tze Lee Tan,1 Kwok Yee See Toh,1 Jia Jong Stephen Tong,1 Fong Seng Lim1  
1Yong Loo Lin School of Medicine, National University of Singapore, Singapore  

Aim: To examine the knowledge, attitudes and practices of doctors in general practice towards chronic obstructive pulmonary disease (COPD) in Singapore and to understand the barriers towards managing COPD by general practitioners (GPs) in Singapore.  

Method: A descriptive cross-sectional study was conducted using a self-administered questionnaire through a postal survey sent to 1619 members of the College of Family Physicians Singapore.  

Results: Out of the 1619 questionnaires mailed out, 425 were returned (26.25%). The survey showed poor awareness of COPD with 8.9% not knowing the prevalence rate and 11.8% stating the prevalence of COPD as less than 5%. There was an over-reliance on symptoms, low use of spirometry and high use of X-rays in the diagnosis of COPD. GPs also had low access to spirometry with 33.1% having direct access. However, they correctly based treatment decisions on symptoms, exacerbation history and COPD assessment scores. The most commonly used pharmaceutical agents were inhaled short acting bronchodilators followed by inhaled corticosteroids with long acting beta agonists. Guideline-recommended inhaled long-acting bronchodilators were not commonly used. Only 42.6% used COPD guidelines with GOLD guidelines being the most commonly used. Half of the GPs felt that their lack of knowledge of COPD was a barrier to treatment, with patients’ lack of knowledge, poor compliance and medication costs being other barriers. GPs with post-graduate qualifications were more likely to use guidelines and spirometry. Private sector GPs had less access to spirometry used less spirometry.  

Conclusion: Despite being an affluent country, COPD diagnosis and treatment in Singapore still falls short of guideline recommendations. More education is clearly needed for both GP and patient, with increased access to spirometry. The cost of medications should also be looked into.  

Declaration of Interest: None  

Corresponding Author: Cher Chee David Cheong, Email: cheongccdc@hotmail.com

CR078  
Chilaiditi syndrome with dispnea disease and chest pain  
Pinar Köksal1, Umut Gök Balç2, Zeynep Altın2, Kurtuluş Öngel3  
1Izmir Tepeck Educational and Research Hospital Family Medicine Department, Izmir, Turkey, 2Tepeck Research and Training Hospital, Tepeck, Turkey, 3Katip Çelebi University, Izmir, Turkey  

Aim: Chilaiditis sign, which means colonic interposition between the liver and diaphragm as a radiologic evidence, first documented in 1865 but named in 1910 by Denetrius Chilaiditi when he reported three cases of asymptomatic patients with this radiologic sign on routine abdominal or chest x-ray. This sign found incidentally in 0.025%–0.28% of chest and abdominalplain films and 1.18%–2.4% of abdominal computed tomography (CT) scans. It is four times more common in male than female. Our major purpose in this case is to emphasize interpreting the patient with history, physical exam, laboratories and plain films on whole as a primary care medicine instead of focusing just previous diagnosis.  

Method: In this case an 82-year-old man, who presented to the emergency department several times with frequent chest pain, dyspnea and extreme abdominal distention, was diagnosed with chilaiditis syndrome with chest x-ray during his clinical follow up visit. His main complement was chest pain as he presented to the Emergency Medicine for six times through the last 5 years. His cardiac enzymes were in normal range or mild above the upper limit. But he has abnormalities in ECG diagnosed as right bundle brunch block and arritma. We informed the patient as a primary care medicine about chilaiditis syndrome, its symptoms and how to manage it like bed rests, fluid supplementation nasogastric decompression laxatives and stool softeners.  

Conclusion: In primary care examinations, Chilaiditi syndrome should be considered in patients with chest or /and abdominal pain. We must be careful about Chilaiditi syndrome in primary care examinations.  

Declaration of Interest: None  

Corresponding Author: Pinar Köksal, Email: dr.pinarkoksal@gmail.com

CR079  
Evidence based practice in using antibiotics for acute tonsillitis in primary care practice  
Valentina Risteska Nejasmic1, Radmila Ristovska1, Vesna Velic2, Irena Kondova Topuzovskà1, Katerina Stavrlik2  
1Medical Faculty, Skopje, Macedonia  

Aim: To assess use of evidence based practice among general practitioners in antibiotic prescribing for acute tonsillitis in R.of Macedonia.  

Method: Data are used from national project about antibiotic prescribing for acute respiratory tract infections which has been run in 2014 November as a part of E quality program. 81 general practitioners from Macedonia have taken participation. The group of 1768 patients, old from 2 months to 88 years of age, with diagnosis of acute tonsillitis was analysed. Antibiotic prescription was compared to the Cochran guidelines which are used as national guidelines.  

Results: 88.8% of patients were treated with antibiotics. Most of the patients (45.2%) are at age range between 3-14 years. Diagnosis is mostly done based on clinical picture. In 2.4% is performed CRP, and in 1.9% streptococcus. According Centor score, 28% of patients with Centor score < 1 the most were treated with antibiotics, while 8% with score 4 and 5 didn’t received antibiotic. In 88% patients (50.8%) with score 2 and 3, 88.5% of them were treated with antibiotics. There is no correlation between prescription of antibiotics for acute tonsillitis and age of the patient, day care or school attendance, parent’s...
education or education of patients and working status of patients (Spearman Rank Order Correlation, \(P > 0.05\)). The most prescribing drug was amoxicillin-clavulanate (622 patients), while only 47% of patients received a recommended antibiotic according the guideline. 25% were treated with amuplar therapy.

Conclusion: There is inappropriate prescribing of antibiotics and broad spectrum antimicrobial drugs in patients with acute tonsilitis in Macedonia. Use of guidelines and Center criteria can help in rational prescribing, but it should be supported with laboratory tests. Although there are guidelines, compliance is still very low.

Declaration of Interest: None

Corresponding Author: Valentina Risteska Nejasomic,
Email: nejasomic@yahoo.com

CR080
COPD guides and inhaled corticosteroids. Do we prescribe them correctly in primary attention?
Sara-Anna Davies-Daunas\(^1\), Xavier Flor-Escriche\(^1\), Silvia Álvarez-Alvárez\(^2\), Maria-Victòria Feijóo-Rodriguez\(^1\), Laia Lamarca-Fornell\(^3\)

\(^1\)Barcelona ICS CAP Chafarinas, Barcelona, Spain, \(^2\)ABS Vall de Tenes CAP, Bigues i Riells, Spain

Aim: To determine the number of patients that are being correctly treated with inhaled corticosteroids (IC) according to the stage and the different guides. To determinate the percentage of patients treated correctly according to the stage, severity and the guide used (GOLD or GesEPOC).

Method: Multicentre transversal study in Barcelona city. A total of 401 patients diagnosed of COPD and with FEV1/FVC after bronchodilatation < 0.70 in spirometry test, from 6 primary attention centres, were included. The treatment prescribed to the patients was analysed and compared to the recommendations given in both guides. Statistical bivariate analysis.

Results: If we analyse the IC treatment according to GOLD's classification, the highest percentage of prescribed IC is in stage B (81.5%). Although, if we analyse it according to GesEPOC's classification, the highest percentage is in phenotype D (80%). The adequacy of prescribed treatment according to GOLD's guide is correct in 89.5% of the patients in stage B. On the other hand, according to GesEPOC's guide, 70.6% of phenotype C patients have IC correctly prescribed.

Conclusion: According to GOLD's guide, there's a high percentage of patients in mild and moderate stages who should not have IC prescribed. Regarding GesEPOC's guide, the same happens with phenotype A patients. There is a correct adequacy of prescribed IC in the other stages and phenotypes. Globally, we can observe a better treatment adequacy in mild and very severe stages according to GOLD's guide, and phenotypes A and C in accordance to GesEPOC's guide.

Declaration of Interest: None

Corresponding Author: Sara-Anna Davies-Daunas,
Email: sara.davies.daunas@gmail.com

CR081
Avoiding infections among patients with COPD: cross sectional analysis of the Birmingham COPD cohort
Rachel Jordan\(^1\), Victoria Woodall\(^1\), Alice Sitch\(^1\), Ainee Khan\(^1\), Andy Dickens\(^1\), Alexandra Enocson\(^1\), David Fitzmaurice\(^1\), Peymane Adab\(^1\)

\(^1\)University of Birmingham, UK

Aim: Most COPD exacerbations are caused by respiratory infections. Methods to avoid infection such as more frequent handwashing have been shown to reduce respiratory infections among healthy adults and children. The aim of this analysis is to explore the association between self-reported infection avoidance behaviours and risk of severe exacerbation using data from the Birmingham COPD cohort.

Method: The Birmingham COPD cohort is a unique primary care cohort which recruited 1558 patients with diagnosed COPD during 2012-13 from 71 general practices in the West Midlands, UK. Patients received one initial face-to-face clinical assessment with questionnaires at 6-month intervals. Questions about infection avoidance practices (hand hygiene and social distancing) were included within the 18 m questionnaire, along with sociodemographic and medical information. The primary outcome was self-reported inpatient hospital respiratory admission over the last 12months/length of stay. Logistic and Poisson regression were used as appropriate in cross-sectional analyses with adjustment for age, sex, smoking status, MRC breathlessness score, GOLD stage and number of co-morbidities.

Results: Complete data for 818 patients were available so far, of whom 534 (65.3%) were male and mean age (SD) was 71.4 (8.4) years. 75% patients washed their hands between 3 and 9 times per day, and 757 (93.3%) usually/always used soap. 200 (27.6%) patients washed their hands more than usual if someone they lived with had cold/flue, and 449 (55.3%) avoided meeting friends/relatives if they had a cold/flue. 77 patients (9.4% of available data) reported respiratory admissions in the previous 12months. After adjustment for potential confounding factors, participants who avoided meeting friends/relatives with respiratory infections reported fewer days in hospital (IRR 0.55 (0.46, 0.65)) and reduced number of admissions (IRR 0.90 (0.58, 1.40)) although this was not statistically significant. Other handwashing behaviours showed inconsistent patterns across outcomes.

Conclusion: This observational data suggests that avoiding friends/relatives with respiratory infections may be beneficial in reducing the impact of severe exacerbations among COPD patients. The effects of other infection avoidance behaviours are inconsistent but may be subject to recall or social acceptability bias, or reverse causation. Longitudinal analysis will be required to confirm if the association is causal.

Declaration of Interest: This abstract summarises independent research funded by the NIHR under its Programme Grants for Applied Research Programme (Grant Reference Number RP-PG-0109-10061). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or Department of Health. There are no competing interests.

Corresponding Author: Rachel Jordan,
Email: r.e.jordan@bham.ac.uk

CR082
An effective COPD case finding strategy in Primary Care
Evangelos Fragkoulis\(^1\), Argyro Kyriakaki\(^2\), Marek Papathanasiou\(^3\), Nikolaos Economou\(^4\), Konstantinos Maragianis\(^5\), Anargiros Mariolis\(^6\)

\(^1\)Solo Practice, Athens, Greece, \(^2\)Health Center of Peristeri, Greece, \(^3\)Solo Practice, Greece, \(^4\)Gennadi, Rhodes Rural Practice, Greece, \(^5\)Health Center of Kalyvia, Greece, \(^6\)Health Center of Areopolis, Lakonia, Greece

Aim: COPD remains widely underdiagnosed worldwide, but the most effective case finding approach is still unknown. We conducted a pilot study to evaluate the effectiveness of an opportunistic, targeted screening approach for COPD in Primary Care. We targeted high risk patients for COPD (smokers, having 2 respiratory symptom).

Method: Patients from different types of general practice settings in Greece (urban, semi-urban and rural) were included. They had to be 40 years, smokers or ex-smokers, with 2 respiratory symptom present (dyspnea, cough, wheeze or phlegm) and with no previous diagnosis of COPD. Smokers completed a short COPD screener questionnaire. Eligible patients were offered a spirometry.

Results: 250 patients from 5 GPs working in different Primary Care settings were included. 213 had an acceptable spirometry. From them, 82 patients (38.5%) were diagnosed with COPD (FEV1 / FVC < 70%). The majority of them had mild or moderate obstruction. The number needed-to-screen (NNS) for a new diagnosis of COPD was 2.6.

Conclusion: Targeting those at higher risk (e.g., smokers) and pre-screening (e.g., using questionnaires) consist a highly effective and feasible strategy to identify undetected patients with COPD in Primary Care.

Declaration of Interest: None

Corresponding Author: Evangelos Fragkoulis,
Email: evan_fragk@yahoo.com
**CR083**
Correlations of Fractional Exhaled Nitric Oxide (FeNO) with asthma control and severity in asthmatic patients in Ho Chi Minh City, Vietnam

Vinh Nhu Nguyen, Ioanna Tsiligianni1, Mike Thomas2, Niels Chavannes3, Sian Williams4, Christos Lionis4
1University of Crete, Heraklion, Greece; 2University of Southampton, UK, 3Leiden University Medical Center, The Netherlands, 4International Primary Respiratory Group, Edinburgh, UK

**Aim:** To determine the association between FeNO and measures of asthma control (GINA classification and Asthma Control Test (ACT) score) and asthma severity (GINA treatment step).

**Method:** Prospective observational study performed at an outpatient respiratory clinic, in the University Medical Center, Ho Chi Minh City, Vietnam from March 2015 to January 2016. We included asthmatics, 12 year olds or older with an asthma diagnosis since at least 6 months (according to GINA criteria) and a non-asthmatic control group. Data collected included asthma history, symptoms, rescue medication use, spirometry and FeNO; in the control group only FeNO was assessed. Asthma control was classified according to GINA categories (uncontrolled, partly-controlled and controlled) and ACT (GINA classification and Asthma Control Test (ACT) score)

**Results:**
175 patients with asthma (73% female) with mean age 40 (±15) and 30 controls (60% female) with mean age 38 (±5) were recruited. Mean FeNO in patients with asthma was significantly higher than in this controls (30 vs. 20.6 ± 13ppb, P=0.037). FeNO was weakly inversely correlated to ACT score (Spearman’s rho = -0.2, P=0.008). FeNO was significantly different among asthmatics with different levels of GINA defined asthma control (uncontrolled, partly-controlled and controlled) with mean FeNO of 37 ± 39ppb, 34 ± 27ppb and 26 ± 19ppb, respectively (P=0.032). Mean FeNO also different among three levels of ACT defined asthma control with 49 ± 38ppb in uncontrolled; 33 ± 28ppb in partly-controlled and 26±16ppb in controlled asthma group (P<0.001). FeNO was not significantly different among those with mild (30 ± 23), moderate (26 ± 21) and severe (31 ± 27) asthma estimated by GINA treatment step (P=0.59).

**Conclusion:** FeNO values were elevated in patients with asthma as compared with patients without asthma FeNO was weakly associated with ACT score and levels of asthma control defined by GINA or ACT score but not with asthma treatment step. FeNO is feasible in low-income country settings and further research is needed to determine its clinical and cost effectiveness in the outpatient clinic setting.

**Declaration of Interest:** Aerocine supplied the equipment for this study to the study team in Vietnam, and the IPCRG supported Nguyen Nhu Vinh as part of its E-Faculty programme.

**Corresponding Author:** Vinh Nhu Nguyen,
Email: nguyen nhu vinh@gmail.com

---

**CR085**
Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients

Jan De Backer1, Cedric Van Holsbeke1, Wim Vos1, Samir Vinchurkar1, Wilfred De Backer2, Juliet Rebbello3, Mayuri Mangale2, Jaideep Gogtay2
1Fluidia nv, Kontich, Belgium, 2Antwerp University Hospital, Belgium, 3Cipla Ltd, India

**Aim:** Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI (250/25 mcg) using functional respiratory imaging (FRI) based computational fluid dynamics (CFD) in asthmatic patients.

**Method:** In this randomised, double-blind, double-dummy, single-dose, twopoint, crossover study, 16 stable adult patients with asthma received 2 puffs of either the test (Cipla Ltd., India) or the reference product (Seretide Evohaler, GlaxoSmithKline UK) on the first treatment day, and the alternative treatment on the second treatment day. The two dosing days were separated by a washout period of 3-7 days. The primary comparison was based on changes in airway volumes (iVaw) and surface area (iSaw) between baseline and post treatment for the test and the reference product assessed using FRI based CFD.

**Results:** Significant post treatment changes from baseline were observed for the test and the reference product (table 1). The difference in treatment effects between the test and reference product was not statistically significant for the imaging tests.

---

**Table 1.** Imaging test results for post treatment changes for the test and reference product

<table>
<thead>
<tr>
<th>IMAGING TESTS</th>
<th>Change Test Mean (SD)</th>
<th>Change Reference Mean (SD)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>iVaw [cm³]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>3.72 (3.36)</td>
<td>3.23 (1.82)</td>
<td>0.393</td>
</tr>
<tr>
<td>Central</td>
<td>1.39 (1.61)</td>
<td>1.03 (1.17)</td>
<td>0.266</td>
</tr>
<tr>
<td>Distal</td>
<td>2.34 (2.12)</td>
<td>2.20 (1.37)</td>
<td>0.698</td>
</tr>
<tr>
<td>iSaw [cm²]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>22.33 (17.37)</td>
<td>20.25 (12.02)</td>
<td>0.660</td>
</tr>
<tr>
<td>Central</td>
<td>3.23 (2.68)</td>
<td>2.92 (3.12)</td>
<td>0.338</td>
</tr>
<tr>
<td>Distal</td>
<td>19.10 (15.73)</td>
<td>17.32 (12.00)</td>
<td>0.567</td>
</tr>
<tr>
<td>iRaw [kPas/L]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>-0.012 (0.013)</td>
<td>0.014 (0.013)</td>
<td>0.453</td>
</tr>
<tr>
<td>Central</td>
<td>-0.0002 (0.003)</td>
<td>0.002 (0.003)</td>
<td>0.897</td>
</tr>
<tr>
<td>Distal</td>
<td>-0.010 (0.011)</td>
<td>0.012 (0.011)</td>
<td>0.485</td>
</tr>
</tbody>
</table>
Conclusion: Lung deposition analysis confirms no significant difference in the treatment effects between the two formulations of fluticasone/salmeterol HFA pMDI.

Declaration of Interest: Juliet Rebbello, Mayuri Mangale and JaidEEP Gogtay are full time employees of Cipla Ltd. The study was funded by Cipla Ltd.

Corresponding Author: Jan De Backer,
Email: Jan.debacker@fluidda.com

CR086
Evaluation of asthma control in primary care using asthma control test and peak expiratory flow rate
Clement Perera1, Seneth Samaranayake2
1Jude Family Clinic, Ja-Ela, Sri Lanka, 2Katukurunda Clinic, Kaluthara, Sri Lanka

Abstract
Aim: Asthma is considered a major health problem in Sri Lanka as well as globally. The burden of asthma is overwhelming. Asthma control has not been formally evaluated in Sri Lanka. This study has comparatively evaluated disease control with Asthma Control Test (ACT) and peak expiratory flow rate (PEFR).

Method: Asthma control was examined in a cross-section of 449 asthmatics above 5 and below 70 years of age using the ACT, and on the PEFR % predicted. Scores below 20 on the ACT and PEFR below 80% predicted indicated uncontrolled asthma. Simultaneously, patients were clinically evaluated, whether their asthma was controlled or uncontrolled. Asthmatics were again evaluated fortnight after treatment according to Global Initiative for Asthma (GINA) guidelines in two primary care clinics in Sri Lanka.

Results: Asthma control numbers were 344(76.6%) according to ACT and 345 (76.8%) according to PEFR. Performance of Asthma control of ACT and PEFR were basically considered for pediatrics (Age < = 12) and adults (Age >12) separately. Kappa statistic indicated substantial agreement of the ACT for pediatrics (0.6099 (CI 95% 0.4506, 0.7692) as well as for adults (0.6345 (CI 95% 0.5212, 0.7478), While PEFR shows moderate agreement for pediatrics (0.5314 (CI 95% 0.3723, 0.6906) as well as for adults 0.6099 (CI 95% 0.4506, 0.7692) when compared with the clinical judgment. Pediatric and Adult status was associated with control on the PEFR (P <0.05) but not with the ACT.

Conclusion: Asthma control evaluation is stable and independent with ACT for both pediatrics and adults age groups and it shows good agreement when compared with clinical evaluation. PEFR constitute poor agreement as compared with ACT and dependent with pediatrics and adults groups. This proves PEFR is unstable in evaluating asthma control but ACT is recommended for all ages.

Declaration of Interest: None

Corresponding Author: Clement Perera,
Email: clement4@gmail.com

CR087
Medical care and self-management support for asthma in primary care: a comparison between France and the United Kingdom
Alexandra Lelia Dima1, Eric van Ganse2, Hélène Le Cloarec3, Marijn de Bruin4
1University of Amsterdam, The Netherlands, 2Claude Bernard Lyon 1 University, Lyon, France, 3Kappa Santé, Paris, France, 4Institute of Applied Health Sciences, University of Aberdeen, Scotland

Abstract
Aim: Managing asthma in primary care relies on delivering both medical care and behavioural support for self-management. Clinical guidelines and behavioural research recommend several routine activities for optimizing asthma-related outcomes. However information on current content of care is scarce across health care systems, as is concrete advice on guideline implementation. We compared practitioner-reported routine asthma care in two European countries to understand variations in care and system- and practitioner-specific facilitators.

Method: Primary care practitioners participating in an asthma cohort study in France and the United Kingdom answered an online survey including 12 medical and 25 behavioural care activities. Questions were developed in English following literature review, back-translated in French, and pre-piloted. We compared the content and structure of asthma care and relationships with possible predictors, via psychometrics and association tests.

Results: The survey was completed by 156 French general practitioners (GPs), and 68 GPs and 52 nurses from 50 UK practices. French and British GPs reported similar behavioural support levels (Fisher’s p)

Conclusion: Asthma care is facilitated in UK primary care by the collaboration between GPs and nurses. In both countries, developing positive beliefs and skills regarding behavioural support might help practitioners offer more comprehensive care.

Declaration of Interest: The research leading to these results has received funding from the European Community’s 7th Framework (FP7/2007-2013) under grant agreement n°282593.

Corresponding Author: Alexandra Lelia Dima,
Email: a.dima@uva.nl

CR088
What anti-smoking therapy lengthens withdrawal time most?
Marta Ramos Díaz de la Rocha1, Rafael Angel-Maqueeda1, Miguel Dominguez-Santaella1, Sara Rodríguez-Ladrón de-Guevara1, Antonio Ubiña-Carbonero1, Marina Crossa-Bueno3, Soledad Campos-Cuenca1, Marcos Castillo-Jiménez1, Francisco Serrano-Guerra1
1Servicio Andaluz de Salud, Málaga, Spain

Abstract
Aim: This study compares the different treatments used to help give up smoking and tests which one keeps the patient smoke-free the longest.

Method: Descriptive cross-sectional study carried out in Primary Care. Collection of the data came from questionnaires, together with informed consents, completed by smokers who participated in the smoking withdrawal workshop. This data was analysed according to the time without smoking and the treatment used.

Results: Analyzed questionnaires: 156. Data collection time: 2010-2015. Urban Health Centre. Males: 46.2%. Females: 53.8%. Average age: 52. Average smoking time: 32.74 years. Average withdrawal time: 14.36 months. 27.6% never tried to quit. 19.1% relapsed in a month. 18% informed of the therapy used to give up smoking, out of which a half used pharmacological treatment (smoke-free average time: 14 months), 22% used cognitive-behavioural therapy (smoke-free average time: 39 months) and the rest used other treatments.

Conclusion: Despite the few smokers that provide information, the cognitive-behavioural therapy exceeds the pharmacological therapy in the cessation time upkeep. It would be interesting to extend the study to a random sample of general population in order to test if these results are similar and assess the long-term effectiveness of the cognitive-behavioural therapy.

Declaration of Interest: None

Corresponding Author: Marta Ramos Díaz de la Rocha,
Email: ramos.diazdelarocha.marta@gmail.com

CR089
What causes smoking relapse?
Marta Ramos-Díaz de la Rocha1, Rafael Angel-Maqueeda1, Miguel Dominguez-Santaella1, Sara Rodríguez-Ladrón -de-Guevara1, Antonio Ubiña-Carbonero1, Marina Crossa-Bueno3, Soledad Campos-Cuenca1, Clara Sánchez Sánchez1, Montserrat Román-Cereto1
1Servicio Andaluz de Salud, Málaga, Spain

Abstract
Aim: This study aims to understand the reasons why the smokers attending our tobacco withdrawal workshops, relapse. By understanding these reasons we will be able to work on those factors that lead to relapse in order to prevent them. Currently, cognitive-behavioural therapy is being used to help withdraw smoking, assuming environment and social events as the most frequent causes of relapse.
Method: Data was collected from Primary Care about smokers who attended the tobacco withdrawal workshop together with their corresponding informed consent. Analysis was carried out of the reasons why the patients relapsed after some time without smoking, the length of this time was noted as was the method used for withdrawing

Results: Questionnaires: 156. Period: 2010–2015. Urban Health Centre. Males: 46.2%. Females: 53.8%. Average age: 52. Average smoking time: 32.74 years. Average withdrawal time: 14.36 months. 62% informed of their reasons to relapse. Most of these (39) related relapse with social events and over-confidence in controlling the habit. There is also a high proportion of smokers who relapse because of stress or low mood (26).

Conclusion: As it was assumed, psychosocial factors such as social events or smoking environments predispose to smoking relapse. We conclude that in the interventions the strategies affecting these factors must be reinforced so that the smokers stay smoke-free longer.

Declaration of Interest: None

Corresponding Author: Marta Ramos-Díaz de la Rocha, Email: ramos.diazdelarocha.marta@gmail.com

CR090

Women and COPD: a systematic review of female gender specificities in primary care

Carl Moubarak1, David Darmon1, Tiphanie Bouchez2

1Nice-Sophia Antipolis University, France

Aim: To describe the relationship between the female gender and the natural history of COPD (diagnosis, treatment, prognostic), in order to determine gender-specific management intended for primary care practitioners.

Method: A systematic literature review was conducted based on the PRISMA statement recommendations. The Medline and Cochrane databases were searched from 2005 to 2015, studies references were examined and grey literature was searched. The studies included were scored using R-AMSTAR scale, Newcastle-Ottawa Assessment Scale and the Cochrane collaboration Tool for assessing risk of bias.

Results: 40 articles were identified. Overall, analytical studies were of moderate quality (46% with a NOS score between 5 and 7). The majority were cross-sectional (n = 18), followed by longitudinal studies (n = 11), systematic reviews (n = 7, 3 with a meta-analysis) that were of mixed quality, case-control studies (n = 3) and finally one randomized controlled trial (n = 1) at a high risk of bias. Hospitals inpatients and outpatients accounted for 61% of the studied population and diagnostic certainty of an isolated COPD was obtained in only 3 studies. Women were more exposed to passive smoking and in low-middle income countries to air pollution. After the age of 50, they showed an annual decline of their Forced Expiratory Volume faster than men (r2 = 0.56; p = 0.008) and the ratio of their severity of a depressive disorder (r = 0.364, p < 0.01) and their tobacco dependence was more behavioural and nicotine replacement therapy less effective than for men. For the same degree of bronchial obstruction, women reported more dyspnoea, which was correlated with the severity of a depressive disorder (r = 0.364, P < 0.01) and finally, women had less sputum. Women were most at risk of being underdiagnosed with COPD than men (RR = 2.6, 95% CI [1.14-6.26], P = 0.24). Their tobacco dependence was more behavioural and nicotine replacement therapy less effective than for men. For the same degree of bronchial obstruction, quality of life was more impaired than men, in its psychological as well as in its physical aspects. Anxiety was specifically associated with the risk of death in COPD women but not in men (HR = 13.76, 95% CI [2.13-88.6], P < 0.006).

Conclusion: Studies had the best level of evidence in showing that women undergo a specific exposure to risk factors for COPD. Primary care research perspectives must be developed taking into account the gender dimension in order to develop gender-specific health care strategies.

Declaration of Interest: None

Corresponding Author: Carl Moubarak, Email: carl.moubarak@gmail.com

CR091

Evaluation of systemic exposure between two nasal spray formulations of mometasone furoate in healthy subjects

Mukul Phatak1, Shrinivas Purandare1, Geena Malhotra1, Kalindi Gandhi1, Jaideep Gogtay2

1Cipla Ltd, India

Aim: The aim of this study was to evaluate the total systemic exposure of mometasone furoate (MF) when administered as nasal spray between the test product (MF aqueous nasal spray suspension 50 mcg/actuation of Cipla Ltd., India) and the reference product (Nasonex, containing MF 50 mcg/actuation of Merck Sharp & Dohme Ltd., UK).

Method: This was an open label, randomized, crossover study, in which 48 healthy adult male human subjects received a single dose of 400 mcg (4 x 50 mcg in each nostril) of test or reference formulation of mometasone furoate nasal spray on two treatment days separated by a washout period of 14 days. Blood samples of the subjects were collected post-dose up to 72 hrs. The primary endpoints were peak plasma concentration (Cmax) and area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72).

Results: Of the 48 subjects screened, 45 completed the study. The mean ± SD values of Cmax (pg/mL) for test and reference products were 17.15 ± 8.34 and 18.28 ± 8.21, respectively, and the mean ± SD values of AUC0-72 (hr.pg/mL) for test and reference products were 192.61 ± 92.15 and 187.63 ± 103.45, respectively. The ratios of log transformed geometric mean of Cmax and AUC0-72 were analyzed to be 1.17 vs 1.08 for Cmax and 1.01 vs 0.97 for AUC0-72. Conclusion: The Cmax and AUC0-72 were within the bioequivalence limit of 80-125% in the study, and hence it can be concluded that the test product (MF nasal spray, Cipla Ltd.) is bioequivalent to the reference product (Nasonex nasal spray, Merck Sharp & Dohme Ltd.).

Declaration of Interest: Mukul Phatak, Shrinivas Purandare, Geena Malhotra, Kalindi Gandhi and Jaideep Gogtay are employees of Cipla Ltd.

Corresponding Author: Mukul Phatak, Email: mukul.phatak@cipla.com

CR092

Fluticasone/Formoterol delivered via Revolizer® as maintenance therapy for persistent asthma: A real world effectiveness study in India

Mahip Saluja1, Pradyut Waghry2, Mayank Agarwal3, Ashish Kumar Deb4, Sneha Limaye5, Ashish Goyal6, Alok Gopal Goshal7, Sudhir Bhatnagar8, Akash Bali9, Sharad Tikkiwal10, Abhijit Vaidya11, Jaideep Gogtay11

1Subharti Medical College and Hospital, Meerut, India, 2Eesha Multi-Speciality Hospital, Hyderabad, India, 3Om Surgicals And Maternity Home, Varanasi, India, 4Sudhakarwana Hospital, Patiala, India, 5Chest Research Foundation, Pune, India, 6Medipoint Hospital, Pune, India, 7National Allergy Asthma Bronchitis Institute, Kolkata, India, 8Abhinav Multi-Speciality Hospital, Nagpur, India, 9Sree Hostals & Critical Care, Nagpur, India, 10Asthma Bhawan, Jaipur, India, 11Cipla Ltd., India

Aim: To assess effectiveness, in real life setting, of fluticasone/formoterol (100/6 or 250/6 mcg) twice daily (FF) delivered via Revolizer® (dry powder inhaler device) in patients with persistent asthma.

Method: This was a 24 weeks, prospective, non-comparative, multi-centre, open-label, real-world observational study. Patients participating in this study were either already on FF at any dose via Revolizer® or were uncontrolled on other treatment via Revolizer® and required a change in their treatment to FF, as per treating physicians’ discretion. We assessed asthma control at baseline, Weeks 4, 8, 16 and 24 using Asthma Control Test™ (ACT). Morning and evening peak expiratory flow rate (PEFR), day and night time symptom scores, and safety were also evaluated.

Results: Out of 401 patients enrolled, [mean age 41.1 ± 14.36, 202(50.37%) males; 140 (34.91%) patients had mild asthma, 192 (47.88%) patients had
moderate asthma and 69 (17.21%) patient had severe asthma], 385 completed the study. At Week 24, the asthma control was significantly improved (mean change ACT score 6.7 (95% Confidence interval: 6.32, 7.06, P < 0.0001) from baseline. A significant increase in ACT scores from baseline were also observed at Weeks 4, 8 and 16, all p

Conclusion: In a real world setting, twice daily fluticasone/formoterol significantly improved asthma control and was well tolerated in patients with persistent asthma.

Declaration of Interest: Mahip Saluja had received financial support for conducting the study by Cipla Ltd. Abhijit Vaidya and Jaideep Gogtay are employees of Cipla Ltd.

Corresponding Author: Mahip Saluja, Email: drmahips@hotmail.com

CR093
Tobacco use and attitudes towards smoking among medical students in the Algarve region (Portugal)
Dyna Torrado1,2, Monica Teixeira1, Ana Marreiros2
1Faro Health Care Center, Algarve, Portugal; 2University of Algarve, Portugal

Aim: As there are no studies on the smoking habits of medical students in our region, it is of interest to determine their smoking behaviours, need for training and attitudes concerning smoking.

Method: Cross-sectional study by self-administered questionnaire to medical students from the University of Algarve (October 2014- February 2015), collecting biographical data, smoking habits, exposure to smoke at home, willingness to quit, need for training in smoking, opinions about anti-tobacco measures, role of physicians and e-cigarettes. The relationships between some of the variables were analysed using the χ² test, with pby SPSS® 19.0.

Results: We obtained 72.4% answers (n = 105): 54.2% female; mean age was 30 ± 4.6 years. The majority had tried smoking (68.5%), average age: 16 years. 21% of students are smokers, 18% are regular and 29% occasional smokers, although an additional 16% rarely smokes. Vast majority consumes manufactured cigarettes and started at 19 ± 2.8 years. There is slightly higher prevalence in men (53.8%); the average consumption is 7 ± 5 cigarettes/day; 5.6% smokes at home; 81% have a low nicotine dependence; 54.4% are determined to stop; 2/3 have tried quitting. Most students agree with banning smoking in public places (92.2%); 70.9% feel need more information about smoking and 50% agree doctors should not smoke as role-models of society -smoking behaviour influences this variable (T-Student P = 0.004) but does not the degree of studies (ANOVA P = 0.909).

Conclusion: The prevalence of smoking among our students is high, with a low dependence and better willingness to stop, in line with other Iberian surveys. Anti-smoking policies seem to reach consensus but not the beliefs about physicians play a key role as models for society, regarding smoking. Our students need to improve their knowledge about smoking and to be promoted for smoking cessation.

Declaration of Interest: None.

Corresponding Author: Dyna Torrado, Email: dynatorrado@gmail.com

CR094
A difficult asthma management case
Yasemin Şimşek1, Umut Gök Balcı2, Kurtuluş Öngen1
1İzmir Tepecik Educational and Research Hospital Family Medicine Department, İzmir, Turkey; 2Tepecik Research and Training Hospital, Tepecik, Turkey; 3Katip Çelebi University, İzmir, Turkey

Aim: Asthma is a complex, variable, recurrent disease with airway obstruction, bronchial hyperactivity and underlying chronic inflammation. The aim in the asthma treatment are reducing /eliminating asthma symptoms, improve daily/ physical activity, improve the sleeping quality (not/less night awakenings), prevent from exacerbations,ensure a normal pulmoner function capacity (fev1/fvc) and less or no need for SABA drugs during follow up. The difficulties in the asthma treatment could be because of the patient or/and health personnel.

Method: A 43 years old (M) patient with HT, epilepsy, major depression, asthma and allergic rhinitis diagnoses applied to our hospital for valproic acid dose regulation. He used valproic acid 500 31, ICS+LABA inhaler 400 21, SABA inhaler 41. The FEV1/FVC rate was 968, the physical examination showed that he had hyperemic tonsils and by pulmoner oscultation you could hear roncus all over. The posteriorialer pulmoner chest x-ray showed no significant changes. The patient was overweight with a BMI: 36 kg/m², was smoking 4 packages/year and had no intention of becoming a non-smoker. He explained that he was in need of SABA inhalers every time he walked more than 100 meters, that he had night awakenings almost every night a week. Also because of family problems he had a bad health follow up since one month he began using montelukast sodium prepartates including his asthma treatment and states that his asthma exacerbations had lessened due to the new treatment.

Results: Conclusion: Difficulties in asthma treatment can be caused by patient or/and health personnel. Patient oriented problems are taking asthma symptoms lightly or ignore them, bad treatment compliance, no faith in the asthma curability, smoking, false usage of inhaler /drugs or the expenses. Health personnel causes are ignorance or false judgement of the asthma stage which causes insufficient treatment, insufficient control follow ups.

Declaration of Interest: None.

Corresponding Author: Yasemin Şimşek, Email: dryasminsimsek@hotmail.com

CR095
Quality of life and asthma control in elderly asthmatics: a seven year follow-up – results from the PRAXIS study
Bjorn Stallberg1, Joyce Hogebrug2, Christer Janson1, Mary Kämpf3, Scott Montgomery2, Tjard Schermer2, Josefín Sundh3, Karin Lisspers1
1Uppsala University, Sweden, 2Radboud University Medical Centre, The Netherlands, 3Örebro University, Sweden

Aim: Asthma in older adults is very common, though we know little about quality of life and asthma control in this population, especially not longitudinally. The aim of this study was to analyse the course of quality of life and asthma control between 2005 and 2012 in older asthmatics. Secondly, to compare these outcomes with younger asthmatics.

Method: 747 randomly selected asthma patients (age 18-75) from primary and secondary care completed two questionnaires seven years apart. The mini Asthma Quality of Life Questionnaire (miniAQLQ) was used to assess quality of life and asthma control was defined according to the Global Initiative for Asthma (GINA) guidelines, using symptoms, medication and emergency visits. Multiple logistic regression was used to evaluate possible predictors for decreased quality of life and uncontrolled asthma.

Results: Of the 747 respondents, 496 patients were younger than 60 years in 2005 and 251 were 60 years or older. At baseline the older age group was more likely to have a lower educational level, to be a former smoker, to have a lower personal best of FEV1% predicted, more comorbidities (except for hypertension), more comorbidities and being in a higher treatment level. The proportion of controlled asthma increased in the both the older (29.3% to 40.4%, P = 0.002) and the younger asthmatics (37.2% to 44.3%, P = 0.003). Predictors for decreased quality of life and uncontrolled asthma were a lower educational level, having a depression or allergy, and being in a higher treatment level.

Conclusion: MiniAQLQ scores were lower for older asthmatics than for younger asthmatics, but did not change in the seven year follow-up period. The proportion of asthma control increased in both the older and the younger asthmatics. Optimizing clinical management is essential, especially also in the older asthmatic.

Declaration of Interest: BS has received honoraria for educational activities/ lectures/advisory boards from AstraZeneca/Boehringer Ingelheim (Bi/
Advantages of case finding for COPD in asymptomatic smokers patients

Enrique Cimas1, Javier Pérez2, Ana Morán3
1Centro de Salud de Contueuves-Vega - SESPA, Gijon, Spain, 2Centro de Salud de La Calzada II - SESPA, Gijon, Spain, 3DCCU Distrito AP Bahia de Cádiz, Cadiz, Spain

Aim: To determine the performance of a program of case finding for COPD in two health centres, among smokers older than 40 years, evaluating the number of newly diagnosed cases of COPD and those who are potentially treatable.

Method: Opportunistic case finding was conducted in two health centres for 6 months, performing spirometry with bronchodilator test in patients over 40 years of smoking more than 10 packs-years, regardless of the presence or absence of symptoms, and the reason of their visit. All of them were asked to complete the questionnaire CAT. Any patient with an obstruction and an FEV1 < 80% (GOLD spirometric stages II, III and IV) was considered for treatment.

Results: In the six-month study to 310 patients, 284 held a valid spirometry to be assessed. Amongst those, COPD (FEV1 / FVC after bronchodilation of all patients diagnosed with COPD, 33.3% had mild spirometric impairment (FEV1 > 80%), 55.6% moderate (FEV1 between 80 and 50%) and 11.1% severe (FEV1 between 50 and 30%). There were no patients with very severe involvement spirometric (FEV1 < 30%). 66.7% of all patients diagnosed were considered suitable for treatment.

Conclusion: It is advisable to perform a spirometry to anyone smoking more than 10 packs-years, regardless of the presence or absence of symptoms, since two-thirds of those diagnosed are likely to require treatment.

Declaration of Interest: None

Corresponding Author: Juan Enrique Cimas, Email: jcimash@gmail.com

Evaluating health seeking behavior of parents regarding ARI in under five year old children

Radmila Ristovska1, Valentina Risteska Nejashmikj1, Katerina Stavrikj1, Vesna Velic1, Zaneta Popeska2
1Center for Family Medicine, Medical Faculty Skopje, Macedonia, 2Faculty of Computer Science and Engineering, Skopje, Macedonia

Aim: Acute respiratory infections (ARIs) are commonly experienced in primary care, adults 2–4 ARIs a year and children 6–8. The perception, knowledge, attitude and practice of parents play an important role in the reduction of morbidity in under 5 years old children. The Aim of this study is to evaluate the health seeking behaviour of parents, regarding ARI in under five year old children, to assess the attitude, practices and estimate the knowledge of parents, regarding ARI.

Method: Data are used from national project (cross sectional study) conducted in November 2013, at primary care settings in Republic of Macedonia as a part of E quality program. Eighty-one physicians were included. Data was entered and analysed on SPSS 22.

Results: Group of 3027 patients, 0-5 years old, were analysed. The duration of illness was less than 2 days in 36, 2% and more than 2 days in 63, 8% of children. 13, 1% children are less than 1 year age, 57, 6% between 1 year and 3 years age and 29, 4% between the age of 4 to 5 years. Leading symptom in all three groups was cough with 81%, 71, 8% and 69% each.

Conclusion: Overall, the study showed that health seeking behaviour of parents indicates low level of knowledge among parents of children with ARI. Interventions like health education sessions, media campaign, banners etc. are needed to improve situation.

Declaration of Interest: None

Corresponding Author: Radmila Ristovska, Email: ristovska@hotmail.com

References

Atopic disorders in Dutch children: an epidemiological study in general practice

David Pols1, Mark Nielens2, Joke Korevaar2, Patrick Bindels1, Arthur Böhnën1
1Erasmus MC, Rotterdam, The Netherlands, 2NIVEL, Netherlands Institute for Health Services Research, Utrecht, The Netherlands

Aim: In many countries, general practitioners (GP) will treat atopic children. The medical records of these children form a reliable source of epidemiological data. Calculating incidences and prevalence will give insight in the burden of these disorders on health care systems. Data on ‘prescriptions’ can be used to assess the accuracy of an atopic diagnosis given by a GP and will in addition also provide insight in frequently prescribed medication among atopic children. Data on ‘comorbidity’ can be used to study the epidemiology of atopic and non-atopic disorders and its interrelationships.

Method: Data of The Netherlands Institute for Health Services Research (NIVEL) Primary Care Database was studied, using routinely recorded data in electronic medical records. Prevalence will be calculated as percentages on the first of

Abstracts
January (point-prevalence), using prescription-data to assess the accuracy of the diagnosis. Incidences are calculated per 1000 persons years at risk. Data regarding comorbidty and prescriptions will be studied by calculating odds ratios.

Results: A total of 862,668 possible eligible children (0-18yrs) were derived from the NIVEL Primary Care Database in the period from 2002-2014. Finally, 478,076 met the inclusion criteria (e.g. a minimum of three year follow up). The mean age at the beginning of the registration is 7.2yrs (SD: 6.0) of which 51.1% were male. On average 2397 days (SD: 1724) of follow-up were available. Conclusion: Data will be presented on incidences, prevalence, medication use and comorbidty of atopic dermatitis, asthma, allergic rhinitis and the combination of these three conditions in children.

Declaration of Interest: None
Corresponding Author: David Pols,
Email: dpols@erasmusmc.nl

CR099
Assessment of anterior segment findings in patients with obstructive sleep apnea syndrome
Tuğba Gönçü1, Ali Akal1, Zafer Hasan Ali Sak1, Aysegül Oney Kurnaz1, Fatih Mehmet Adibelli1, Dursun Çadırcı1, Mehmet Düşünür2
1Harran University, Sanliurfa, Turkey
2Hacettepe University, Ankara, Turkey

Aim: To evaluate the anterior segment findings of the patients with obstructive sleep apnea syndrome (OSAS). Also we aimed to assess the findings in anterior segment which strongly indicating this syndrome.

Method: This is a prospective, comparative study of the 32 patients with OSAS and 36 age and sex-matched control subjects. After routine eye examination, anterior segment evaluation, including, keratometry, Schirmer test, Schirmer testing, tear break-up time, lower and upper eyelid laxity measurements.

Results: There was no significant difference between two groups in respect of age and sex (P = 0.10 and P = 0.19 respectively). In our study group, all were severe OSAS cases. The mean keratometry value was 43 diopter in both groups and did not differ significantly (P = 0.748). Schirmer test comparison showed that the score was significantly higher in the OSAS group compared to the control group (P = 0.004). However tear break-up time was significantly lower in OSAS group, as compared with the control (P < 0.001). Both lower eyelid and upper eyelid laxity were significantly more in the OSAS group (P = < 0.001 ve P = 0.011 respectively).

Conclusion: In the present study, the eyelid laxity and Schirmer test were found to be higher in patients with OSAS compared to the controls. Additionally, tear break-up time was found to be lower than controls. Thus, ophthalmologists should refer their patients who have tear dysfunction and poorly respond conventional treatment for OSAS investigation. Similarly chest disease specialists and family physicians should be alert to the possibility of eye disorders in their patients with OSAS.

Declaration of Interest: None
Corresponding Author: Tuğba Gönçü,
Email: drtgoncu@hotmail.com

CR100
Change in health status in COPD over seven years of follow-up
Josefin Sundh1, Scott Montgomery1, Mikael Hasselgren2, Mary Kempe2, Christer Janson2, Björn Stallberg2, Karin Lisspers2
1Örebro University, Sweden, 2Uppsala University, Sweden

Aim: Health status is important in assessment of COPD. The aim was to examine associations of different clinical factors with change in health status measured by CCQ over a seven-year follow-up period.

Method: In 2005, 970 randomly selected primary and secondary care patients with a COPD diagnosis completed questionnaires including clinical characteristics and health status assessed by the Clinical COPD Questionnaire (CCQ). In 2012, 413 of 501 patients with information from 2005 completed the CCQ (main study group). Linear regression used difference in mean total CCQ score between 2005 and 2012 as dependent variable, and as independent variables: baseline CCQ score 2005, sex, age, educational level, BMI, smoking status, heart disease, diabetes, depression, number of exacerbations recent year, mMRC, and in a subgroup, COPD stage (n = 237).

Results: Health status worsened from mean total CCQ (+SD) 2.03 (+1.26) in 2005 to 2.16 (+1.37) in 2012 (P = 0.011). Linear regression with adjustment for baseline CCQ showed significant associations with worsened health status at the follow-up in 2012 for higher age, lower education, higher mMRC and higher COPD stage at baseline, and with improved health status at follow-up for BMI 26-30 kg/m2 at baseline. When sex, age and all statistically significant measures in the main study group were included simultaneously, higher mMRC at baseline was associated with worsened health status at the follow up (adjusted regression coefficient (95%CI) 0.26 (0.16 to 0.36), P = 0.0001), and BMI 26-30 kg/m2 at baseline with improved health status at follow-up (-0.32 (-0.56 to -0.09), P = 0.008).

Conclusion: In this study, higher mMRC is associated with decline in health status and overweight with improving health status in COPD. Strategies for decreasing dyspnea and awareness of the possible increased risk of worsening disease in under and normal weight patients with COPD might be of clinical importance.

Declaration of Interest: JS has received lecture fees from AstraZeneca, Boehringer Ingelheim, Novartis, Takeda, SM, MH, MK have no conflicts of interest. CJ has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and TEVA, and has served on advisory boards arranged by AstraZeneca, TEVA and Boehringer Ingelheim. BS has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, MEDA and TEVA, and has served on advisory boards arranged by AstraZeneca, Novartis, GSK and Boehringer Ingelheim. KL has received honoraria for educational activities and lectures from AstraZeneca, GlaxoSmithKline, Novartis, Meda and Takeda and has served on advisory boards arranged by Meda, Novartis.
Corresponding Author: Josefin Sundh,
Email: josefin.sundh@oru.se

CR101
Micropirometry as a ‘point of care’ test to facilitate the diagnostic process in subjects at risk of COPD in general practice. A cluster-randomised trial
Tjard Schermer1, Lisette van den Bemt1, Joke Grootens1, Riet Cretier1, Reinier Akkersmans1, Joke Denis2, Patrick Poels3
1Radboud University Medical Center, The Netherlands, 2Zorro Primary Care Group, The Netherlands, 3General Practice Bles & Poels, The Netherlands

Aim: To investigate whether the use of FEV1/FEV6-based micropirometry as a point-of-care (POC) test during routine general practice consultations in subjects at risk of undiagnosed COPD who consult their GP with respiratory complaints is able to facilitate the diagnostic process for these individuals.

Method: We performed an 8-month clustered RCT. GPs allocated to micropirometry (MI) were instructed through e-learning in how to use a COPD-6 (Vitalograph Ltd) micropirometer in subjects who consulted them with respiratory complaints that could indicate undiagnosed COPD. The GPs were instructed to refer patients for full spirometry if pre-BD FEV1/FEV6 from a COPD-6 was lower than 0.73. Introduction of the COPD-6 was postponed in practice allocated to usual care (UC). Medical records of subjects at risk of undiagnosed COPD who consulted their GP with respiratory complaints is able to facilitate the diagnostic process in subjects at risk of COPD in general practice.

Results: 21 practices (83 GPs) participated. 78 subjects (of all 192 eligible subjects) were listed by GPs in the MI group and DP was completed in 60 subjects (77%), compared to 61 (out of 224 eligible) subjects and 27 (44%) completed DPs by GPs in the UC group (Odds Ratio: OR 2.9, 95%CI 1.0; 8.3). Final diagnostic conclusions were more frequent in MI subjects (OR 3.7, 95%CI 1.2; 11.0). Proportions of potential COPD patients that were identified by the GPs were 39% in the MI and 27% in the UC group, respectively.
Conclusion: Microspirometry facilitated the diagnostic process in subjects who consulted their GP with respiratory complaints that may indicate undiagnosed COPD.

Declaration of Interest: This investigator-initiated study was sponsored by Boehringer Ingelheim.

Corresponding Author: Tjard Schermer,
Email: tjard.schermer@radboudumc.nl

CR102
Symptoms, comorbidities, mental health and frailty in patients with COPD in Greek primary care settings

Maria Kampouraki1, Ioannis Poulorinakis2, Marilena Anastasaki1, Ioanna Tsiliangianni1
1University of Crete, Heraklion, Crete, Greece, 2Health Care Practice of Agia Varvara, Heraklion Crete, Greece

Aim: To explore symptoms and their diurnal variation in patients with COPD in Greek primary care settings. To explore which diseases are comorbid, if mental disorders and frailty is present.

Method: This was a cross sectional study. Thirty primary care practices were invited to participate across Greece. The plan was to obtain a general sample of more than 500 patients with COPD or asthma. The patients through an interview with the investigator answered 18 different questionnaires about their medical history, symptomatology, psychological status (GAD and PHQ), sleep habits (Sleep Index), medications, frailty (simple frailty questionnaire), etc. Spirometry measurements were recorded. A pre-tested questionnaire to explore which are the more bothering symptoms and their diurnal variability was constructed and distributed. Descriptive statistics are presented at this stage.

Results: We present preliminary results based on a sample of 146 COPD patients participating mainly from the island of Crete. All patients of the specific sample were male (n = 146, 100%), mean age 64 (median = 58, SD = 15.2), married (n = 144, 98.6%), pensioners (n = 134, 91.7%), active smokers (n = 136, 91.3%). The most bothering symptom was dyspnea (n = 83, 55.3%) mainly in awaking (n = 110, 77.3%), followed by bad sleep due to dyspnea (n = 61, 40.7%). Comorbid diseases were hypertension (n = 97, 66.4%) dyslipidemia (n = 38, 26%) and in a less rate diabetes (n = 4, 2.7%). Feelings of anxiety and disappointment were reported. Those have never been evaluated by their physician before. In the sample regarding GAD and PHQ9 none of the patients scored high enough to be classified with psychological disorder, however there was a specific question for each questionnaire that many patients answered positively. In the frailty questionnaire only feelings of vanity were referred (n = 56, 37.3%).

Conclusion: General practitioners should give importance in diurnal variability, focus on smoking cessation, recognize common comorbidities and investigate frailty and mental disorders in order to evaluate the patient holistically.

Declaration of Interest: Grant provided by IPCRG (International Primary Care Respiratory Group) following the UNLOCK project.

Corresponding Author: Maria Kampouraki,
Email: kamstitch@yahoo.gr

CR103
Spirituality, coherence and self-efficacy of patients with COPD in Greek primary care settings

Maria Kampouraki1, Ioannis Poulorinakis2, Ioanna Tsiliangianni1
1University of Crete, Heraklion, Crete, Greece, 2Health Care Practice of Agia Varvara, Heraklion Crete, Greece

Aim: To explore the role that spirituality, coherence and self-efficacy have in patients with COPD.

Method: This was a cross sectional study. Thirty primary care practices were invited to participate in the study. Patients with COPD answered the following questionnaires: the Royal Free Interview for Religious and Spiritual Beliefs (RFI), the coherence scale and the self-efficacy scale (SES). Coherence questionnaire investigates the positive thoughts and attitude of a person and self-efficacy is a scale to measure determination and self-esteem. High scores in these questionnaires indicate a high capability coping with problems. The data were collected and recorded. Descriptive statistics are presented.

Results: Of the 580 participants we present the preliminary results of 146 patients with COPD. They declared to be spiritual (n = 108, 74%) and all spiritual patients were found with higher scores in coherence and self-efficacy questionnaires in comparison to those that answered to have weak opinion about religion (n = 21, 3%). The mean score of each question in SES questionnaire was for spiritual patients 3 (median = 4.5, SD = 1) and for coherence scale was 6 (median = 7, SD = 1) compared to non-spiritual that the mean score for SES was 2 (median = 3, SD = 1) and for the coherence questionnaire respectively (median = 6, SD = 1). They fast in the fasting periods that religion suggests. As main religious related activity they refer praying.

Conclusion: These preliminary results show that spiritual patients are more self-confident and coherent. Better coherence and self-efficacy are parameters that enable a person to cope more effectively with daily stress. In that direction spirituality may help improving patients coping with life. Physicians of primary care should feel comfortable in discussing spirituality and try to promote it so to achieve a better coping with the disease.

Declaration of Interest: None

Corresponding Author: Maria Kampouraki,
Email: kamstitch@yahoo.gr

CR104
Challenges in recruiting primary care doctors for a randomized controlled trial to study change in prescription practices due to our educational intervention

Monica Barne1, Sharad Agarkhedkar2, Avinash Bhondawe3, Priyanka Thakare1, Noopur Hedawoo1, Sapna Madas1, Aarti Nagarkar1, Sundeeb Salvi1
1Chest Research Foundation, Pune, India, 2Dr. D. Y. Patil Medical College, Pune, India, 3Indian Medical Association, 4Savitribai Phule Pune University, India

Aim: To recruit primary care doctors for a randomized controlled trial to study the change in prescription practices as an impact of our educational intervention.

Method: From the database of Primary Care Physicians from Pune and adjoining districts of the Indian Medical Association, we recruited doctors telephonically. Those who consented, received customized prescription pads to record respiratory cases, their symptoms, diagnosis and treatment prescribed. Their prescriptions were scored by a blinded study coordinator to identify a pool of doctors who did not manage Asthma according to the GINA guidelines. These doctors were enrolled in the study and randomized into study and control groups. Study group had to attend a one day training on Asthma diagnosis and management. Both groups are again keeping the prescription record for us to analyse if there is any change in prescription practices.

Results: 118/907 (12%) doctors we contacted telephonically agreed to participate in this study. Of the 118 only 52 doctors (44%) gave us their recorded prescriptions while 36% said they were too busy to record, 8% prescription pads were lost in transit, 2.5% lost them due to shift in practice, 4.23% dropped out and 4.23% cited other reasons for not recording. Out of the 52 doctors, 84.6% (44) doctors were managing their asthma cases inappropriately and we randomized them into study and control group. However of the 22 in study group only 13 (59%) came for the educational intervention. At the post training follow up, one dropped out leaving us with only 12 in the study group.

Conclusion: It is a real world challenge to enrol primary care doctors in a randomized controlled study involving them keeping prescription records and attending a training on Asthma. We need alternate, more simple methods to evaluate the impact of our training programmes.

Declaration of Interest: None

Corresponding Author: Dr. Monica Barne,
Email: drmonica@crfindia.com
CR105
Quality of spirometry performed by French general practitioners. A national descriptive retrospective study
Gwenâëlle Joncour¹, Tiphanie Bouchez², David Darmon²
¹Nice-Sophia Antipolis University, France, ²PrimAir/Nice-Sophia Antipolis University, France

Aim: To assess the reliability of spirometry performed by the general practitioners (GPs) in France, in terms of conformity and reproducibility of forced vital capacity (FVC) manoeuvres. To identify the GPs characteristics significantly linked with highest conformity of spirometry.

Method: A retrospective descriptive study was performed randomly among all the French GPs practising spirometry according to the national health system. GPs were asked to send the last ten anonymized spirometry curves they performed and to fulfill a questionnaire about them and their practice. The FVC manoeuvre was evaluated by a scale based on the ATS/ERS guidelines, including three criteria evaluable on paper: good start of the test, volume plateau reached or exhalation ≥ 6 seconds and no cough during the first blow second. A manoeuvre was considered acceptable if it met all three criteria, usable if it met the first two criteria, unusable otherwise. The spirometry test was sorted by conformity degree: high conformity if at least three manoeuvres were acceptable and reproducible, good conformity if at least three manoeuvres were acceptable but not reproducible, intermediary conformity if at least three manoeuvres were usable, non-conformity otherwise. Statistics tests used were chi-square test for univariate analysis and a linear regression for multivariate analysis.

Results: 33 GPs were included. 547 manoeuvres were analysed: 400 (89.6%) were acceptable, 45 (8.2%) usable. 327 spirometry tests were analysed: 250 (76.5%) were non-conform whereas 51 (15.6%) met the high conformity criteria. Only 5 tests used were chi-square test for univariate analysis and a linear regression for multivariate analysis.

Conclusion: French GPs performed conform FVC manoeuvres but spirometry tests are mainly non-conform, due to a lack of repetition of the manoeuvres to reach the repeatability criteria. GPs formation and duration of the test are leads to explore how French GPs spirometry tests conformity.

Declaration of Interest: None
Corresponding Author: Gwenâëlle Joncour,
Email: jgwen06@gmail.com

CR106
Evaluation of the Spirometry quality in primary care in relation to the reference hospital
Javier Perez¹, Juan Enrique Cimas Hernando²
¹Calzada Health Center, Gijon, Spain, ²Contrueces Health Center, Gijon, Spain

Aim: To evaluate and compare the quality of spirometries done in several primary care centers in relation to a reference general hospital.

Method: A cross-sectional study assessing a systematic random sample of the spirometries done during 2 months to people older than 14 years at 10 health centres and one general hospital. It was evaluated the quality of spirometry according to the regulations of ERS / ATS as a good start, adequate effort, no artifacts, duration of the test, number of tests performed and reproducibility, calculating the percentage of completion of each section and global compliance.

Results: We studied 547 spirometries (60.5% in PC and 39.5% in hospital). Compiled the criteria good start, effort and the absence of artifacts the 63.7% of spirometries done in PC compared 75.8% in Hospital. The two most frequent errors were variable effort and duration of the test over 6 seconds only in 34.7% at PC, and 48.7% at HN. Overall, the quality was adequate at 26.6% in PC, and 29.9% in Hospital, with no significant differences between PC and Hospital.

Conclusion: The quality of spirometries can be improved, especially as it relates to the effort and duration of the test. The quality of Spirometry in PC is comparable to that obtained in a hospital.

Declaration of Interest: None
Corresponding Author: Javier Perez,
Email: jfpontica@hotmail.com

CR107
Adherence and beliefs to medication/inhalers in patients with COPD
Maria Kampouraki¹, Ioannis Poulornakis², Ioanna Tsiligiani¹
¹University of Crete, Greece, ²Health Care Practice of Agia Varvara, Heraklion, Crete, Greece

Aim: To assess whether or not patients with COPD have an adequate adherence to their therapy for inhalers and other medications, investigate if there is any difference between adherence to inhalers and other medications and if this is influenced by their beliefs.

Method: This was a cross sectional study where primary care practices across Greece were invited to participate. The questionnaires that patients were asked to complete were: a detailed personal medical history, the measure of beliefs about medicines (BMQ), the Medication Adherence Rating Scale (MARS), the MARS for inhalers and the Test of the Adherence to Inhalers (TAI). Descriptive statistics are presented.

Results: We present preliminary results of 146 patients with COPD (out of 580). Most of the patients were using dry powder inhalers (n = 78, 53.4%), take three medications per day (n = 89, 61.6%) as recorded in BMQ). They took their medication the last week for 6.8 days (mean = 6.8, median = 7.5, SD = 1), have difficulty in remembering all dosages (n = 80, 56.4%) BMQ). They had a good opinion about effectiveness (n = 138, 94.6%) BMQ questionnaire) and presented not to be careless about taking their inhaler (n = 141, 97.3% MARS questionnaire). Many of them interrupt the use of their inhaler when they feel better (n = 52, 39.4%) MARS questionnaire). Most of them don’t know the proper dose (n = 89, 61%) TAI questionnaire) and do crucial mistakes in utilization of their inhaler (n = 114, 78% TAI questionnaire). Because BMQ and MARS questionnaires do not distinguish adherence for medications and inhalers, the differential between these parameters can be conducted after the general sample is examined and scores of TAI, MARS and BMQ questionnaires are compared.

Conclusion: General practitioners must be aware of the proper use of inhalers and demonstrate repeatedly the inhaler technique, investigate patients’ beliefs and opinions about medication and explore if they take them constantly.

Declaration of Interest: This study was granted by IPCRG (International Primary Care Respiratory Group) following the UNLOCK project.
Corresponding Author: Maria Kampouraki,
Email: kamstitch@yahoo.gr

CR108
Evaluating the prevalence and patterns of multimorbidity in children with asthma and their families from a disadvantaged Chilean population
Mauricio Soto¹, Javiera Corbalan²
¹Pontificia Universidad Católica de Chile/GRAP, Chile ²Dirección de Salud, Corporación de Desarrollo Social de Providencia/ GRAP Chile

Aim: Multimorbidity has been defined as the “coexistence of two or more chronic diseases in the same individual”. Individuals with multimorbidity are difficult to manage, need frequent health care, frequent hospitalizations, and represent a major cost to the health system. Primary health care professionals have reported difficulties to serve them in a time of limited consultation, leading to the adoption of a model of “sequential additive” decision-making, leaving important issues unprioritized during the consultation. This has
motivated studies about the prevalence of multimorbidity to structure more appropriate care for these patients. Although, studies in younger population are scarce, particularly those about chronic respiratory diseases like asthma. The aim of the study is to identify the prevalence and patterns of multimorbidity in children with asthma and their families.

Method: Descriptive study using clinical data from a population of 72437 patients belonging to three primary health care centers in disadvantaged neighborhoods of Santiago de Chile. For the analysis the case mix ACG software system of the John Hopkins University was used. Data were extracted from the electronic medical record in use since 2005.

Results: The prevalence of asthma and multimorbidity in children (under 10 years) was identified: (a) Children (b) Children with asthma 2667 (21.3%) (c) Children with asthma and multimorbidity 675 (5.4%) (Figure 1). (d) Chronic respiratory conditions represent the most common health problem in children with multimorbidity. We identified 825 different patterns of multimorbidity. Individually, the association of childhood asthma were more frequent with mental health, oral health and nutritional problems. At family level the association of childhood asthma was more frequent with mental health problems within the family. Conclusion: A significant prevalence of multimorbidity in children with asthma was identified in our population. Individual and family patterns of multimorbidity indicate the need for health care based on a model of family health rather than the sequential approach used today in primary health care also promoted by specific disease guidelines and many secondary level specialties.

Declaration of Interest: None
Corresponding Author: Mauricio Soto,
Email: msotod@gmail.com

CR109
The impact of incentives on the implementation of asthma or diabetes self-management: a systematic review
Tracy Jackson1, Liam Heaney2, Mike Shields2, Marilyn Kendall3, Chi Yan Hui2, Hilary Pinnock3
1Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, UK; 2Queen’s University Belfast, UK; 3University of Edinburgh, UK

Aim: To systematically review the evidence investigating the impact of financial incentives for implementation of supported self-management on organisational process outcomes, individual behavioural outcomes, and health outcomes for individuals with asthma or diabetes; both conditions with a mature evidence base for self-management.

Method: We followed Cochrane methodology, using a PICOS search strategy to search 8 databases, including a broad range of implementation methodologies. Selection was undertaken by TJ and CYH. Studies will be classified by robustness of methodology, number of participants and the quality score (Cochrane). We used narrative synthesis due to heterogeneity.

Results: We identified 2017 articles; 11 met our inclusion criteria. The articles were from the US (n=7) with and UK (n=4). Self-management outcomes that were measured were practice or practitioner performance scores for HbA1c testing (n=9), written self-management plan for asthma (n=1) and hospital/emergency department visits (n=1). Three of the studies were part of a larger incentive scheme including many conditions; one focused on asthma; seven focussed on diabetes. The majority of interventions involved financial incentives being paid on target achievement except one which investigated reimbursement for intensive case management components. In asthma, the proportion receiving ‘perfect care’ (which includes written self-management plan) increased from 4% to 88% in one study, and there were fewer hospitalisations/emergency department visits in another study. In nine diabetes studies, quality-of-care/PG performance scores improved in 2/9, was unchanged in 6/9 and deteriorated in 1/9.

Conclusion: Results for the impact of financial incentives for the implementation of self-management were mixed. Overall, the evidence in diabetes suggests no impact in diabetes. There was evidence from single studies of improved process and health outcomes in asthma. Further research is needed to confirm these findings and understand the process by which financial incentives impact (or not) on care.

Declaration of Interest: None
Corresponding Author: Tracy Jackson,
Email: tracy.jackson@ed.ac.uk

CR110
The prevalence of smoking and tobacco addiction among university students
Huseyin Elbi1, Suheyla Rahman1, Ayse Aktas1, Selim Altan1, Beyham Cenzig Özyurt1
1Celal Bayar University School of Medicine, Manisa, Turkey

Aim: Five million people die worldwide each year because of health problems related to smoking. In our country, about 100 thousand deaths each year are performed for this reason (1). Smoking habits is also identified as a significant public health problem in our country (2). According to 2008 global Adult Tobacco Survey of Turkey, daily tobacco consumption is 21.7% in the 15-24 age group, the rate was 34.9% in men and 9.1% in women. The same survey showed that 39.3% of daily smokers started to smoke at “15-17” age group (3).

In this study, we aim to determine the prevalence of smoking in university students, to study the socio-demographic factors associated with smoking and to contribute preventive examinations to the program.

Method: This cross-sectional study was carried out on students of the Celal Bayar University between March and May 2015. Sample size and sampling method used in the study was initiated in order to reach approximately 3,000 students. The research data was collected by questionnaires created by researchers after obtaining verbal consent with students face to face interview. The dependent variable of the study was defined as smoking status. The independent variables were age, class, departments, current location and family smoking. Also Fagerstrom Tolerance Test (nicotine addiction measurement test) to measure the level of nicotine dependence were used. The data was evaluated with descriptive statistics and chi-square test.

Results: 2170 students participated in the study. 53.4% of the students were female, 46.6% of them were male. The average age of students was 21.5 ±2.034. 23.6% of students (n=518) were current smokers, 68.8% of students (n=1493) said that they never smoked and 7.3% of them quit smoking. When we look at the current smoking, men were significantly more smokers than female students (P < 0.001). Table-1. Significant differences in smoking status were observed according to the location (With Family, Dorm, With Friends, Alone) of the students Table-2. The interesting note here is that the girls in the dormitory significantly higher smoking rate (P < 0.001). Current smoking rate in the Faculty of Engineering students (33.2%) was highest and the lowest was at the students of vocational school of health Table-3. Based on Fagerstrom Tolerance Test, 8.9% of students identified as addicts. Addiction was detected higher at male students and which were rest with friends.

Conclusion: As a result, smoking is a common behaviour among university students and increased rates of smoking was demonstrated at the later years of education. Lessons regarding the prevention of starting smoking should be...
added to the curriculum. It should also be included in the curriculum in support of smoking cessation programs for smokers.

**Declaration of Interest:** None

**Corresponding Author:** Huseyin Elbi,
Email: hsynelbi1@hotmail.com

**References**


**[CR110]**

**Table 1.** Current smoking status according to sex of students

<table>
<thead>
<tr>
<th>Students</th>
<th>N (%)</th>
<th>Male (%)</th>
<th>Female (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current smokers</td>
<td>518</td>
<td>312</td>
<td>206</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ex-smokers</td>
<td>159</td>
<td>81</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Never smoked</td>
<td>1493</td>
<td>528</td>
<td>965</td>
<td></td>
</tr>
</tbody>
</table>

**[CR110]**

**Table 2.** Current smoking status according to location and family smoking

<table>
<thead>
<tr>
<th>Location</th>
<th>N (%)</th>
<th>Male (%)</th>
<th>Female (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total = 2170</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorm</td>
<td>732</td>
<td>33.7</td>
<td>48 (9.0)</td>
<td>75 (61.0)</td>
</tr>
<tr>
<td>Friends</td>
<td>596</td>
<td>27.5</td>
<td>48 (9.0)</td>
<td>75 (61.0)</td>
</tr>
<tr>
<td>Alone</td>
<td>83</td>
<td>3.8</td>
<td>43 (8.9)</td>
<td>6 (27.0)</td>
</tr>
<tr>
<td>Total = 518</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With</td>
<td>159</td>
<td>31.9</td>
<td>56 (11.0)</td>
<td>61 (37.0)</td>
</tr>
<tr>
<td>Family</td>
<td>512</td>
<td>31.9</td>
<td>106 (20.8)</td>
<td>75 (46.5)</td>
</tr>
<tr>
<td>Dorm</td>
<td>327</td>
<td>63.3</td>
<td>90 (17.4)</td>
<td>69 (34.6)</td>
</tr>
<tr>
<td>Friends</td>
<td>190</td>
<td>58.1</td>
<td>41 (8.1)</td>
<td>40 (20.9)</td>
</tr>
<tr>
<td>Alone</td>
<td>122</td>
<td>63.9</td>
<td>29 (5.7)</td>
<td>23 (12.0)</td>
</tr>
<tr>
<td>Total = 518</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**[CR111]**

**A randomized switch trial of indacaterol and salmeterol/fluticasone combination in patients with moderate COPD: Symptom score analysis from the INSTEAD study**

Pankaj Goyal1, Andrea Rossi2, Thys Van der Molen3, Ricardo Del Olmo4, Alberto Papi5, Luis Wehbe6, Matthew Quinn1, Pablo Altman6

1Novartis Pharma AG, Basel, Switzerland. 2Azienda Ospedaliera Universitaria Integrata, Verona, Italy. 3University Medical Center Groningen, The Netherlands. 4Fundación CIDEA, Hospital Maria Ferrer, Buenos Aires, Argentina, 5University of Ferrara, Italy. 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States

**Aim:** Patients at a low risk of exacerbation and moderate airflow limitation have been frequently prescribed inhaled corticosteroids, contrary to GOLD recommendations. Data from INSTEAD study showed that patients with moderate COPD and no exacerbations in the previous year can be switched from salmeterol/fluticasone combination (SFC) to indacaterol (IND) with no efficacy loss. Here we present the exploratory analysis of the INSTEAD study to investigate the efficacy of IND versus SFC in terms of change in symptom scores.

**Method:** INSTEAD was a 26-week, double-blind, parallel-group, double-dummy, non-inferiority study conducted in patients with moderate COPD and no history of exacerbation, which recruited patients who had been receiving SFC 50/500 μg b.i.d. for at least 3 months prior to entry. Patients were randomized (1:1) either to continue to receive SFC 50/500 μg b.i.d. or were switched to IND 150 μg o.d. with no washout period. Morning/evening daily respiratory symptoms (cough, wheezing, sputum volume and colour, breathlessness, sore throat, cold and fever), percentage of ‘nights with no night-time awakenings’, ‘days with no daytime symptoms’ and ‘days able to perform usual daily activities’ were recorded by means of electronic diaries over 12 and 26 weeks of treatment.

**Results:** No statistically significant differences were observed in symptom scores, percentage of ‘nights with no night-time awakenings’, ‘days with no daytime symptoms’ and ‘days able to perform usual daily activities’ between IND versus SFC at Weeks 12 and 26 (Table).

**Conclusion:** The INSTEAD study demonstrated that patients with moderate airflow limitation and low risk of exacerbations could be switched to indacaterol from salmeterol/fluticasone with no deterioration in symptoms/ symptom scores.

**Declaration of Interest:** AR received grants, personal fees and non-financial support from Novartis, personal fees and non-financial support from Glaxosmithkline and Boehringer Ingelheim, grants and personal fees from Chiesi Farmaceutici SPA outside the submitted work. PG, MQ and PA are employees of Novartis.

**[CR111]**

**Table 1.** Exploratory symptom efficacy outcomes

<table>
<thead>
<tr>
<th>Daily score</th>
<th>Treatment difference</th>
<th>Week 12</th>
<th>Week 26</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LS mean (CI)</td>
<td>P value</td>
<td>LS mean (CI)</td>
</tr>
<tr>
<td>Cough</td>
<td>0.04 (−0.07, 0.16)</td>
<td>0.458</td>
<td>0.03 (−0.09, 0.16)</td>
</tr>
<tr>
<td>Wheezing</td>
<td>0.00 (−0.11, 0.11)</td>
<td>0.954</td>
<td>−0.02 (−0.14, 0.09)</td>
</tr>
<tr>
<td>Production of sputum</td>
<td>0.02 (−0.11, 0.14)</td>
<td>0.806</td>
<td>−0.01 (−0.13, 0.12)</td>
</tr>
<tr>
<td>Colour of sputum</td>
<td>0.06 (−0.04, 0.16)</td>
<td>0.273</td>
<td>0.04 (−0.07, 0.14)</td>
</tr>
<tr>
<td>Breathlessness</td>
<td>0.00 (−0.12, 0.13)</td>
<td>0.961</td>
<td>0.02 (−0.12, 0.15)</td>
</tr>
<tr>
<td>Sore throat</td>
<td>−0.03 (−0.10, 0.04)</td>
<td>0.428</td>
<td>0.04 (−0.11, 0.03)</td>
</tr>
<tr>
<td>Cold</td>
<td>0.00 (−0.12, 0.12)</td>
<td>0.999</td>
<td>−0.03 (−0.16, 0.10)</td>
</tr>
<tr>
<td>Fever</td>
<td>0.00 (−0.02, 0.03)</td>
<td>0.827</td>
<td>0.01 (−0.02, 0.03)</td>
</tr>
</tbody>
</table>

Treatment difference (indacaterol versus salmeterol/fluticasone) in change from baseline in daily individual symptom scores at Weeks 12 and 26. LS mean, least square mean; CI, confidence intervals.
CR112
Study of indoor pollution from fine particles (PM 2.5) delivered by electronic cigarettes (e-cig) and tobacco smoke
Rodrigo Córdoba-Garcia1, Araceli Fernández-Revuelta1
1University of Zaragoza, Spain

Aim: To assess the concentration of fine particles (PM2.5) in dual consumers of e-cigs and tobacco
Method: Experimental study of fine particles concentration consuming e-cigs with nicotine concentrations 6, 12 and 19 mg/ml versus conventional cigarette measured in a space of 48 m3 for 30 minutes on different days on the same stage. The scenario reproduces average of smoker’s density in bars and cafeterias in countries were e-cigs consumption in indoor places are not banned. To measure particles every minute during 30 minutes a Monitor SidePack aerosol monitor AMS510 was used. Threshold of PM 2.5 on average for 24 hours proposed by WHO: 25 μg/m3 and by American EPA: 35 μg/m3.
Results: Particle pollution from e-cigs was 211.8 mg/m3 (SD: 214.4), 6-8 times higher than international standards allow for a period of 24 hours (EPA and WHO: 35-25 μg/m3). Particle pollution from conventional cigarettes was 1181.3 mg/m3 (SD: 456.0), 33-47 times higher than that recommended by international organizations. Maximum peak for e-cigs were 6685.1 μg/m3 at 20 minutes and for cigarettes were 7540.1 μg/m3 also at 20 minutes.
Conclusion: The e-cigs releases particles PM 2.5 in amount less than conventional cigarettes but bigger than recommended by international standards. This data must be considered together many others for public policy on indoor environment pollutants.
Declaration of Interest: None
Corresponding Author: Rodrigo Córdoba-Garcia, Email: rcordoba1954@gmail.com

CR113
Therapeutic validity and effectiveness of supervised physical exercise in patients with COPD - A systematic review and meta-analysis
Martijn Vooijs1, Petra Siemonsma2, Inge Heus1, Jacob Sont3, Ton Rövekamp2, Nico Van Meeteren4
1Rijnlands Rehabilitation Centre, Leiden, The Netherlands 2Healthy Living, TNO, Leiden, The Netherlands 3Leiden University Medical Center, The Netherlands 4Maastricht University Medical Center, The Netherlands

Aim: Background: In patients with COPD the effects of physical exercise on exercise capacity seem only modest and the type, dose and duration of exercise training to optimize exercise capacity unclear. Up until now no significant attention has been given to the therapeutic validity of physical exercise training programs. Our aim was to determine the effectiveness of supervised physical exercise training in patients with COPD taken into consideration indices such as therapeutic validity of the interventions, methodological quality of studies and exercise volume.
Method: RCTs comparing supervised exercise training with usual care were identified. Therapeutic validity of exercise training and methodological quality of included studies were assessed. Overall effects were calculated using a random effects model for maximal and endurance exercise capacity.
Results: 12 RCTs involving 613 patients with COPD were included. Significant differences in maximal exercise capacity (MD 0.72, 95% CI 0.45-0.96) and endurance exercise capacity (MD 0.82, 95% CI 0.56-1.08) in favour of supervised physical exercise training were found. Surprisingly, overall effects were not significantly influenced by methodological quality of included studies, therapeutic validity of the interventions, exercise volume per week, or total exercise volume.
Conclusion: Supervised physical exercise training for patients with COPD increases both maximal and endurance exercise capacity. The optimal type, dose and duration of physical exercise training however remains unclear and probably needs further thorough in depth meta-analysis of the clustered data of all the here included trials.
Declaration of Interest: None
Corresponding Author: Martijn Vooijs, Email: voo@rrc.nl

CR114
Validity and usability of low-cost accelerometers for internet-based self-monitoring of physical activity in patients with COPD
Martijn Vooijs, Laurence Alpay5, Jiska Snoeck-Stroband3, Thijs Beethuizen4, Petra Siemonsma2, Jannie Abbink1, Jaap Sont2, Ton Rövekamp2
1Rijnlands Rehabilitation Centre, Leiden, The Netherlands 2Health Living, TNO, Leiden, The Netherlands 3Leiden University Medical Center, Leiden, Netherlands

Aim: The importance of regular physical activity for patients with COPD is well established. However many patients do not meet the recommended daily amount. Accelerometers might provide patients with the information needed to increase physical activity in daily life. Our objective was to assess the concurrent validity and usability of two low-cost internet-connected accelerometers.
Method: First, to assess validity we conducted a field validation study with patients who wore two low-cost accelerometers (Fitbit and PAM) at the same time along with a validated multisensor accelerometer (SenseWear Armband) for forty-eight hours. Data on energy expenditure assessed from registrations from the two low-cost accelerometers were compared to the reference criterion. Usability was examined in a cross-over study with patients who, in succession, wore the Fitbit and the PAM for seven consecutive days and filled out a sixteen item questionnaire with regards to the use of the corresponding device.
Results: The agreement between energy expenditure from SenseWear Armband with METs estimated by the Fitbit and PAM was good (r = 0.77) and moderate (r = 0.41), respectively. With regards to the usability both the Fitbit and PAM were well rated on all items with no significant differences between the two devices.
Conclusion: The low-cost Fitbit and PAM are valid and usable devices to measure physical activity in patients with COPD. Therewithal, as patients showed willingness to monitor physical activity for longer periods, these devices may be useful in long-term self-management interventions aiming at increasing physical activity levels in these patients.
Declaration of Interest: None
Corresponding Author: Martijn Vooijs, Email: voo@rrc.nl

CR115
Pulmonary function and fraction exhaled nitric oxide in people with a GP diagnosis of asthma
Marise Kasteleyn1, Tobias Bonten1, Renée de Mutsert1, Willemien Thijs2, Pieter Hiemstra3, Saskia Cessie3, Frits Rosendaal1, Niels Chavannes1, Christian Taube1
1Leiden University Medical Center, The Netherlands

Aim: Obesity has impact on respiratory function, including an increased risk of developing asthma. Asthma as a result of obesity is recognized as being a distinct asthma phenotype. More evidence on differences between obese and non-obese patients with asthma can help to improve diagnostic accuracy of asthma and to optimize treatment. This study aims to explore pulmonary function, inflammation and complaints in asthma patients.
Method: The Netherlands Epidemiology of Obesity (NEO) study is a population based cohort study in 6,671 men and women, aged 45 to 65 years, of which 582 have a GP diagnosis asthma at baseline. Differences in pulmonary function, fractional exhaled nitric oxide (FeNO) and complaints between obese
and non-obese subjects with a GP diagnosis asthma, are explored using chi-square tests, independent t-tests and Mann Whitney U tests.

Results: Of the 582 patients with asthma, 314 have obesity (BMI ≥ 30). Asthma patients without obesity have better FEV1 values and FVC values compared to their counterparts with obesity (100.2% pred vs. 96.5% pred, P = 0.015; 112.1% pred vs. 107.0% pred, P = 0.038). Patients with obesity report more often the complaints wheezing and dyspnoea than patients without obesity (33.3% vs 42.0%, P = 0.031 and 16.9% vs 33.4%, p < 0.001).

Conclusion: Asthma patients without obesity have better spirometry outcomes than asthma patients with obesity, but have higher FeNO levels, indicating more inflammation. Patients with obesity experience more asthma-related complaints. It can be thought that these obese patients represent a distinct asthma phenotype in which inflammation is less often present. Different treatment strategies might be more efficient in these patients.

Declaration of Interest: None

Corresponding Author: Marise Kasteleyn,
Email: mkasteleyn@lumc.nl

CR116
Asthma prescribing practices and risk of hospital admission: an analysis of linked primary and secondary care data in East London

Sally Hull1, Kate Homer1, Shauna McKibben1, Stephanie Taylor1, Katy Pike2, Chris Griffiths1

1Queen Mary University of London, UK, 2University College London, UK

Aim: The National Review of Asthma Deaths (UK) highlighted inappropriate prescribing in primary care in nearly half of asthma deaths reviewed. In particular, excess prescribing of short acting beta2-agonist inhalers (> 12 a year SABA), under-prescribing of inhaled corticosteroid inhalers (a) is the inappropriate prescribing of asthma medication associated with risk of hospital admission? b) Which population groups are at increased risk of hospitalisation with asthma?

Method: In August 2015, anonymised EMIS-Web data for 36,126 people with asthma (aged 5-75 years) across 139 ethnically diverse practices in Hackney, Tower Hamlets and Newham Clinical Commissioning Groups (CCGs) was extracted from the North and East London Commissioning Support Unit (NELCSU), which holds data linked to hospital Secondary Uses Services (SUS).

Results: The greatest burden of emergency hospital admissions (51%) occurs in those prescribed Multivariate analyses in adults shows risk of admission rises with increasing BTS step (Step 3 OR 2.8, Step 4/5 OR 9.1), increasing use of SABA inhalers (4-12 SABA OR 1.7, > 13 SABA OR 3.3) and in people from Black (OR 2.3) and south Asian ethnic groups (OR 1.9). Results in children are similar, but risk is not related to ethnic group.

Conclusion: We confirm that prescription of >3 SABA inhalers/year is associated with increased risk of hospital admission. Adults (but not children) from Black and South Asian groups are at increased risk of admission. Further work is needed to target care for these at-risk groups.

Declaration of Interest: This work was partly supported by funding from the Asthma UK Centre for Applied Research.

Corresponding Author: Sally Hull,
Email: s.a.hull@qmul.ac.uk

CR117
View of adolescents with asthma on adherence and derived recommendations

Antje-Henriette Fink-Wagner1, Christine Rolland1, Giuseppe De Carlo1

1European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium

Aim: Asthma is the most chronic disease in childhood. Adolescents are less adherent than children between the ages of 7 to 9. Reasons are unknown. So far research focused on the views of parents and physicians. EFA interviewed adolescents directly to understand their poor adherence and become able to recommend on how to improve adherence of adolescents with asthma. Primary Care Physicians are involved in the treatment of adolescents with asthma.

Method: A multi-national survey was conducted with 200 12-17 year old adolescents with asthma in France, Germany, Spain and United Kingdom from July to October 2015. The telephone interviews included items on health status, asthma severity, attitude, treatment, role of physicians and health literacy.

Results: The survey indicated two factors that could largely explain variety of adherence: Attitude and Daily Impact of Asthma. Within these factors, six drivers of adherence with adolescents were identified: Forgetfulness, Rebellion, Good days, Support, Careless, and Ignorant. Health literacy did not have direct relation to adherence, but did correlate with Attitude, and may thus impact adherence indirectly. High trust in the physician advice was confirmed.

Conclusion: Adolescents’ trust in physicians indicates the need for them to take on a mentoring role. Primary care physicians, due to their familiarity with the patients may play a key role in informing and advising adolescents with asthma to make well-informed decisions regarding the management of their condition.

Declaration of Interest: No conflict of interest regarding the content of this presentation. The project was supported by an unrestricted educational grant of AstraZeneca, GSK, Novartis and TEVA.

Corresponding Author: Antje-Henriette Fink-Wagner,
Email: antje.finkwagner@gmx.de

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/